

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
8 July 2004 (08.07.2004)


PCT

(10) International Publication Number
WO 2004/057021 A2


- (51) International Patent Classification⁷: C12Q 1/68 (72) Inventor; and
(21) International Application Number: PCT/CA2003/001994 (75) Inventor/Applicant (for US only): BOIVIN, Guy [CA/CA]; 2531 Montbray, Sainte-Foy, Québec G1V 1E7 (CA).
(22) International Filing Date: 19 December 2003 (19.12.2003) (74) Agent: OGILVY RENAULT; Suite 1600, 1981 McGill College Avenue, Montreal, Québec H3A 2Y3 (CA).
(25) Filing Language: English (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
(26) Publication Language: English (84) Designated States (regional): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ...)
(30) Priority Data:
2,411,264 19 December 2002 (19.12.2002) CA
2,418,004 24 January 2003 (24.01.2003) CA
(71) Applicant (for all designated States except US): UNIVER-
SITÉ LAVAL [CA/CA]; Danielle Allard, Pavillon des sci-
ences de l'éducation, bureau 1474, Québec, Québec G1K
7P4 (CA).

[Continued on next page]

(54) Title: MOLECULAR METHODS AND COMPOSITIONS FOR DETECTING AND QUANTIFYING RESPIRATORY VIRUSES



(57) Abstract: There is provided compositions and methods for the detection and/or quantification of respiratory viruses using specific nucleic acid sequences. In particular methods and composition are provided to detect human Metapneumovirus (hMPV). The invention also provides with multiplex assays for detecting respiratory viruses in test samples.



BEST AVAILABLE COPY

WO 2004/057021 A2



ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

- *without international search report and to be republished upon receipt of that report*

- 1 -

MOLECULAR METHODS AND COMPOSITIONS FOR DETECTING AND
QUANTIFYING RESPIRATORY VIRUSES

CROSS-REFERENCE TO RELATED APPLICATIONS

- 5 This application claims priority on Canadian applications serial number 2,411,264 filed on December 19, 2002 entitled "Sequences for detection and identification of the human metapneumovirus" and serial number 2,418,004 filed on January 24, 2003 entitled "Multiplex assays for detection and identification of viral respiratory pathogens.

10

TECHNICAL FIELD

This application relates to the field of microorganisms detection and more particularly to the detection of respiratory tract viruses using virus specific nucleic acids.

15

BACKGROUND OF THE INVENTION

- Respiratory tract infections are a significant cause of morbidity and mortality in all age groups but especially in young children, elderly subjects, and immunocompromised patients. Most of these infections are caused by viruses with influenza A and B and the human respiratory syncytial virus (hRSV) being associated with the most frequent and severe complications i.e. pneumonitis and death (Dowell et al., 1996, J. Infect. Dis. 174:456-462; Simonsen et al., 2000, J. Infect. Dis. 181:831-837; Han et al., 1999, J. Infect. Dis. 179:25-30; Neuzil et al., 2000, N. Engl. J. Med. 342:225-231; Simoes, 1999, Lancet 354:847-852.). Other viruses such as adenoviruses (> 50 serotypes), parainfluenza viruses (PIV) (4 serotypes), rhinoviruses (> 100 serotypes), and coronaviruses also contribute to acute respiratory tract infections (Trecanor, 2002, Clinical Virology, 2nd ed., ASM Press, Washington, D.C., 7-26). Also, recent studies by the inventor and others have suggested that the new human metapneumovirus (hMPV) should be added to the list of human respiratory viral pathogens in all age groups (van den Hoogen et al., 2001, Nat. Med. 7:719-724;

Peret et al., 2002, J. Infect. Dis. 185:1660-1663; Boivin et al., 2002, J. Infect. Dis. 186:1330-1334).

The hMPV was initially isolated from nasopharyngeal aspirates recovered from 28 children suffering from respiratory tract infections. Based on partial nucleic acid sequences, gene organization, and electron microscopy (EM) findings, this virus was preliminary assigned to the *Paramyxoviridae* family, subfamily *Pneumovirinae*, genus *Metapneumovirus*. Since then, hMPV has been isolated in North America by our group (Peret et al., 2002, J. Infect. Dis. 185:1660-1663), in Australia (Nissen et al., 2002, Med. J. Aust. 176:188), and in England (Stockton et al., 2002, Emerg. Infect. Dis. 8:897-901).

Preliminary virological characteristics of hMPV.

The initial report by Van Den Hoogen *et al.* (van den Hoogen et al., 2001, Nat. Med. 7:719-724) indicated that the new virus replicated slowly in tertiary monkey kidney (TMK) cells with cytopathic effects (CPE) consisting of syncytium formation appearing 10-14 days post inoculation. Notably, the virus grew very poorly in Vero and A549 cells and could not be propagated in Madin Darby canine kidney (MDCK) cells. Virus-infected TMK cell-culture supernatants also did not display any hemagglutinating activity. The supernatants of infected TMK cells were used for EM studies, which revealed the presence of paramyxovirus-like pleomorphic particles in the range of 150-600 nm with short envelope projections in the range of 13-17 nm. However, RT-PCR studies with primer sets specific for known paramyxoviruses were initially all negative. Using a random PCR amplification procedure known as RAP-PCR (Welsh et al., 1990, Nucleic Acids Res. 18:7213-7218; Ralph et al., 1993, Proc. Natl. Acad. Sci. U.S.A. 90:10710-10714), the Dutch investigators identified differentially displayed bands (compared to human parainfluenza-1 virus) which, upon sequencing, were found to be most closely related to the avian pneumovirus (APV).

APV, the agent of turkey rhinotracheitis, has been the sole member of the recently assigned *Metapneumovirus* genus within the *Pneumovirinae* subfamily (Taxonomy Virus, 2000, Seventh Report of the International Committee on Taxonomy of Viruses. San Diego. 551, 557, 559-560). The latter virus is a major respiratory pathogen of turkeys and other domestic fowl worldwide (Yu et al., 1992, Virology. 186:426-434; Jones et al., 1987, Vet. Rec. 120:301-302; Jones, 1996, Avian Pathol. 25:639-648; Seal et al., 2000, Virus Res. 66:139-147). There are four serotypes of APV with serotype C (present in US) being the most closely related to hMPV (van den Hoogen et al., 2001, Nat. Med. 7:719-724). The metapneumoviruses (including APV and hMPV) are structurally similar to the human respiratory syncytial virus (hRSV), which also belongs to the *Pneumovirinae* subfamily, except for two features: they lack the two non-structural proteins (NS1 and NS2) and they have a different genomic organization (Yu et al., 1992, Virology. 186:426-434). Recently, an almost complete hMPV sequence (13.4 kb) was reported in GenBank (accession number: AF371337) (van den Hoogen et al., 2002, Virology. 295:119-132). The overall percentage of amino acid sequence identity for the N (nucleoprotein), P (phosphoprotein), M (matrix), F (fusion), M2 (membrane), and L (polymerase) proteins is in the range of 56-88% between hMPV and APV whereas it is 18-44% between hMPV and hRSV. However, the G (glycoprotein) and SH (small hydrophobic) proteins of hMPV do not possess significant amino acid sequence identity with those of any other viruses. In contrast to APV, hMPV was shown to be unable to replicate in turkeys and chickens but the human virus replicated efficiently in the respiratory tract of cynomolgous macaques inducing upper respiratory tract symptoms that correlated with peak viral replication in throat samples between 2 to 8 days post infection (van den Hoogen et al., 2001, Nat. Med. 7:719-724). Thus, these preliminary data indicated that hMPV was a primate pathogen associated with respiratory diseases.

Clinical importance of hMPV.

There is little information about the clinical presentation of hMPV infection. In the original report by Van Den Hoogen *et al.*, 27 of the 28 infected children from the Netherlands were below the age of five (van den Hoogen *et al.*, 2001, Nat. Med. 7:719-724). It was mentioned that those infected patients were diagnosed with a range of acute respiratory tract infections (ARTI) from mild to severe including bronchiolitis and pneumonia although no detailed clinical data were provided. In a limited study conducted in the winter of 2000, the same authors found that 7 ($\approx 10\%$) of 68 pediatric patients with unexplained ARTI had evidence of acute hMPV infection by RT-PCR (van den Hoogen *et al.*, 2001, Nat. Med. 7:719-724). In addition, Australian investigators reported the detection of hMPV by RT-PCR in 3/200 (1.5%) nasopharyngeal aspirates from children whose specimens were negative for the common respiratory viruses during the winter of 2001 (Nissen *et al.*, 2002, Med. J. Aust. 176:188). Recently, hMPV RNA was detected by RT-PCR in 9/405 (2.2%) of nasopharyngeal swabs from English patients who consulted for influenza-like illnesses and had negative tests for other pathogens (Stockton *et al.*, 2002, Emerg. Infect. Dis. 8:897-901). These studies, however, suffer from major limitations such as their small size (in most cases), the superficial description of clinical features, the lack of morbidity/mortality data, their retrospective nature, the exclusion of patients who tested positive for other viruses, and the absence of a control group.

Thus far, seroprevalence studies have been limited to the Dutch population. An indirect immunofluorescence assay (IFA) using infected TMK cells has revealed that 25% of the children aged between 6 and 12 months had hMPV antibodies and 70% had become seropositive by the age of 5 years ($n=60$) (van den Hoogen *et al.*, 2001, Nat. Med. 7:719-724). Retrospective serological testing also indicates that hMPV has been circulating in the Dutch population for at least half a century.

Diagnosis of hMPV infections

Our laboratory was the first to report the presence of hMPV in America and the second in the world following the initial report from the Netherlands (Peret et al., 2002, *J. Infect. Dis.* 185:1660-1663). Our first 11 hMPV strains were isolated on LLC-MK2 cells, a continuous cell line from rhesus monkey kidneys that is used in our center to recover parainfluenza viruses (PIV). Electron microscopy studies of these isolates revealed pleomorphic, spherical and filamentous particles with characteristics (nucleocapsid diameter and pitch spacing, length of projections) that were consistent with paramyxoviruses. RT-PCR and immunofluorescent assays for paramyxoviruses (PIV 1-3, hRSV) and other respiratory viruses (adenoviruses, coronaviruses, influenza viruses A and B, rhinoviruses) were negative for all 11 isolates. In contrast, amplification of the hMPV F (fusion) and M (matrix) genes based on published partial sequences (van den Hoogen et al., 2001, *Nat. Med.* 7:719-724; van den Hoogen et al., 2002, *Virology*. 295:119-132) was positive for all isolates (Peret et al., 2002, *J. Infect. Dis.* 185:1660-1663).

Subsequently, the virological features and clinical findings associated with a larger set of 38 hMPV strains from subjects hospitalized at our institution (CHUL, Québec City) since 1993 were examined in our laboratory (Boivin et al., 2002, *J. Infect. Dis.* 186:1330-1334). With all cell lines used in our laboratory, we were able to determine that the previously unidentified hMPV strains only consistently grew on LLC-MK2 cells after a mean incubation time of 17.3 days (range 3-23 days). Interestingly, most isolates recovered before 2002 produced only limited syncytia on LLC-MK2 cells, whereas some of the recent strains produced large syncytia typical of those induced by hRSV. Notably, we also observed a seroconversion for hMPV in two adult patients for whom acute and convalescent sera were available using an IFA test designed in our laboratory. Such seroconversion episodes (titers from < 1/10 to 1/80 and from < 1/10 to 1/160 over 2 and 4 weeks, respectively) occurred during the course of the patients' illness suggesting that hMPV was a true respiratory pathogen. A phylogenetic analysis of hMPV Canadian strains based on F gene sequences identified two major phylogenetic groups. At the nucleotide level, we found a similarity of 94.2-100% and 92.6-100% for isolates of groups 1 and 2, respectively, whereas the similarity at the amino acid level was higher i.e. 96.8-100% (group 1) and

97.2-100% (group 2) suggesting a functional/immunological conservation of the F protein. Interestingly, co-circulation of the two hMPV groups during some years was observed.

5 Over the past 9 years, most (86.7%) hMPV strains from our center were isolated during a 5-month period, from December to May. As an indication of the relative frequency of detection of hMPV compared to other respiratory viruses, we reviewed all respiratory samples (n = 862) sent to our virology laboratory for viral culture during the winter season (Dec. to May) of 2000-01. During this period, hMPV was
10 recovered in 2.3% of all respiratory samples tested by viral culture compared to 2.3% for PIV, 3.4% for adenoviruses, 4.8% for hRSV, and 19.8% for influenza A or B viruses. Overall, hMPV represented 7.1% of all positive cultures from respiratory samples during that winter season with percentages of 4.1%, 2.8%, and 29.3% for patients aged 0-5, 5-65, and > 65 years, respectively. A retrospective review of the
15 clinical charts from hMPV-infected subjects identified for the first time the role of this virus as a cause of severe lower respiratory tract infections in all age groups but especially in young children, elderly subjects, and immunocompromised patients. More specifically, the most frequent diagnoses associated with hMPV infection in hospitalized children were pneumonitis (66%) and bronchiolitis (58.3%) whereas
20 bronchitis/bronchospasm (60%) and pneumonitis (40%) were most commonly seen in elderly subjects (Boivin et al., 2002, J. Infect. Dis. 186:1330-1334). Although no histopathological studies were available, hMPV was the only pathogen identified in respiratory tract secretions of 3 subjects (including 2 with immunosuppressive conditions) who died of respiratory insufficiency.

25 We recently studied in greater details one of the cases associated with a fatal hMPV infection (Pelletier et al., 2002, Emerg. Infect. Dis. 8:976-978). Interestingly, this child with acute lymphoblastic leukemia was successively infected by two genetically-distinct hMPV strains on two consecutive winter seasons. On each
30 occasion, hMPV was the only pathogen isolated from a nasopharyngeal aspirate obtained during the course of lower respiratory tract infections (bronchiolitis in the

first year, bronchiolitis followed by fatal pneumonitis in the second year). Comparative sequence analysis of the amplified F gene products (759 bp) revealed that the two viral isolates differed by 114 nucleotides (10 amino acids) and belonged to two different hMPV groups. Overall, our data suggest that many hMPV strains may co-circulate in a specific population during a given period and such viral diversity coupled with a waning immunity (as found in elderly subjects and immunocompromised patients) may lead to multiple and sometimes fatal reinfections similar to those reported with hRSV (Hall, 2001, *N. Engl. J. Med.* 344:1917-1928; Couch et al., 1997, *Am. J. Med.* 102:2-9).

10

The role and relative contribution of hMPV were recently further expanded in a prospective case-control study performed at our institution during the winter of 2001-02 (Dec. 15-April 20). All children ≤ 3 years were eligible as cases if they were hospitalized for a lower respiratory tract infection (bronchiolitis, croup, pneumonitis) whereas controls consisted of children matched for age and hospitalized for an elective surgery during the same period with no respiratory symptoms. Nasopharyngeal aspirates were obtained from all participants for real-time PCR studies performed on a LightCycler (Roche). The latter included a multiplex RT-PCR for common respiratory viruses (influenza A, influenza B, hRSV) and a real-time RT-PCR assay for hMPV (analytical sensitivity of 100 copies per PCR reaction). No viruses were detected in samples from the 51 control patients. In contrast, at least one virus was identified in samples from 163 (78.4%) of the 208 cases (51% hRSV, 21.6% influenza A, 0% influenza B, 5.8% hMPV, and 5.9% co-infections). hRSV and influenza A infections occurred predominantly in the period between January and March 2002, whereas hMPV infections increased after February. In fact, 11/12 hMPV cases occurred within a 4-week period from mid-March to mid-April accounting for 18.9% of all ARTI in children during this period. Data collected from our virology laboratory indicated that the hMPV outbreak extended after the end of the study protocol (April 20) which suggests that hMPV seasonal pattern may differ from that of other respiratory viruses. A bronchiolitis was diagnosed in 67% of hMPV-infected children whereas 16.7% developed a pneumonia. In brief, there was no statistical

30

difference between the different viruses with regard to the symptomatology and reported diagnoses. Similarly, the median duration of hospitalization for the 3 viruses was identical (4-5 days).

- 5 In view of the above, it will be appreciated that diagnosis assay that can rapidly detect the presence of many respiratory viruses is needed.

Respiratory viruses have been classically identified by viral culture using a variety of permissive cell lines. However, viral culture is not convenient for clinical
10 management due to the need of specialized techniques (cell culture, immunofluorescence methods), the long turnaround time before appearance of typical cytopathic effects for many viruses (up to a few weeks), and the need for rapid inoculation of an infectious virus into multiple cell lines for optimal sensitivity (Specter et al., 2002, Clinical Virology, 2nd ed., ASM Press, Washington, D.C., 243-
15 272).

Antigenic detection kits for some respiratory viruses (influenza viruses and hRSV) have been developed by many companies. Most are immunoenzymatic assays (ELISA) based on the capture of a viral antigen by a specific monoclonal antibody.
20 Although such assays eliminate many of the problems inherent to viral cultures (no need for specialized equipment, rapid turnaround time in < 30 min, no need to recover an infectious virus), they have not been widely adopted due to poor sensitivity and/or specificity compared to viral culture. For instance, the sensitivity and specificity of some rapid antigenic tests for influenza has varied from 46 to 96 % and from 52 to 99
25 %, respectively, compared to viral culture. The performance of these tests is dependent on many variables such as the patient's age, the type of specimen and the duration of the disease (Hayden et al., 2002, Clinical Virology, 2nd ed., ASM Press, Washington, D.C., 891-920). The performance of the rapid antigenic tests for hRSV has been considered quite good in children with sensitivity and specificity varying
30 from 80 to 95 % (Piedra et al., 2002, Clinical Virology, 2nd ed., ASM Press, Washington, D.C., 763-790) but poor in adults (Englund et al., 1996, J. Clin.

Microbiol. 34:1649-1653). Detection of antibodies against viral pathogens (serology) has a limited value in the diagnosis of acute viral infections since two serums, collected at a 2 to 3 week interval, are required in order to document a significant rise in viral antibody titers.

5

More recently, PCR or RT-PCR assays have been developed for many respiratory viruses allowing detection of small amounts of viral DNA or RNA in a clinical sample. In the so-called "multiplex" format, PCR assays have been designed to amplify more than one viral target in the same PCR reaction (Ellis et al., 1997, J. Clin. Microbiol. 35:2076-2082; Fan et al., 1998, Clin. Infect. Dis. 26:1397-1402; Liolios et al., 2001, J. Clin. Microbiol. 39:2779-2783; Grondahl et al., 1999, J. Clin. Microbiol. 37:1-7). However, most multiplex PCR assays reported to date do not allow the simultaneous detection of all viruses involved in acute respiratory tract infections of humans and they require separate steps for the amplification and detection of viral genes, greatly increasing the assay's turnaround time and preventing reliable quantification of the amplicons. At present, only one multiplex PCR assay (the Hexaplex test from Prodesse, Waukesha, WI) is commercially-available. The Hexaplex detects 6 respiratory viruses (influenza A and B, PIV 1-3 and hRSV) using specific viral probes in a microplate format (Fan et al., 1998, Clin. Infect. Dis. 26:1397-1402; Kehl et al., 2001, J. Clin. Microbiol. 39:1696-1701). This assay does not use real-time amplification methodologies and has a turnaround time of about one full working day. Thus, there is a need for developing more rapid molecular assays that permit detection of a larger panel of respiratory viral pathogens.

25 Rapid and sensitive detection of respiratory viruses is an important clinical goal to help physicians select the most appropriate antiviral, reduce nosocomial transmission of pathogens, decrease the length of hospitalization, and reduce antibiotic use and bacterial resistance. The present invention relates to the development of multiplex assays based on nucleic acids detection for sensitive and rapid diagnosis of most viral
30 respiratory pathogens of humans.

SUMMARY OF THE INVENTION

It is an object of the present invention to provide a rapid and sensitive method using amplification primers and/or probes for determining the presence and/or the amount in a test sample of nucleic acids from clinically important respiratory viral pathogens including human metapneumovirus.

In another aspect there is provided multiplex assays aimed at detecting conserved genes of common respiratory viral pathogens such as influenza A and B, human respiratory syncytial virus (hRSV) A and B, human metapneumovirus (hMPV), parainfluenza viruses (PIV) types 1-4, adenoviruses, rhinoviruses, enteroviruses, and coronaviruses.

The nucleic acid amplification method is preferably but not exclusively PCR. In a preferred embodiment, identification of the amplicons produced by the amplification of nucleic acids from respiratory viruses is achieved by verifying the specific melting temperature of amplified viral products or by hybridization with specific viral probes. Other amplification technologies including target and probe amplification techniques as well as signal amplification techniques performed in liquid phase or onto solid supports may also be used.

It is an object of the present invention to provide a method using nucleic acid amplification and/or detection for determining the presence and/or the amount of nucleic acids of the human metapneumovirus (hMPV).

In a preferred embodiment, the nucleic acid amplification method is PCR. However, other amplification technologies including target and probe amplification techniques as well as signal amplification performed in liquid phase or onto solid support may also be used.

11

This invention provides a method to detect the presence of hMPV in a test sample based on the detection of a nucleotide sequence from either the nucleocapsid (N), phosphoprotein (P), matrix (M), fusion (F), membrane (M2), polymerase (L), glycoprotein (G), and small hydrophobic (SH) genes. In a particularly preferred
5 embodiment, the method to detect the presence of hMPV in a test sample is based on the detection of a nucleotide sequence from the nucleoprotein (N) or polymerase (L) genes.

In another embodiment, identification of amplified hMPV products is achieved by
10 verifying the specific melting temperature of amplified viral products or by hybridization with hMPV-specific probes.

It is another object of this invention to provide a method for typing hMPV strains which comprises the steps of reproducing the above amplification method followed
15 by either hybridization using type-specific probes, DNA sequencing or restriction enzyme analysis. Typing is done preferentially, but not exclusively, on the most variable hMPV genes i.e. the fusion (F) and glycoprotein (G) genes.

All the proprietary DNA fragments and oligonucleotides useful in the detection or
20 identification of a hMPV strain are further objects of this invention as well as any composition of matters that include them (recombinant vectors, hosts, diagnostic kits...).

25 BRIEF DESCRIPTION OF THE DRAWINGS

Further features and advantages of the present invention will become apparent from the following detailed description, taken in combination with the appended drawings, in which:

12

Figure 1 represents a melting curve analysis of amplified hMPV strains using specific nucleoprotein primers (Sequence ID Nos. 92 and 94);

Figure 2 shows an ethidium bromide-stained agarose gel showing restriction fragment
5 length polymorphism of amplified hMPV fusion (F) gene sequences digested with
enzymes ApaL I and Avr II. PCR products of the hMPV F gene (amplified with
primers sequence ID Nos. 97 and 98) were digested with ApaL I and Avr II. Strains
belonging to hMPV genotype F-1 were digested only by ApaL I resulting in two
fragments of 532 bp and 227 bp whereas strains belonging to hMPV genotype F-2
10 were digested only by Avr II resulting in fragments of 447 and 312 bp.;

Figure 3 shows the age at admission of children hospitalized for acute respiratory tract
infections (ARTI) caused by hMPV (A), hRSV (B), and influenza A (C) as well as for
the whole study population (D) described in example 4;

15

Figure 4 represents the biweekly distribution of virologically cases with acute
respiratory tract infections and their controls in the study reported in example 4;

Figure 5 represents the biweekly distribution of hMPV isolates in the study group
20 (hospitalized children) described in example 4 and in respiratory specimens tested at
the regional virology laboratory (RVL);

Figure 6 illustrates a phylogenetic tree of hMPV strains recovered as part of the study
described in example 4 also including the prototype strain from the Netherlands
25 (GenBank af371367) and a Canadian isolate from season 2000-01 (hMPV35-2001).
The dates of sample collection are in parentheses;

Figure 7 is a melting curve analysis of viral strains amplified using the respiratory-1
multiplex real-time PCR assay. A- Multiplex real-time PCR assay using hMPV N
30 primers (SEQ ID NOS. 95 and 96). B- Multiplex real-time PCR assay using hMPV L

13

primers (SEQ ID NOS. 112 and 114). Note: the internal control is apparent (T_m : 91°C) in the absence of amplification of specific viral products;

5 Figure 8 is a melting curve analysis of viral strains amplified using the respiratory-2 multiplex real-time PCR assay. Note: The internal control is apparent (T_m : 91°C) in the absence of amplification of specific viral products;

10 Figure 9A is a fluorescence signal as a function of elongation step for the determination of the hMPV load in clinical samples using quantitative real-time PCR;

Figure 9B is a standard curve for determination of the hMPV using quantitative real-time PCR;

15 Figure 10A is a phylogenetic tree for the F gene of hMPV;

Figure 10B is a phylogenetic tree for the G gene of hMPV;

20 Figure 11 is a melting curve analysis of amplified viral genes and of an internal control as determined by the LightCycler instrument. Note that high amounts of amplified viral products may preclude detection of the internal control in some PCR runs; and

Figure 12 is a melting curve analysis SARS-coronavirus using a real time PCR assay.

25 It will be noted that throughout the appended drawings, like features are identified by like reference numerals.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

The invention provides nucleic acid based diagnostic methods and compositions to detect and quantify respiratory viruses.

5

In a preferred embodiment respiratory viral pathogens targeted by the diagnostic assays include all genotypes of influenza A and B viruses, hRSV, hMPV, PIV, adenoviruses, rhinoviruses, and enteroviruses. Other less common (coronaviruses, reoviruses) and yet to be discovered respiratory viruses are also targets under the scope of the present invention.

10

In the description of this invention, the terms «nucleic acids» and «sequences» might be used interchangeably. However, «nucleic acids» are chemical entities while «sequences» are the pieces of information encoded by these «nucleic acids». Both nucleic acids and sequences are equivalently valuable sources of information for the matter pertaining to this invention.

15

In one embodiment the method targets conserved hMPV nucleotide sequences for diagnostic purposes and variable hMPV sequences for epidemiological typing purposes. Nucleotide sequences were selected either from a number of hMPV viral sequences obtained in the inventor's laboratory or from public databases (GenBank accession number AF371337).

20

Our proprietary DNA fragments and oligonucleotides (a non-restrictive list of primers and probes) are listed in the following tables.

25

It will be understood by those skilled in the art that sequences that can selectively hybridize to the sequences of the present invention are also comprised in the scope of the invention. By selectively hybridizing it is meant that a nucleic acid molecule binds to a given target in a manner that is detectable in a different manner from non-target

15

sequence under moderate, or more preferably under high, stringency conditions of *hybridization*. "Complementary" or "target" nucleic acid sequences refer to those nucleic acid sequences which selectively hybridize to a nucleic acid molecule. Proper annealing conditions depend, for example, upon a nucleic acid molecule's length, base composition, and the number of mismatches and their position on the molecule, and must often be determined empirically. For discussions of nucleic acid molecule (probe) design and annealing conditions, see, for example, Sambrook et al. 1989 (Sambrook, et al., *Molecular Cloning: A Laboratory Manual*, 2d Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989)) or Ausubel et al. 1987 (Ausubel, F., et al., *Current Protocols in Molecular Biology*, New York (1987)).

The detection of the viruses including the hMPV is conducted through compositions of matters such as diagnostic kits comprising the amplification primers or probes of this invention.

15

In the methods and kits of the present invention, probes and primers are not limited to nucleic acids and may include, but are not restricted to, analogs of nucleotides. The diagnostic reagents constituted by the probes and the primers may be present in any suitable form (bound to a solid support, liquid, lyophilized, etc.) for detection and/or amplification of nucleic acid sequences of the viruses.

20

In the methods and kits of the present invention, amplification reactions may include but are not restricted to: a) polymerase chain reaction (PCR), b) ligase chain reaction (LCR), c) nucleic acid sequence-based amplification (NASBA), d) self-sustained sequence replication (3SR), e) strand displacement amplification (SDA), f) branched DNA signal amplification (bDNA), g) transcription-mediated amplification (TMA), h) cycling probe technology (CPT), i) nested PCR, j) multiplex PCR, k) solid phase amplification (SPA), l) nuclease dependent signal amplification (NDSA), m) rolling circle amplification technology (RCA), n) anchored strand displacement amplification, o) solid-phase (immobilized) rolling circle amplification.

30

In the methods and kits of the present invention, detection of the nucleic acids of target genes may include real-time or post-amplification technologies. These detection technologies can include, but are not limited to, the use of intercalating agents such as SYBR green, fluorescence resonance energy transfer (FRET)-based methods such as adjacent hybridization of probes (including probe-probe and probe-primer methods), *TaqMan* probe, molecular beacon probe, Scorpion probe, nanoparticle probe and Amplifluor probe. Other detection methods include target gene nucleic acids detection via immunological methods, solid phase hybridization methods on filters, chips or any other solid support. In these systems, the hybridization can be monitored by fluorescence, chemiluminescence, potentiometry, mass spectrometry, plasmon resonance, polarimetry, colorimetry, flow cytometry or scanometry. Nucleotide sequencing, including sequencing by dideoxy termination or sequencing by hybridization (e.g. sequencing using a DNA chip) represents another method to detect and characterize the nucleic acids of target genes.

Amplification of hMPV sequences

In one aspect of the invention there is provided methods and compositions for detecting hMPV in a sample.

In a preferred embodiment, a reverse-transcription (RT)-PCR protocol is used for nucleic acid amplification. The single-stranded viral RNA is converted to complementary DNA using an enzyme possessing a reverse transcriptase activity and a specific hMPV primer. Alternatively, random hexamer primers can be substituted to the specific hMPV primer. In a preferred embodiment, viral RNA was prealably extracted from 200 μ l of naso-pharyngeal aspirates using the QIAamp Viral RNA Mini Kit (QIAGEN). Complementary DNA was synthesized using 10 μ l of eluted RNA, 0.75 μ M of a specific hMPV primer (Table 2, sequences ID Nos. 91, 97, 100, 102, 109, 112), and the Omniscript Reverse Transcriptase Kit (QIAGEN, Mississauga, ON, Canada) following the manufacturer's recommendations.

- For DNA amplification by the widely used PCR method, primer pairs were derived from our proprietary DNA fragments or from public database sequences (Table 1). During DNA amplification by PCR, two oligonucleotide primers binding respectively to each strand of the heat-denatured target DNA from the microbial genome are used to amplify exponentially *in vitro* the target DNA by successive thermal cycles allowing denaturation of the DNA, annealing of the primers and synthesis of new targets at each cycle (Persing, 1993, Diagnostic Molecular Microbiology: Principles and Applications, American Society for Microbiology, Washington, DC. 88-109).
- 10 In a preferred embodiment, complementary DNA was amplified using a real-time PCR procedure with the LC Faststart DNA Master SYBR Green 1 Kit (Roche Diagnostics, Laval, QC, Canada) or the SYBR Green TAQ ReadyMix for quantitative PCR capillary formulation (Sigma-Aldrich, Oakville, ON) in a LightCycler instrument (Roche Diagnostics). Each reaction had a total volume of 20 μ l including 2
- 15 μ l of RT mixture and 18 μ l of a reaction mixture containing 4 mM $MgCl_2$, 2 μ l of Faststart DNA SYBR Green Master Mix or the SYBR Green TAQ ReadyMix for quantitative PCR capillary formulation, 3% DMSO, and 0.5 μ M of each hMPV primer (see Tables 2 and 4 for sequence ID Nos. and specific combinations of primers for amplification, respectively). Cycling conditions typically included an initial
- 20 denaturation step of 10 min. at 94°C, followed by 50 cycles of 15 s at 94°C, 5 s at 54°C, and 30 s at 72°C. However, the cycling conditions could slightly vary according to the hMPV gene to amplify.
- The person skilled in the art of nucleic acid and/or signal amplification knows the
- 25 existence of other rapid amplification procedures such as ligase chain reaction (LCR), reverse transcriptase PCR (RT-PCR), transcription-mediated amplification (TMA), self-sustained sequence replication (3SR), nucleic acid sequence-based amplification (NASBA), strand displacement amplification (SDA), branched DNA (bDNA), cycling probe technology (CPT), solid phase amplification (SPA), rolling circle
- 30 amplification technology (RCA), solid phase RCA, anchored SDA and nuclease dependent signal amplification (NDSA) (Persing, 1993, Diagnostic Molecular

Microbiology: Principles and Applications, American Society for Microbiology, Washington, DC. 88-109; Lee, 1997, Nucleic Acid Amplification Technologies: Applications to Disease Diagnosis, Eaton Publishing, Boston, MA. 61-125; Westin et al., 2000, Nat. Biotechnol. 18:199-204). The scope of this invention is not limited to the use of amplification by PCR, but rather includes the use of any nucleic acid amplification method or any other procedure which may be used to increase the sensitivity and/or the rapidity of nucleic acid-based diagnostic tests. The scope of the present invention also covers the use of any nucleic acid and/or signal amplification and detection technology including real-time or post-amplification detection technologies, any amplification technology combined with detection, any hybridization nucleic acid chips or array technologies, any amplification chips or combination of amplification and hybridization chip technologies. Detection and identification by any nucleotide sequencing method is also under the scope of the present invention.

15

Any oligonucleotide, useful for diagnosis, and which are derived from hMPV sequences and used with any nucleic acid amplification and/or hybridization technologies are also under the scope of this invention.

20 Detection of amplification products

Classically, the detection of PCR amplification products is performed by standard ethidium bromide-stained agarose gel electrophoresis. Using this approach, primers specific for a nucleotide sequence from either the nucleocapsid (N), phosphoprotein (P), matrix (M), fusion (F), polymerase (L), glycoprotein (G), genes generated amplicons of various lengths depending on the selected primers pairs (Table 4). It is however clear that other detection methods of amplified products may be faster, more sensitive, and more practical. Amplicon detection may also be performed by solid support or liquid hybridization using strain-specific internal DNA probes hybridizing to an amplification product. Such probes may be generated from sequences from our repertory (Table 1) and designed to specifically hybridize to DNA amplification

products which are objects of the present invention. Amplicons can also be characterized by DNA sequencing. Alternatively, a rapid detection method developed with real-time PCR assays consists of determining the specific melting temperature of amplicons at the end of the amplification reaction.

5

In a preferred embodiment, detection of hMPV amplicons was characterized using the melting curve analysis feature of a real-time PCR instrument. Briefly, following the last amplification cycle on a LightCycler instrument, the internal temperature was rapidly increased to 94°C then decreased to 60°C for 30 seconds, followed by slowly increasing to 94°C at a rate of 0.1°C per second, with continuous fluorescence lecture. Using this procedure, the specific melting temperature obtained with the specific amplicons produced by the pairs of primers specific for the N (SEQ ID No 92+94), M (SEQ ID No 100+101), F (SEQ ID 97+98), P (SEQ ID No 102 +103) and L (SEQ ID No 112 + 113) gene sequences was found to be 82.63°C \pm 0.87°C, 82.75°C \pm 0.80°C, 10 83.29°C \pm 0.45°C, 80.48°C \pm 0.46°C, and 77.99 \pm 0.33°C, respectively (Table 5 and see also Figure 1 for example of the melting temperature obtained for different hMPV strains with the N primers). Alternatively, we also designed specific adjacent and TaqMan fluorescent probes for the various hMPV gene products (N, M, F, G, P and L) that can be used for real-time detection and quantification of amplicons (Table 3). 15 Here, quantification of hMPV gene products is achieved through fluorescence resonance energy transfer (FRET) when the two probes hybridize nearby on a complementary DNA sequence. Other types of detection methods including the use of TaqMan or molecular beacon probes specific for the hMPV sequences described above are also under the scope of this invention.

25

Typing of hMPV

Previous studies have shown that two major genotypes of hMPV circulate in North America and Europe (van den Hoogen et al., 2001, Nat. Med. 7:719-724; Boivin et 30 al., 2002, J. Infect. Dis. 186:1330-1334). We also designed a rapid molecular typing method for epidemiologic studies based on amplification of a portion of the F (fusion)

glycoprotein (primer sequence ID Nos. 97 and 98, Tables 2 and 4) followed by DNA sequencing or digestion with restriction enzymes (ApaI I and Avr II). Table 6 summarizes the size of the F fragments obtained for different hMPV isolates following enzymatic digestion and the corresponding genotype (see also Figure 2 for an example of the band pattern following electrophoresis on an agarose gel). Alternative typing methods based on the use of type-specific hMPV F primers and/or probes as well as DNA sequencing of amplified products are also within the scope of this invention. hMPV subtyping using similar methodologies for the other surface glycoprotein (i.e. the G gene) may also be used.

10

A method for detection of a plurality of potential hMPV strains having different genotypes may be conducted in separate reactions and physical enclosures, one type at the time. Alternatively, it could be conducted simultaneously for different types in separate physical enclosures, or in the same physical enclosures. In the latter scenario a multiplex PCR reaction could be conducted which would require that the oligonucleotides are all capable of annealing with a target region under common conditions. Since many probes or primers are specific for a determined genotype, typing an hMPV strain is under the scope of the present invention. When a mixture of oligonucleotides annealing together with more than one type of hMPV is used in a single physical enclosure or container, different detection labels would be used to distinguish one type from another.

20

The diagnostic kits, primers and/or probes mentioned above can be used to detect and/or identify hMPV, whether said diagnostic kits, primers and probes are used for *in vitro* or *in situ* applications. The said samples may include but are not limited to: any clinical sample, any environmental sample, any viral culture, any tissue, or any cell line.

25

It is also an object of the present invention that said diagnostic kits, primers and/or probes can be used alone or in combination with any other assay suitable to detect and/or identify other microorganisms (i.e. viruses, bacteria, fungi, and parasites) including but not limited to: any assay based on nucleic acids detection, any

30

immunoassay, any enzymatic assay, any biochemical assay, any lysotypic assay, any serological assay, any culture on specific cell lines, and any infectivity assay on animals.

- 5 In the methods and kits described herein below, the oligonucleotide probes and amplification primers have been derived from larger sequences (i.e. DNA fragments of at least 100 base pairs). All DNA sequences have been obtained either from our proprietary sequences (Table 1) or from SEQ ID No. 1 from public databases.
- 10 It is clear to the individual skilled in the art that oligonucleotide sequences other than those described in the present invention and which are appropriate for detection and/or identification of hMPV may also be derived from the proprietary fragment sequences or selected public database sequences. For example, the oligonucleotide primers or probes may be shorter but of a length of at least 10 nucleotides or longer
- 15 than the ones chosen; they may also be selected anywhere else in the proprietary DNA fragments or in the sequences selected from public databases; they may also be variants of the same oligonucleotide. If the target DNA or a variant thereof hybridizes to a given oligonucleotide, or if the target DNA or a variant thereof can be amplified by a given oligonucleotide PCR primer pair, the converse is also true : a given target
- 20 DNA may hybridize to a variant oligonucleotide probe or be amplified by a variant oligonucleotide PCR primer. Alternatively, the oligonucleotides may be designed from said DNA fragment sequences for use in amplification methods other than PCR. Consequently, the core of this invention is the detection and/or identification of hMPV by targeting DNA sequences which are used as a source of specific and
- 25 ubiquitous oligonucleotide probes and/or amplification primers. Although the selection and evaluation of oligonucleotides suitable for diagnostic purposes require much effort, it is quite possible for the individual skilled in the art to derive, from the selected DNA fragments, oligonucleotides other than the ones listed in Tables 2 and 3 which are suitable for diagnostic purposes. When a proprietary fragment or a public
- 30 database sequence is selected for its specificity and ubiquity (i.e. ability to detect all

hMPV strains), it increases the probability that subsets thereof will also be specific and ubiquitous.

5 The proprietary DNA fragments have been obtained as a repertory of sequences created by amplifying hMPV nucleic acids with proprietary primers. These primers and the repertory of nucleic acids as well as the repertory of nucleotide sequences are further objects of this invention (Tables 1-3).

10 As part of the design rules, all oligonucleotides were evaluated for their suitability for hybridization or PCR amplification by computer analysis using standard programs (i.e. the GCG Wisconsin package programs, the primer analysis software Oligo™ 6 and MFOLD 3.0). The potential suitability of the PCR primer pairs was also evaluated prior to their synthesis by verifying the absence of unwanted features such as long stretches of the same nucleotide and a high proportion of G or C residues at
15 the 3' end (Persing, 1993, Diagnostic Molecular Microbiology: Principles and Applications, American Society for Microbiology, Washington, DC. 88-109). Oligonucleotide amplification primers were synthesized using an automated DNA synthesizer (Applied Biosystems).

20 The oligonucleotide sequence of primers or probes may be derived from either strand of the duplex DNA. The primers or probes may consist of the bases A, G, C, or T or analogs and they may be degenerated at one or more chosen nucleotide position(s) (Nichols et al., 1994, Nature. 369:492-493). Primers and probes may also consist of nucleotide analogs such as Locked Nucleic Acids (LNA) (Koskhin et al., 1998, Tetrahedron Lett. 54:3607-3630), and Peptide Nucleic Acids (PNA) (Egholm et al.,
25 1993, Nature. 365:566-568). The primers or probes may be of any suitable length and may be selected anywhere within the DNA sequences from proprietary fragments, or from selected database sequences which are suitable for the detection of hMPV.

30 Variants for a given target microbial gene are naturally occurring and are attributable to sequence variation within that gene. For example, different strains of the same viral

species may have a single or more nucleotide variation(s) at the oligonucleotide hybridization site. The person skilled in the art is well aware of the existence of variant nucleic acids and/or sequences for a specific gene and that the frequency of sequence variations depends on the selective pressure during evolution on a given gene product. The detection of a variant sequence for a region between two PCR primers may be demonstrated by sequencing the amplification product. In order to show the presence of sequence variations at the primer hybridization site, one has to amplify a larger DNA target with PCR primers outside that hybridization site. Sequencing of this larger fragment will allow the detection of sequence variation at this primer hybridization site. A similar strategy may be applied to show variations at the hybridization site of a probe. Insofar as the divergence of the target nucleic acids and/or sequences or a part thereof does not affect significantly the sensitivity and/or specificity and/or ubiquity of the amplification primers or probes, variant microbial DNA is under the scope of this invention. Variants of the selected primers or probes may also be used to amplify or hybridize to a variant target DNA.

In an other aspect of the invention there is also provided newly isolated human metapneumoviruses deposited with International Depository Authority of Canada on December 11 2003 and bearing IDAC numbers 111203-01 and 111203-02 (also referred herein as CAN 97-83 and CAN 98-75 respectively).

In a further aspect of the invention the diagnostic method is designed at performing simultaneous detection of nucleic acids from a variety of respiratory viruses using specific primers and/or probes. The method is aimed at detecting and/or quantifying conserved viral sequences from respiratory viruses for diagnostic purposes. Target nucleotide sequences were selected public databases and from viral strain sequences obtained in the inventor's laboratory.

The specific respiratory viral pathogens targeted by the diagnostic assays include all genotypes of influenza A and B viruses, hRSV, hMPV, PIV, adenoviruses, rhinoviruses, and enteroviruses. Other less common (coronaviruses, reoviruses) and

yet to discover respiratory viruses are also targets under the scope of the present invention.

The specific combination of oligonucleotides (primers and/or probes) in a multiplex format is also another object of this invention.

Composition of matters such as diagnostic kits comprising amplification primers and/or probes for the detection of respiratory viruses are also objects of the present invention.

10

Amplification of viral sequences

In a preferred embodiment, a PCR protocol is used for nucleic acid amplification. Multiplex assay, aimed at amplifying a plurality of respiratory viruses in the same physical enclosure, is an object of the present invention.

15

We aim at developing DNA-based tests or diagnostic kits to detect and identify most respiratory viruses in a limited number of amplification reactions using specific primers (Table 10) and/or probes (Table 11). Although some of the primer sequences used for amplification of the various respiratory viruses, with the exception of hMPV (SEQ. ID. Nos. 95 and 96 or 112 and 114), PIV-1 (SEQ. ID. Nos. 147 and 148), PIV-3 (SEQ. ID. Nos. 151 and 152), and adenovirus (SEQ. ID. Nos. 153), have been described previously by others (Fouchier et al., 2000, J. Clin. Microbiol. 38:4096-4101 for influenza A virus / SEQ. ID. Nos. 139 and 140; Li et al., 2001, J. Clin. Microbiol. 39:696-704 for influenza B virus / SEQ. ID. Nos. 141 and 142; Mazulli et al., 1999, J. Infect. Dis. 180:1686-1689 for hRSV / SEQ. ID. Nos. 143 and 144; Osioy et al., 1998, J. Clin. Microbiol. 36: 3149-3154 for PIV-1, PIV-3, and adenovirus / SEQ. ID. Nos. 145 and 146, 149 and 150, and 154 and 155, respectively; Atmar et al., 1993, J. Clin. Microbiol. 31: 2544-2546 for rhinovirus and enterovirus / SEQ. ID. Nos. 160 and 161) and that one influenza A primer (SEQ. ID. No. 139) is

20

25

30

almost identical to the one described in another patent (U.S. patent number 6,015,664), the object of the present invention is to combine many sets of primers and/or probes in the same physical enclosure (multiplex format).

5 Briefly, viral RNA was extracted from 200 µl of naso-pharyngeal aspirates or other respiratory tract samples using the QIAamp Viral RNA Mini kit (QIAGEN, Mississauga, ON, Canada). Complementary DNA (cDNA) was then synthesized using 10 µl of the RNA preparation, 0.75 µM of random hexamer primers (Amersham Pharmacia Biotech, Baie d'Urfé, QC, Canada), 300 copies of an internal control
10 template, and the Omniscript Reverse Transcriptase Kit (QIAGEN, Mississauga, ON, Canada) following the manufacturer's instructions. The internal control template consisted of a 554 or 558 bp (depending on the multiplex assay) transcribed region of an herpes simplex virus type 2 DNA polymerase region flanked by either influenza B or rhinovirus/enterovirus complementary primer sequences (depending on the
15 multiplex assay) cloned in the pDrive plasmid (QIAGEN).

For DNA amplification by the widely used PCR method, primer pairs were mostly derived from public database sequences (Table 10). During DNA amplification by PCR, two oligonucleotide primers binding respectively to each strand of the heat-
20 denatured target DNA from the viral genome are used to amplify exponentially *in vitro* the target DNA by successive thermal cycles allowing denaturation of the DNA, annealing of the primers and synthesis of new targets at each cycle (Persing, 1993, Diagnosis Molecular Microbiology: Principles and Applications, American Society for Microbiology, Washington, D.C., 88-109).

25

In a preferred embodiment, cDNA was amplified using a real-time PCR procedure with the LC Faststart DNA Master SYBR Green 1 Kit (Roche Diagnostics, Laval, QC, Canada) or the SYBR Green TAQ ReadyMix for quantitative PCR capillary formulation (Sigma-Aldrich, Oakville, ON) in a LightCycler instrument (Roche
30 Diagnostics). Each reaction had a total volume of 20 µl including 2 µl of cDNA and 18 µl of a reaction mixture containing 4 mM MgCl₂, 2 µl of LC Faststart DNA SYBR

Green 1 Master Mix or the SYBR Green TAQ ReadyMix for quantitative PCR capillary formulation, 3% DMSO, and 0.3-1.0 μ M of each viral primer (see Tables 10, 12, and 13 for primer sequence ID NOs., length of amplicons, and specific combination of primers, respectively). Cycling conditions typically included an initial
5 denaturation step of 10 min at 94°C, followed by 50 cycles of 15 s at 94°C, 5 s at 58°C, and 25 s at 72°C. However, the cycling conditions could vary slightly according to the multiplex PCR assay.

In a preferred embodiment, two real-time multiplex PCR assays were used to amplify
10 and detect the panel of common respiratory viruses (Table 13). The respiratory-1 multiplex assay combines 4 sets of primers for amplification of influenza A and B viruses, hRSV, hMPV, and an internal control template. The respiratory-2 multiplex assay comprises 4 other sets of primers for amplification of PIV-1, PIV-3, adenoviruses, rhinoviruses/enteroviruses, and an internal control template. The use of
15 any other combinations of the same or similar primer sequences in two or more than two multiplex assays for detection of common respiratory viral pathogens is also under the scope of this invention.

The person skilled in the art of nucleic acid amplification knows the existence of other
20 rapid amplification procedures such as ligase chain reaction (LCR), reverse transcriptase PCR (RT-PCR), solid phase PCR, transcription-mediated amplification (TMA), self-sustained sequence replication (3SR), nucleic acid sequence-based amplification (NASBA), strand displacement amplification (SDA), branched DNA (bDNA), cycling probe technology (CPT), solid phase amplification (SPA), rolling
25 circle amplification technology (RCA), solid phase RCA, anchored SDA, and nuclease dependent signal amplification (NDSA) (Persing, 1993, Diagnosis Molecular Microbiology: Principles and Applications, American Society for Microbiology, Washington, D.C., 88-109; Lee, 1997, Nucleic Acid Amplification Technologies: Application to Disease Diagnosis, Eaton Publishing, Boston, MA., 61-125; Westin et
30 al., 2000, Nat. Biotechnol.18:199-204). The scope of this invention is not limited to the use of amplification by PCR, but rather includes the use of any nucleic acid

amplification method or any other procedure which may be used to increase the sensitivity and/or the rapidity of nucleic acid-based diagnostic tests. The scope of the present invention also covers the use of any nucleic acids amplification and detection technology including real-time or post-amplification detection technologies, any
5 amplification technology combined with detection, any hybridization nucleic acid chips or array technologies, any amplification chips or combination of amplification and hybridization chip technologies. Detection and identification by any nucleotide sequencing method is also under the scope of the present invention.

10 Detection of amplification products

Classically, the detection of PCR amplification products is performed by standard ethidium bromide-stained agarose gel electrophoresis. Using this approach, the amplicons may be discriminated based on their size. In the present invention, the
15 length of the different amplicons varies from 84 to 929 bp (Table 12). It is however clear that other detection methods of amplified products may be faster, more sensitive, and more practical. Amplicon detection may also be performed by solid support or liquid hybridization using strain-specific, internal DNA probes hybridizing to an amplification product. Such probes may be generated from sequences designed to
20 specifically hybridize to DNA amplification products which are objects of the present invention. Amplicons can be also characterized by DNA sequencing. Alternatively, a rapid detection method developed with real-time PCR assays consist of determining the specific melting temperature of amplicons at the end of the amplification reaction.

25 The detection of viral amplicons was first characterized using the melting curve analysis feature of a real-time PCR instrument. Using this procedure, the different viral targets amplified in each of the multiplex PCR assays could be differentiated by their specific melting temperature (Table 13 and Fig. 7 and 8). Alternatively, specific
30 fluorescent probes (Table 11) for each viral target can be used for real-time detection and quantification of amplicons in a single amplification/detection assay. Real-time quantification of viral products can be performed through a variety of fluorescence-

based technologies such as adjacent probes, Taqman probes, and molecular beacons. Alternatively, these probes may be used in a separate post-amplification step.

5 The diagnostic kits, primers and probes mentioned above can be used to detect and/or identify respiratory viruses, whether said diagnostic kits, primers and/or probes are used for *in vitro* or *in situ* applications. The said samples may include but are not limited to: any clinical sample, any environmental sample, any viral culture, any tissue, and any cell line.

10 It is also an object of the present invention that said diagnostic kits, primers and/or probes can be used alone or in combination with any other assay suitable to detect and/or identify and/or quantify microorganisms, including but not limited to: any assay based on nucleic acids detection, any immunoassay, any enzymatic assay, any biochemical assay, any serological assay, any culture on specific cell lines, and any
15 infectivity assay on animals.

In the methods and kits described herein, the oligonucleotide probes and amplification primers have been derived from larger sequences (i.e. DNA fragments of at least 100 base pairs). It is clear to the individual skilled in the art that oligonucleotide sequences
20 other than those described in the present invention and which are appropriate for detection and/or identification of any respiratory viruses may also be derived from those selected in the present invention. For example, the oligonucleotide primers or probes may be shorter but of a length of at least 10 nucleotides or longer than the ones chosen; they may also be variants of the same oligonucleotide. If the target DNA or a
25 variant thereof hybridizes to a given oligonucleotide, or if the target DNA or a variant thereof can be amplified by a given oligonucleotide PCR primer pair, the converse is also true; a given target DNA may hybridize to a variant oligonucleotide probe or be amplified by variant oligonucleotide PCR primers. Alternatively, the oligonucleotides may be designed for use in amplification methods other than PCR. Consequently, one
30 aspect of the present invention is the simultaneous detection and/or identification of various respiratory viruses by targeting nucleic acid sequences which are used as a

source of specific and ubiquitous oligonucleotide probes and/or amplification primers. Although the selection and evaluation of oligonucleotides suitable for diagnostic purposes require much effort, it is quite possible for the individual skilled in the art to derive, from the selected oligonucleotides (listed in Tables 10 and 11), other
5 oligonucleotides which are suitable for diagnostic purposes.

Thus, the specific primers and/or probes selected for amplification and detection of respiratory viruses and their specific combination in multiplex assays are objects of this invention (Tables 10-13).

10

EXAMPLES:

Example 1: Evaluation of different primers for hMPV detection

15

An evaluation of the sensitivity of different hMPV primer sets in a real-time PCR assay was performed using 20 positive hMPV cultures grown in LLC-MK2 cells and 10 naso-pharyngeal aspirate specimens. These samples were collected in the Québec City area (QC, Canada) over a period of 3 years (2000-2002). Viral RNA was
20 preably extracted from 200 µl of viral culture supernatants or naso-pharyngeal aspirates using the QIAamp Viral RNA Mini Kit (QIAGEN). Complementary DNA was synthesized using 10 µl of eluted RNA, 0.75 µM of a specific hMPV primer (Table 2, sequences ID Nos. 91, 97, 100, 102, 112), and the Omniscript Reverse Transcriptase Kit (QIAGEN, Mississauga, ON, Canada) following the manufacturer's
25 recommendations. Complementary DNA was amplified using a real-time PCR procedure with the LC Faststart DNA Master SYBR Green 1 Kit (Roche Diagnostics, Laval, QC, Canada) in a LightCycler instrument (Roche Diagnostics). Each reaction had a total volume of 20 µl including 2 µl of RT mixture and 18 µl of a reaction mixture containing 4 mM MgCl₂, 2 µl of Faststart DNA SYBR Green Master Mix,
30 3% DMSO, and 0.5 µM of each hMPV primer (Table 4: sequence ID Nos.: 92 and 94; 100 and 101; 97 and 98; 102 and 103; and 112 and 113, for the nucleoprotein (N),

30

matrix (M), fusion (F), phosphoprotein (P), and polymerase (L) genes respectively). Cycling conditions typically included an initial denaturation step of 10 min. at 94°C, followed by 50 cycles of 15 s at 94°C, 5 s at 54°C, and 30 s at 72°C. However, the cycling conditions could slightly vary according to the hMPV gene to amplify.

- 5 Detection of hMPV amplicons was characterized using the melting curve analysis feature of a real-time PCR instrument. Briefly, following the last amplification cycle on a LightCycler instrument, the internal temperature was rapidly increased to 94°C then decreased to 60°C for 30 seconds, followed by slowly increasing to 94°C at a rate of 0.1°C per second, with continuous fluorescence lecture.

10

Using this procedure, the specific melting temperature obtained with the hMPV amplicons produced by the primers specific for target genes coding for N, M, F, P and L proteins was found to be $82.63^{\circ}\text{C} \pm 0.87^{\circ}\text{C}$, $82.75^{\circ}\text{C} \pm 0.80^{\circ}\text{C}$, $83.29^{\circ}\text{C} \pm 0.45^{\circ}\text{C}$, $80.48^{\circ}\text{C} \pm 0.46^{\circ}\text{C}$, and $77.99 \pm 0.33^{\circ}\text{C}$, respectively. As shown in Table 5, a real-time
15 PCR assay using primers complementary to the N gene successfully amplified RNA from all 20 cultures and 10 clinical specimens. In contrast, hMPV primers specific for the M, F, P, and L genes had sensitivities of only 70%, 63.3%, 50%, and 89.7% respectively. Thus, primers aimed at amplifying the hMPV N gene appear to target more conserved regions of the hMPV genome and, consequently, were selected for
20 further detailed evaluation (see example 2).

Example 2: Validation of a real-time PCR assay for the hMPV nucleoprotein (N) gene in a pediatric population

- 25 An hMPV N plasmid was constructed by subcloning the amplified hMPV N region in the plasmid pDrive (QIAGEN, Mississauga, ON, Canada). The new plasmid was transcribed using the RNA Transcription Kit (Stratagene, Vancouver, BC, Canada) for sensitivity analysis. Using the previously described RT procedure (N primer, sequence ID No. 91) and real-time PCR protocol (N primers, sequence ID Nos. 92
30 and 94) reported in example 1, the sensitivity of the assay was estimated at 100 copies per reaction with a specific melting temperature of 82 °C. The assay was found to be

specific with no amplification signal observed when viral cultures positive for the human respiratory syncytial virus, the parainfluenza viruses, the influenza viruses A and B, and the adenoviruses were tested. The real-time PCR assay for the hMPV N gene was subsequently validated in a prospective case-control study in children below the age of 3 years hospitalized at Laval University Hospital Center (CHUQ-CHUL) in Québec City, Canada, during the winter season of 2001-02. Cases consisted of children hospitalized for a respiratory syndrome whereas controls consisted of children hospitalized during the same period for a surgery with no respiratory symptoms. At admission, a nasopharyngeal aspirate was collected for viral antigen tests, viral cultures, and RT-PCR studies for influenza A and B viruses, the human respiratory syncytial virus (hRSV), and the hMPV N gene.

No virus was detected in any of the samples from the 51 control children. Among the 208 cases tested by real-time PCR for hMPV, hRSV, influenza A and B viruses, the positivity rates were 5.8%, 51.0%, 21.6%, and 0%, respectively. Viral culture was positive for hMPV in only 2 cases whereas the real-time hMPV PCR assay for the N gene was positive for 12 cases including the 2 positive by viral culture. All positive hMPV PCR results for the N gene were confirmed by a second PCR assay targeting the hMPV fusion (F) gene and by the use of DNA sequencing which indicated the presence of multiple hMPV strains clustering in the two previously-reported F genotypes. Thus, the real-time PCR assay describes in this invention appears to be much more sensitive than conventional viral culture for the detection of hMPV in clinical samples.

Example 3: Typing of hMPV clinical strains using restriction enzyme analysis

We designed a rapid molecular typing method for hMPV epidemiological studies based on amplification of a portion of the fusion (F) gene which is then digested with specific restriction enzymes. Briefly, a 759-bp fragment of the hMPV F gene was amplified by a real-time PCR procedure as described in example 1 using specific primers (sequence ID Nos. 97 and 98). After PCR amplification, two aliquots (10 uL) of the PCR product were digested during 2 hours at 37°C with 10 units of ApaI I and 4 units of Avr II (New England Biolabs, Mississauga, ON, Canada) according to the manufacturer's recommendations. Digested products were then loaded on an 1% agarose gel for electrophoresis.

Table 6 summarizes the size of the F fragments obtained for different hMPV isolates following enzymatic digestion and the corresponding genotype as defined by DNA sequencing and phylogenetic studies. In brief, all hMPV isolates belonging to the genotype F-I were digested by ApaI I (fragments of 532 and 227 bp) but not by Avr II whereas those belonging to the genotype F-II were digested by Avr II (fragments of 447 and 312 bp) but not by ApaI I (see Figure 2 for an example of the band pattern following electrophoresis on an agarose gel).

Example 4 : A prospective case-control study for defining the role of respiratory viruses in children hospitalized for acute respiratory tract infections**Summary**

The human metapneumovirus (hMPV) is a new paramyxovirus recently isolated from young children with respiratory syndromes. The objectives of this study were to estimate the relative contribution of hMPV in children's hospitalization for acute respiratory tract infections (ARTI) and to define its clinical presentation and seasonal pattern.

We evaluated the percentage of hospitalizations for ARTI in children aged 0-3 years attribute to hMPV and other respiratory viruses in a prospective case-control study during the winter/spring seasons of 2002. We used multiplex real-time PCR assays and other conventional diagnostic methods to detect hMPV, the human respiratory syncytial virus (hRSV), and the influenza viruses in nasopharyngeal aspirates of children.

hMPV was detected in 12 (5.8%) of the 208 children hospitalized for ARTI as compared to 118 (56.7%) for hRSV and 49 (23.6%) for influenza A. In contrast, none of the 51 controls harbored any of the respiratory viruses. Most hRSV and influenza infections occurred in January and February whereas the peak hMPV activity was in March and April. The peak age for hospitalizations for hRSV and hMPV infections was < 3 months and 3-5 months, respectively. Diagnoses of bronchiolitis and pneumonia were made in respectively 67% and 17% of hMPV-infected children compared to 84% and 25% for those with hRSV infection. None of the hMPV-infected children was admitted to the intensive care unit compared to 15% for those with hRSV or influenza A infections.

hMPV causes significant morbidity in young children and its clinical presentation is similar although less severe than that of hRSV.

Introduction

The human metapneumovirus (hMPV) is the first human member of the new *Metapneumovirus* genus within the *Paramyxoviridae* family (van den Hoogen BG, de Jong JC, Groen J, et al.. Nat Med 2001;7:719-24; van den Hoogen BG et al. Virology 2002;295:119-32.) The human respiratory syncytial virus (hRSV) belongs to a separate genus within the same family (Taxonomy V. Seventh Report of the International Committee on Taxonomy of Viruses. Academic, San Diego, 2000.).

hMPV has been recently identified in nasopharyngeal aspirates of children and adults suffering from a range of respiratory tract infections in various parts of the world (van

den Hoogen BG, de Jong JC, Groen J, et al. Nat Med 2001;7:719-24; Nissen MD, et al. Med J Aust 2002;176:188; Peret TC, Boivin G, Li Y, et al. J Infect Dis 2002;185:1660-3; Stockton J, et al. Emerg Infect Dis 2002;8:897-901). The clinical syndrome of the infected children encompasses mild respiratory problems to bronchiolitis and pneumonitis (van den Hoogen BG, de Jong JC, Groen J, et al. Nat Med 2001;7:719-24; Pelletier G, et al. Emerg Infect Dis 2002;8:976-8; Boivin G, Abed Y, Pelletier G, et al. J Infect Dis 2002;186:1330-4).

Using reverse-transcription polymerase chain reaction (RT-PCR), the rate of hMPV detection in nasopharyngeal aspirates (NPA) of pediatric patients with unexplained ARTI varied between 1.5 and 10% (van den Hoogen BG, de Jong JC, Groen J, et al. Nat Med 2001;7:719-24; Nissen MD, et al. Med J Aust 2002;176:188). These retrospective studies are small, excluded patients who tested positive for other viruses, only superficially describe the clinical features of the disease and lack morbidity/mortality data. In absence of a control group, these studies cannot differentiate if hMPV is a colonizing or a pathogenic virus. More recently, Stockton et al. identified hMPV RNA in 2.2% of 405 specimens from patients with influenza-like illnesses who consulted general practitioners in England although few swabs were collected from children < 5 years (Stockton J, et al. Emerg Infect Dis 2002;8:897-901).

The objectives of this study were to estimate the relative contribution of hMPV in children's hospitalization for acute respiratory tract infections (ARTI) and to define its clinical presentation and seasonal pattern.

Materials and Methods

Study design. Participants were children aged ≤ 3 years hospitalized between December 15, 2001 and April 20, 2002 at Laval University Hospital Center (CHUQ-CHUL) in Québec City, Canada. Cases were admitted for an ARTI (bronchiolitis, pneumonia, laryngotracheobronchitis, etc...) whereas controls were hospitalized for an elective surgery and had no respiratory symptoms or fever. Children hospitalized twice were counted as two cases. At admission, after signed consent was obtained from their parents, all children had an NPA (1-2 ml) collected and tested for hRSV antigen (TestPack, Abbott Laboratories, Abbott Park, IL). The specimen was frozen at -80°C until subsequent RT-PCR studies. Additionally, viral cultures, direct immunofluorescence staining, and microbiological testing were performed according to the treating physician. A standardized questionnaire was completed at admission by a single research nurse with the parents. At the end of the hospitalization, the children's charts were reviewed to collect clinical and laboratory data. The study was approved by the CHUQ-CHUL research ethics board.

RNA extraction and cDNA synthesis. Viral RNA was extracted from 200 µl of NPA specimens using the QIAamp viral RNA Mini Kit (QIAGEN, Mississauga, ON, Canada). Complementary cDNA was synthesized using 10 µl of eluted RNA and the Omniscript Reverse Transcriptase kit (QIAGEN). Random hexamer primers (Amersham Pharmacia Biotech, Baie d'Urfé, QC, Canada) were used in the RT step of the multiplex respiratory PCR assay whereas a specific primer (5'-TGGGACAAGTGAAAATGTC-3') serves to synthesize hMPV cDNA in a separate PCR assay. An internal control (300 copies) consisting of a 534-bp transcribed region of the pDrive plasmid (QIAGEN) flanked by influenza B complementary primer sequences (see below) was spiked in the RT reaction of the multiplex respiratory PCR assay to verify the presence of PCR inhibitors.

RT-PCR assays and phylogenetic studies. The multiplex respiratory PCR assay was designed to amplify conserved regions of the influenza A (SEQ. ID Nos.139-140) (Fouchier RA, et al. J Clin Microbiol 2000;38:4096-101) and B (SEQ. ID Nos. 141-

142) (Li J, Chen S, Evans DH. J Clin Microbiol 2001;39:696-704) matrix genes as well as the fusion gene of hRSV (SEQ. ID Nos. 143-144) (Mazzulli T, Peret TC, McGeer A, et al. J Infect Dis 1999;180:1686-9).

- 5 Complementary DNA was amplified using a real-time PCR procedure with the LC Faststart DNA Master SYBR Green 1 Kit (Roche Diagnostics, Laval, Québec, Canada) in a LightCycler instrument (Roche Diagnostics). Each reaction had a total volume of 20 µl including 2 µl of cDNA and 18 µl of a reaction mixture containing 2.4 mM MgCl₂, 2 µl of Faststart DNA SYBR Green Master Mix, 3% DMSO, 0.3 mM
- 10 each of influenza A and B primers, and 0.8 mM of hRSV primers. The thermal cycling incubations consisted of an initial denaturation step at 94°C for 10 min, followed by 50 cycles of 15 s at 94°, 5 s at 58°C, and 25 s at 72°C. At the end of each cycle, the fluorescent signal was measured at a wavelength of 530 nm using the LightCycler Fluorimeter. The melting curve analysis program of the LightCycler was
- 15 used to identify specific PCR products of influenza A (T_m: 85°C), influenza B (T_m: 83°C), hRSV (T_m: 79°C), and the internal control (T_m: 92°C). The sensitivity of the multiplex respiratory PCR assay was estimated at 50 copies for each viral target when mixed with 300 copies of the internal control.
- 20 A specific PCR assay was designed for amplification of the hMPV Nucleoprotein (N) gene in the LightCycler instrument. The sequences of the forward (MPV-NCS) and reverse (MPV-NCA) primers were respectively 5'-GAGTCTCAGTACACAATTAA-3' (SEQ ID NO 92) and 5'-GCATTTCGAGAACAACAC-3' (SEQ ID NO 94). The specific cDNA was amplified using conditions similar to those of the multiplex
- 25 respiratory PCR assay except that 0.5 mM of each primer was added to the master mix. Cycling conditions included an initial denaturation step of 10 min at 94°C, followed by 50 cycles of 15 s at 94°C, 5 s at 54°C, and 30 s at 72°C. The melting temperature of the amplified hMPV N fragment was 82°C and the sensitivity of the PCR assay was 100 copies. For phylogenetic studies, nucleotide sequences were
- 30 determined from amplified hMPV F (fusion) gene products then analyzed using the

neighbor joining algorithm and Kimura-2 parameters. (Boivin G, Abed Y, Pelletier G, et al. J Infect Dis 2002;186:1330-4).

hMPV in the general population. To further assess the seasonal distribution, affected age groups and frequency of hMPV, we compared data from the study to those of the general population derived from the viral cultures found positive for hMPV in our regional virology diagnostic laboratory, the only one performing viral cultures for the Québec City area (population approximately 600 000). Respiratory specimens were inoculated in 96-well plates containing ten cell lines (MDCK, LLC-MK2, Hep-2, human foreskin fibroblast, Vero, mink lung, A-549, rhabdomyosarcoma, 293, and HT-29) then incubated for a period of 21 days. A positive cytopathic effect was confirmed by immunofluorescence testing using monoclonal antibodies or by RT-PCR (hMPV).

1.5 Statistical analyses. Proportions were compared by the χ^2 test.

Results

The study population included a total of 208 hospitalized cases with ARTI (including 8 children who were admitted twice) and 51 children who served as controls.

20

Description of the study population and viral etiologies. The age distribution of children with ARTI is presented in Fig. 3: 56% (116) were male and 44% (92) were female. Hospitalization was the highest in infants ≤ 3 months of age and steadily decreased thereafter. Most (90%) children had no underlying medical conditions at admission.

25

All 208 cases had an NPA. The mean delay between the onset of symptoms and collection of NPA was 6 days (median 4 days). This delay did not differ for the different viruses detected. All 208 cases were tested by PCR, 204 had an hRSV

antigen detection test, 100 had a direct examination procedure for other viruses, and 100 had a viral culture. At least one respiratory virus was detected in 164 (79%) cases whereas none was detected in 44. Twelve children (5.8%) were positive for hMPV, 118 (56.7%) for hRSV, 49 (23.6%) for influenza A, and none for influenza B (Table 7). There was no PCR testing for adenoviruses and PIV type 2 but these two viruses were found in 6% and 2%, respectively, of the 100 viral cultures or antigenic assays. Single virus infections occurred in 141 (86%) of the 164 positive cases and mixed infection was present in 23 (14%). Two of the 12 hMPV infections were mixed (hMPV-influenza and hMPV-hRSV). The other combinations were hRSV-influenza A (18 cases), hRSV-adenovirus (2), and influenza A-adenovirus (1).

Among the 208 cases tested by PCR for hMPV, hRSV, influenza A and B viruses, the positivity rates were 5.8%, 51.0%, 21.6%, and 0%, respectively (Table 7). In addition, 16 other cases had one of the four latter respiratory viruses identified only by culture (3 influenza A and one hRSV), only by an antigen detection test (10 hRSV and one influenza A) or by both culture and antigen detection test (1 hRSV). Among the 8 children hospitalized twice, none had the same viral infection at both admissions. The combinations observed were hMPV - hRSV (2), hMPV - no virus (1), hRSV - no virus (2), hRSV - influenza (2), no virus - no virus (1).

The biweekly distribution of cases with respiratory tract viruses is shown in Fig. 4. hRSV and influenza A infections occurred predominantly between January and March, whereas hMPV infections occurred mostly in March and April. The proportion of children with virologically-confirmed respiratory tract infection decreased after February.

Clinical features of cases. The distribution of the age distribution by different viral infections is shown in Fig. 3. While the peak age for hMPV infection was 3-5 months, it was before 3 months for hRSV infection. For influenza A, it spread evenly during the first year of life. The peak age for mixed infection was 6-11 months and decreased thereafter. Gender was distributed evenly with each virus group but more males

(70%) had mixed viral infections. The majority (75% with hMPV, 93% with hRSV, 90% with influenza A virus infection) of the children in different etiological groups had no medical underlying conditions. Three (25%) children with hMPV infection had a cardiac disorder, one having concomitant cardiac, pulmonary, and neurological problems.

Signs and symptoms recorded with the different respiratory viruses were generally similar except for the vomiting which occurs more frequently with hMPV infections ($p = 0.05$) (Table 8). The mean and median duration of hospitalization was similar for hMPV, hRSV and influenza A viruses being respectively 5.5 and 4.5, 5.8 and 5.0, and 4.9 and 4.0 days. Of note, one third of hMPV-infected children were hospitalized more than 7 days. None of the children with hMPV infection was admitted to the intensive care unit (ICU) contrasting with 15% and 16% of children with hRSV and influenza A, respectively. There was no death as part of this study. The duration of the hospitalization in children with no detectable virus was shorter than that in children with single or mixed infection (Kruskal-Wallis Test, $p < .0001$). Two-thirds of the children were given antibiotics during their hospitalization, independently of the etiology of their respiratory disease.

At hospital discharge, a final diagnosis of bronchiolitis was given to 67% of children with hMPV, 84% with hRSV, and 51% with influenza A ($p < 0.001$) (Table 9). Otitis occurred in about half of children with hMPV, hRSV, and influenza A infections. Pneumonitis was less frequently diagnosed in children with hMPV compared to those with hRSV or influenza A (17%, 25%, and 37%, $p=0.22$). Final diagnoses were similar with single and mixed infections.

Controls. There were 51 children in the control group, 29 (56.9%) males and 22 (43.1%) females. The age distribution of the controls was similar to that of the cases (Fig. 3) as was the period of hospital admission (Fig. 4). None of the controls had a virus detected by PCR.

hMPV in the general population. The regional virology laboratory received 1505 respiratory specimens for viral culture between January 1 and June 30, 2002. In total, 36 (including two study participants) or 2.9% were positive for hMPV: 24 (66.6%) in children < 2 years of age, 5 in those 2 to 4 years, 4 in adults 30-49 years, and 3 in those 70 years or older. Most cases (81%) were isolated over a two-month period (from March 23 to May 18) (Fig. 5). When comparing the seasonal distribution of hMPV in hospitalized children (study population) and in the general population, it appears that the study in hospitalized children did not cover the entire hMPV season as it was stopped just after the peak time of hMPV transmission (April 6-20).

Phylogenetic analyses of hMPV strains. The 12 hMPV strains isolated in the prospective study clearly clustered into two F lineages with nine strains belonging to group 1 and three to group 2 (Fig. 6). Seven of the 9 group 1 strains had identical F gene sequences. At the nucleotide level, there was 84-85% similarity between groups versus 98-100% (group 1) and 93-99% (group 2) similarity within groups. There were fewer differences at the amino acid level i.e. 94-96% similarity between groups versus 99-100% (group 1) and 98-99% (group 2) among strains within the same group. Although there was a trend for more recent strains to cluster in group 2, the correlation between genotypes and date of hospitalization was not perfect as two strains detected on the same day (No. 216 and 217) belonged to two different F lineages.

Discussion

Our prospective study has revealed important clinical and epidemiological features related to hMPV. First, our data indicate that hMPV is really a respiratory pathogen. Second, we found that it contributes to ARTI leading to children's hospitalization in proportion similar to adenoviruses or PIV but significantly less than hRSV and influenza viruses. Third, the symptoms and complications associated with hMPV were indistinguishable from those caused by hRSV. Finally, our results suggest that the epidemiology of hMPV infection in children may differ from that of hRSV and

influenza viruses both in terms of the age of first acquisition and in the timing of the seasonal epidemics.

Recent studies by our group (Pelletier G, et al. *Emerg Infect Dis* 2002;8:976-8; Boivin G, Abed Y, Pelletier G, et al. *J Infect Dis* 2002;186:1330-4) and others (van den Hoogen BG, de Jong JC, Groen J, et al. *Nat Med* 2001;7:719-24; Nissen MD et al. *Med J Aust* 2002;176:188; Stockton J, et al. *Emerg Infect Dis* 2002;8:897-901) had suggested that hMPV should be added to the list of human respiratory viral pathogens (Dowell SF, Anderson LJ, Gary HE, Jr., et al. *J Infect Dis* 1996;174:456-62; Treanor JJ. *Respiratory Infections*. In: Richman DD, Whitley, R.J., Hayden, F.G., ed. *Clinical Virology*. Vol. 1. Washington: ASM Press, 2002:7-26).

The absence of hMPV in respiratory tract of our 51 control children, the absence of other respiratory viruses in 83% of the 12 hMPV-infected children and the severity of their symptoms (bronchiolitis and/or pneumonitis) provide further evidence that hMPV is really a pathogenic respiratory virus. The absence of underlying medical conditions in 75% of the hMPV-infected children further demonstrates its pathogenicity. The use of PCR assays was particularly advantageous for hMPV because its growth in culture is fastidious and limited to a few permissive cell lines (Boivin G, Abed Y, Pelletier G, et al. *J Infect Dis* 2002;186:1330-4) and because rapid antigenic detection tests are currently unavailable.

Our study provides for the first an estimate of the proportion of ARTI hospitalizations attributable to hMPV in a pediatric population. During the period ranging from December 15 to April 20 2002, hMPV accounted for 5.8% of all hospitalizations for respiratory tract infections in children aged 0-3 years. This underestimates the real proportion as our hospitalization study stopped before the end of the hMPV season prevailing in the community (Fig. 5). Although we did not perform PCR testing for adenoviruses and PIV, the percentage of hospitalizations caused by hMPV seems similar to that attributable to these two viruses and much smaller than that of hRSV or influenza A.

One of the most important conclusion of our study is that hMPV disease cannot be distinguished on clinical findings from that caused by hRSV and influenza A (Tables 8 and 9) but tended to be somewhat less severe with fewer pneumonia and no admission in the ICU. Nevertheless, hMPV infection was associated with a significant clinical and economical burden as shown by a mean hospital stay of 5.5 days and one-third of hMPV-infected cases being hospitalized for > 7 days.

A small serological study from the Netherlands showed that all children over the age of 5 years had hMPV antibodies suggesting a high level of transmission.¹ Data from our study suggest that morbidity caused by hMPV is greatest in children < 2 years of age as they represented 83% (10/12) of our hospitalized cases and two-thirds of the hMPV isolates recovered in our diagnostic virology laboratory. This suggests that similar to other paramyxoviruses such as hRSV, the morbidity of hMPV in children occurs through primo-infection. In contrast to hRSV which peaked during the first three months of life, hMPV infections peaked at a slightly older age i.e. between the third and fifth month of life. Whether this difference depends on a longer persistence of maternal antibodies or a less efficient transmission mode in the case of hMPV would require additional studies.

During the 4-week period from mid-March to mid-April, hMPV infections clustered (11/12 detected) and accounted for 18.9% of all hospitalizations for ARTI in children. This contrasts with hRSV and influenza A which occurred mostly in January and February (Figure 4). Based on passive surveillance data from our regional virology laboratory, the peak time of hMPV transmission in the community occurred between April 6-20, 2002, and continued beyond the end of our study in hospitalized children (Fig. 5). Year-long active surveillance studies will be required to better assess the seasonal patterns of hMPV transmission.

As described for hRSV (Mazzulli T, Peret TC, McGeer A, et al J Infect Dis 1999;180:1686-9), several strains of hMPV circulated during a very short period of

43

time (one month) in our study area. The hMPV strains segregated into two F subgroups in agreement with previous studies although one strain clearly predominated accounting for 58.3% of all isolates (van den Hoogen BG, de Jong JC, Groen J, et al. Nat Med 2001;7:719-24; Peret TC, Boivin G, Li Y, et al. J Infect Dis 2002;185:1660-3; Boivin G, Abed Y, Pelletier G, et al. J Infect Dis 2002;186:1330-4).

Due to the small number of hMPV strains belonging to one of the F subgroup, we did not attempt to correlate hMPV genotype with clinical outcome. Such viral heterogeneity may allow multiple reinfections throughout life especially in elderly subjects and immunocompromised patients (Pelletier G, Dery P, Abed Y, Boivin G Emerg Infect Dis 2002;8:976-8).

In conclusion, our study supports the concept of the epidemic nature of hMPV infection and establishes its role as a significant pathogen in severe ARTI of children.

Example 5: Determination of the hMPV Load in Clinical Samples Using Quantitative Real-time PCR

An evaluation of a quantitative real-time PCR hMPV assay using a TaqMan probe was performed using naso-pharyngeal aspirate specimens collected from children and adults in Québec City during the winter seasons of 2001-02 and 2002-03. Viral RNA was first extracted from 200 µl of naso-pharyngeal aspirates using the QIAamp Viral RNA Mini Kit (QIAGEN) and eluted in a volume of 40 µl. Serial concentrations (5X10² to 1X10⁹ copies) of a transcribed hMPV plasmid were used to construct the standard curve of the assay. Complementary DNA was synthesized using 10 µl of eluted RNA from clinical samples or hMPV plasmid dilutions, 50 ng (0.75 µM) of random hexamer primers (Amersham Pharmacia Biotech), 0.5 mM of dNTPs, 1X Omniscript buffer and 4 units of the Omniscript reverse transcriptase (QIAGEN) in a final volume of 20 µl. The reverse transcription (RT) mixture was incubated during 1.5 hr. at 37°C and inactivated at 70°C during 10 min. Complementary DNA was amplified by real-time PCR with a TaqMan probe for the hMPV L gene and the LC

Master Hybridization Probe Mix (Roche Diagnostics) in a LightCycler instrument (Roche Diagnostics). Each reaction had a volume of 20 μ l including 2 μ l of RT mixture, 4 mM MgCl₂, 0.3 μ M of specific hMPV L primers (sequence ID Nos. 112 and 114), 0.6 μ M of a specific hMPV L probe (SEQ. ID. No. 127), and 2 μ l of the LC Master Hybridization Probe Mix (Roche Diagnostics). Cycling conditions included an initial denaturation step of 30 s at 94°C, followed by 60 cycles of 5 s at 94°C, 5 s at 56°C, and 25 s at 72°C. A fluorescence lecture was taken after each elongation step (Fig. 9A). A standard curve for the PCR reaction was constructed by plotting cycle threshold values against log concentrations of each hMPV plasmid dilution. The number of hMPV copies present in clinical samples was calculated by interpolating cycle threshold values into the assay's standard curve (Fig. 9B).

Example 6: Determination of hMPV genotypes based on amplification and sequencing of the viral F and G genes.

Determination of hMPV genotypes was achieved by PCR amplification of the F or G genes followed by DNA sequencing of the viral amplified products. Different sets of primers were used for PCR amplification and DNA sequencing of the F (SEQ. ID. Nos. 97 and 98) and G (SEQ. ID. Nos. 104 and 107 or 108 and 109) genes. Alignment of viral DNA sequences was done with the CLUSTAL W software version 1.7 for Unix and phylogenetic trees were computed by maximum parsimony, distance and maximum likelihood-based criteria analysis using PAUP version 4.0.d8. Phylogenetic trees for both the F (Fig. 10A) and G (Fig. 10B) genes from Canadian and non-Canadian viral isolates revealed the existence of two hMPV groups (genotypes A and B) with two subgroups (subtypes 1 and 2) within each group.

Example 7: Comparison of viral culture and multiplex PCR assay for detection of influenza A virus.

A multiplex PCR assay (including PCR primers defined in SEQ. ID. Nos. 139, 140, 141, 142, 143, and 144) aimed at detecting influenza A and B viruses and the respiratory syncytial virus was used to assess the etiology of severe acute respiratory

tract infections (ARTI) necessitating hospitalization in children aged 0-3 years during the winter season 2001-02 at the CHUL, an university-based hospital, in Québec City (Canada). Nasopharyngeal (NPA) samples from all 208 children with ARTI were tested by multiplex PCR whereas a subset of 100 NPA specimens was inoculated on

5 Madin Darby Canine Kidney (MDCK) cells for influenza culture. Briefly, viral RNA was prealably extracted from 200 µl of naso-pharyngeal aspirates using the QIAamp Viral RNA Mini kit (QIAGEN, Mississauga, ON, Canada). cDNA was then synthesized using 10 µl of the RNA preparation, 0.75 µM of random hexamer primers (Amersham Pharmacia Biotech, Baie d'Urfé, QC, Canada), 300 copies of an internal

10 control template, and the Omniscript Reverse Transcriptase Kit (QIAGEN, Mississauga, ON, Canada) following the manufacturer's instructions. The internal control template consisted of a 558-bp transcribed region of an herpes simplex virus type 2 DNA polymerase region flanked by influenza B complementary primer sequences cloned into the pDrive plasmid (QIAGEN). cDNA was amplified using a

15 real-time PCR procedure with the LC Faststart DNA Master SYBR Green 1 Kit (Roche Diagnostics, Laval, QC, Canada) in a LightCycler instrument (Roche Diagnostics). Each reaction had a total volume of 20 µl including 2 µl of complementary DNA and 18 µl of a reaction mixture containing 4 mM MgCl₂, 2 µl of LC Faststart DNA SYBR Green Master 1 Mix, 3% DMSO, 0.3 µM of influenza A

20 and influenza B primers, and 0.8 µM of human respiratory syncytial virus primers (Table 10). Cycling conditions included an initial denaturation step of 10 min. at 94°C, followed by 50 cycles of 15 s at 94°C, 5 s at 58°C, and 25 s at 72°C. Detection of viral amplicons was characterized using the melting curve analysis feature of a real-time PCR instrument. Briefly, following the last amplification cycle on a

25 LightCycler, the reaction temperature was rapidly increased to 94°C and was then decreased to 60°C for 30 seconds followed by a slow increase to 94°C at a rate of 0.1°C per second, with continuous fluorescence lecture. Using this procedure, the amplified products of influenza A, influenza B, hRSV, and the internal control could be differentiated by virtue of their specific T_m values i.e. 85, 83, 79, and 91°C,

30 respectively (Table 13 and Fig. 11).

Influenza A virus was detected by multiplex PCR (specific T_m value of 85°C) in 45/208 (21.6%) of the samples tested whereas the culture was positive for this virus in 14/100 (14%) tested NPA samples from children. For the subset of 100 NPA specimens tested by both methods, 88 (88%) had concordant results (11 positive, 77 negative) whereas discordant results were obtained for 12 (12%) samples (3 culture⁺/PCR⁻, 9 culture⁻/PCR⁺). Assuming that all positive results (by either culture or PCR) were true positive, the sensitivity values of the culture and the multiplex PCR for influenza A virus were 60.9% and 87.0%, respectively. There was no positive result for influenza B virus by any detection method as part of this study.

10

Example 8: Comparison of antigen detection and multiplex PCR assay for detection of the human respiratory syncytial virus.

Same as example 1, except that the multiplex PCR assay was used to detect hRSV from NPA samples obtained from 211 children with ARTI and compared with an antigen detection test for hRSV (TestPack, Abbott Laboratories, Abbott Park, IL).

hRSV was detected by the multiplex PCR (specific T_m value of 79°C) in 109/211 (51.7%) of the tested samples whereas the hRSV antigen detection test was positive in 93/211 (44.1%) tested NPA samples from children. Concordant results were found in 183 (86.7%) samples (87 positive, 96 negative) whereas discordant results were obtained for 28 (13.3%) samples (6 antigen⁺/PCR⁻, 22 antigen⁻/PCR⁺). A second RT-PCR assay for detection of another hRSV gene (glycoprotein G) was used to resolve the discrepancies (Peret et al., 1998, J Gen Virol.79:2221-2229). After the resolution of the discrepant results, the sensitivity values of the antigen detection test and the multiplex PCR for hRSV were 80.5% and 96.5%, respectively.

Example 9: Evaluation of multiplex real time PCR assay for Influenza and human respiratory syncytial viruses.

5 We developed a real-time multiplex PCR assay for influenza viruses and HRSV using the melting curve analysis feature of the LightCycler instrument to rapidly distinguish viral products.

Materials and methods

10 **Study population and antigenic test.** Nasopharyngeal aspirates (NPA) were prospectively collected from children aged 0-3 years hospitalized for ARTI during the winter season 2001-02 at a single, university-based hospital, in Québec City (Canada) (Boivin, G., et al. 2003. Emerg. Infect. Dis. 9:634-640). The study was approved by the institutional review board of the Centre Hospitalier Universitaire de Québec. All samples were tested by the multiplex real-time PCR assay whereas antigen detection
15 tests were performed on a subset of samples upon request by the treating physician. An aliquot (750 µl) of fresh NPA was first tested for the presence of HRSV and influenza A/B antigens using respectively the RSV TestPack (Abbott Laboratories, Abbott Park, IL) and the Directigen Flu A+B test (Becton Dickinson, Sparks, MD). The rest of the specimen was frozen at -80°C for a maximum of 3 months before
20 nucleic acid extraction and PCR testing.

RNA extraction and cDNA synthesis. Viral RNA was extracted from 200 µl of NPA samples using the QIAamp Viral RNA Mini kit (QIAGEN, Mississauga, ON, Canada). Complementary DNA was then synthesized using 10 µl of the RNA preparation, 0.75
25 µM of random hexamer primers (Amersham Pharmacia Biotech, Baie d'Urfé, QC, Canada), and the Omniscript Reverse Transcriptase kit (QIAGEN) in presence of 300 copies of an internal control. The internal control template consisted of a 558-bp transcribed region of the herpes simplex virus type 2 DNA polymerase gene flanked by influenza B complementary primer sequences (see below) cloned into the pDrive
30 plasmid (QIAGEN).

Real-time multiplex and conventional PCR assays. The multiplex PCR respiratory assay was designed to amplify conserved regions of the influenza A (Fouchier, R. A., et al. . 2000.. J. Clin. Microbiol. 38:4096-4101) and B (Li, J., S. Chen, and D. H. Evans. 2001.. J. Clin. Microbiol. 39:696-704) matrix genes as well as the fusion gene of HRSV (Mazzulli, T., et al, 1999. J. Infect. Dis. 180:1686-1689). Complementary DNA was amplified using a real-time PCR procedure with the LC Faststart DNA Master SYBR Green 1 kit (Roche Diagnostics, Laval, QC, Canada) in a LightCycler instrument (Roche Diagnostics). Each reaction had a total volume of 20 µl including 2 µl of cDNA and 18 µl of a reaction mixture containing 2.4 mM MgCl₂, 2 µl of Faststart DNA SYBR Green 1 Master Mix, 3% DMSO, 0.3 mM of influenza A and B primers (SEQ. ID Nos. 139-140 and 141-142), and 0.8 mM of HRSV primers (SEQ. ID Nos. 143-144). Cycling conditions included an initial denaturation step of 10 min at 94°C, followed by 50 cycles of 15 s at 94°C, 5 s at 58°C, and 25 s at 72°C. At the end of each cycle, the fluorescent signal was measured at a wavelength of 530 nm using the LightCycler Fluorimeter. The melting curve analysis program of the LightCycler was used to identify specific PCR products. Briefly, following the last amplification cycle, the reaction temperature was rapidly increased to 94°C and was then decreased to 60°C for 30 s followed by a slow increase to 94°C at a rate of 0.1°C per s, with continuous fluorescence monitoring. For resolution of discrepant results between the multiplex PCR assay and antigenic tests, conventional RT-PCR assays for detection of the glycoprotein G gene of HRSV (Peret, T. C., et al. 1998. J. Gen. Virol. 79:2221-2229) and the M2 gene of influenza A viruses (Klimov, A. I., et al. . 1995. J. Infect. Dis. 172:1352-1355) were performed retrospectively.

Results

Assay's characteristics. The sensitivity of each individual real-time PCR assay and of the multiplex PCR respiratory assay was determined for each target by testing serial dilutions of transcribed plasmids containing specific viral sequences. The lower limit of detection for influenza A, influenza B, and HRSV was found to be 10, 50 and 50 copies, respectively, in individual PCR assays whereas it was 50 copies for each target (10 out of 10 times for influenza A and 9 out of 10 times for influenza B and

HRSV) in the multiplex PCR test. No amplification signal was detected in the real-time multiplex assay when testing viral DNA or RNA from adenoviruses, rhinoviruses, enteroviruses (echo 11), parainfluenza viruses 1-3, human metapneumovirus, and herpesviruses (herpes simplex virus type 1 and 2, cytomegalovirus, and varicella-zoster virus). Specific melting temperature (T_m) values were first determined by testing a set of clinical isolates and vaccine strains (11 influenza A/H1, 10 influenza A/H3, 10 influenza B, and 17 HRSV) from different years (Table 14). A representative set of results is shown in Fig.11. The mean T_m values were 85.27 ± 0.22 , 83.47 ± 0.46 , and 79.51 ± 0.30 °C for influenza A, influenza B, and HRSV corresponding to fragments of 245, 524, and 380 bp, respectively, after gel electrophoresis (Table 14). We found no influence of influenza A subtype (H1 and H3) and HRSV genotype (A and B) on the T_m values (Table 14). The addition of 300 copies of the internal control in the assay's master mix resulted in a specific amplification peak with a T_m value of 91°C (558 bp) in the absence of amplified viral products.

Evaluation of the multiplex PCR respiratory assay in a pediatric population. The multiplex PCR assay was evaluated using extracted RNA from 208 NPA samples collected during a prospective pediatric study aimed at assessing the role of the human metapneumovirus in hospitalized children (0-3 years) with ARTI (Boivin, G., et al. 2003. *Emerg. Infect. Dis.* 9:634-640). The number of positive samples by multiplex PCR for influenza A, influenza B, and HRSV was found to be 45 (21.6%), 0 (0%), and 106 (51.0%), respectively. Overall, the rate of positivity for any of the 3 viruses was 66.8% (139/208) including 5.8% (12/208) of co-infections with influenza A and HRSV. None of the samples was considered to contain PCR-inhibitory samples as verified by the amplification of the internal control in all PCR-negative samples. The ranges of T_m values for influenza A- and HRSV-positive samples were 85.10 ± 0.39 and 79.60 ± 0.42 °C, respectively. All amplified products with one of the latter T_m values were confirmed as specific viral targets by visualizing the appropriate band on agarose gel. As none of the samples contained influenza B virus sequences (which correlates with the very occasional isolation of influenza B viruses in the Québec City

area during the 2001-2002 season), a clinical evaluation of the multiplex PCR assay was conducted for influenza A and HRSV only.

Evaluation of the multiplex PCR respiratory assay for detecting influenza A virus. From the 208 NPA evaluated by multiplex PCR, a subset of 172 samples were also tested for the presence of influenza antigens using the Directigen Flu A+B test (Table 15). Concordant results were obtained for 145 (84.3%) samples including 17 positive and 128 negative results by the two tests. A total of 27 (15.7%) samples showed discordant results with 25 being positive by the multiplex PCR assay only and two positive by the antigenic test only. In order to resolve the discrepant results, a second RT-PCR test targeting a conserved gene (M2) of influenza A viruses was performed as reported (Klimov, A. I., et al. . 1995. J. Infect. Dis. 172:1352-1355). As shown in Table 15, influenza A virus M2 sequences were detected by the conventional RT-PCR assay in 22 (81.5%) of the 27 discordant samples. Using the M2 RT-PCR assay as the reference test, the sensitivity, specificity, positive predictive and negative predictive values of the multiplex real-time PCR assay and the antigenic test for influenza A virus were 100%, 97.7%, 92.8%, 100% and 43.6%, 98.5%, 89.5%, 85.6%, respectively. The multiplex PCR respiratory assay was positive for HRSV in 12 (44.4%) of the 27 discordant influenza A samples with 10 of these samples showing dual HRSV/influenza A infections by the multiplex PCR assay (Table 16). The mean cycle threshold (C_T) values, which are inversely correlated with the amounts of viral RNA, were 28.1 and 33.0 for PCR-positive/antigen-positive and PCR-positive/antigen-negative samples, respectively (Table 16). These values correspond to approximately 5000 and 50 copies, respectively, when a specific influenza A plasmid was tested in the multiplex PCR assay.

Evaluation of the multiplex PCR respiratory assay for detecting HRSV. A total of 204 NPA samples could be evaluated by both the multiplex real-time PCR assay and the presence of HRSV antigens using the RSV TestPack (Table 17). Concordant results were found in 172 (84.3%) samples including 83 positive and 89 negative results by the two tests. Thirty-two (15.7%) samples had discordant results with 21

being positive by the multiplex PCR assay only and 11 by the antigenic test only. Conventional RT-PCR tests for the HRSV glycoprotein G (A and B subtypes) were performed as previously described (Peret, T. C., et al. 1998. *J. Gen. Virol.* 79:2221-2229) to resolve discrepant results. Specific sequences were detected by RT-PCR assays for the HRSV glycoprotein G gene in 26 (81.2%) of the 32 discordant samples including 11 A and 15 B strains (Table 18). Using the latter test as "gold standard", the sensitivity, specificity, positive predictive and negative predictive values of the multiplex real-time PCR assay and the antigenic test for HRSV were 94.5%, 98.9%, 99.0%, 94.0% and 81.6%, 94.7%, 94.7%, 81.8%, respectively. Four (66.7%) of the six false-negative HRSV results by multiplex PCR were positive for influenza A (Table 18). The mean C_T values of the PCR-positive/antigen-positive and PCR-positive/antigen-negative samples were 28.6 and 32.7, respectively (Table 18). These values correspond to approximately 1000 and 100 copies, respectively, when a specific HRSV plasmid was tested in the multiplex PCR assay.

Discussion

In this report, we describe a new multiplex real-time PCR assay for the most commonly detected respiratory viral pathogens, namely influenza viruses (A and B) and HRSV. The key features of this novel assay include its rapidity (turnaround time of approximately 2h30 including 30 min for sample preparation, 60 min for RT and 60 min for real-time PCR including viral identification), and its sensitivity (50 copies per assay for each viral target). Our results clearly demonstrate that our multiplex real-time PCR assay is more sensitive than commercially-available antigenic detection tests for both influenza A and HRSV with the greatest difference in sensitivity noted for influenza viruses.

Multiplex RT-PCR assays targeting up to nine different respiratory pathogens have been previously reported (Fan, J., K. J. Henrickson, and L. L. Savatski. 1998. *Clin. Infect. Dis.* 26:1397-1402, Grondahl, B., et al. 1999. *J. Clin. Microbiol.* 37:1-7, Kehl, S. C., et al. 2001. 39:1696-1701, Osiowy, C. 1998. *J. Clin. Microbiol.* 36:3149-3154, Stockton, J., et al. 1998. *M J. Clin. Microbiol.* 36:2990-2995, Valassina, M., A. M.

Cippone, M. G. Cusi, and P. E. Valensin. 1996: Clin. Diag. Virol. 8:227-232). More recently, a TaqMan-based real-time PCR assay for simultaneous detection of influenza A and B viruses has also been described (van Elden, L. J., et al. 2001. J. Clin. Microbiol. 39:196-200). Compared to conventional multiplex PCR assays, our
5 real-time PCR test is much more rapid because it avoids additional nested amplification and/or hybridization steps required for identification of viral products. Furthermore, the real-time amplification procedure minimizes the chances of contamination because there is no post-PCR processing of the samples. Although our multiplex real-time PCR assay based on melting curve analysis of amplicons does not
10 permit absolute quantification of the viral targets as in the TaqMan PCR procedure (van Elden, L. J., et al. 2001. J. Clin. Microbiol. 39:196-200), it allows for a larger number of viral targets to be simultaneously detected since there is no limitation related to the capability of the system to detect multiple dyes linked to detection probes with distinct emission wavelengths. Eventually, more than three viral targets
15 could be simultaneously detected in the LightCycler assay assuming the absence of interaction between PCR primers and a reproducible and discriminative T_m value for each viral amplicon.

Evaluation of our multiplex real-time PCR assay in a pediatric population with severe
20 ARTI clearly illustrated its clinical potential. Indeed, our assay identified a viral pathogen (influenza or HRSV) in two-thirds of the hospitalized children. These numbers are similar to the ones previously reported by our group in the same population using individual real-time assays for these viral pathogens (Boivin, G., et al. 2003. Emerg. Infect. Dis. 9:634-640). Notably, we were able to show that 6% of
25 hospitalized children had dual viral infections, a finding that has been reported albeit at a lower frequency by other investigators (Grondahl, B., et al. 1999. J. Clin. Microbiol. 37:1-7, Kehl, S. C., et al. 2001. 39:1696-1701, Osowy, C. 1998. J. Clin. Microbiol. 36:3149-3154). Rapid identification of these viral pathogens (influenza and HRSV) is of paramount importance for isolation purposes in the hospital setting
30 and early institution of specific antiviral therapy (Whitley, R. J., et al. 2001. Pediatr. Infect. Dis. J. 20:127-133). We are currently designing additional multiplex assays

based on the same technology to cover the whole spectrum of respiratory pathogens including parainfluenza viruses (PIV), adenoviruses, enteroviruses, and coronaviruses (Treanor, J. 2002. Respiratory Infections, p. 7-26, In Richard J. Whitley, Douglas D. Richman and Frederick G. Hayden (eds.). Clinical Virology. 2nd ed. ASM Press. Washington, D.C.). To this list, we should also add the recently described human metapneumovirus which has been reported by our group and others in up to 10% of ARTI in hospitalized children (Boivin, G., et al. 2003. Emerg. Infect. Dis. 9:634-640, Jartti, T., B. van den Hoogen, R. P. Garofalo, A. D. Osterhaus, and O. Ruuskanen. 2002.. Lancet. 360:1393-1394, Nissen, M. D., et al 2002. Med. J. Aust. 176:188, van den Hoogen, B. G., J. C. de Jong, J. Groen, T. Kuiken, R. de Groot, R. A. Fouchier, and A. D. Osterhaus. 2001.. Nat. Med. 7:719-724);

A specific evaluation of the real-time multiplex PCR assay for influenza A revealed that it was twice as sensitive as the rapid antigen detection test in use at our institution during the winter season of 2001-2002. None of the two PCR-negative, antigen-positive samples were confirmed by a second PCR targeting another conserved gene (M2) of influenza A whereas most (22/25, 88.0%) multiplex PCR-positive, antigen-negative were. In general, the false-negative antigenic test results could be explained by low amounts of viral RNA in those NPA samples as demonstrated by high C_T values in the corresponding real-time PCR assays. Three multiplex PCR test results were not confirmed by the influenza A M2 PCR test and were thus considered false-positive results. However, as we have not formally evaluated the sensitivity of the M2 PCR test and since viral cultures were not routinely done, we cannot rule out the possibility that such discrepant results were indeed true positive. We and other investigators have shown the superiority of RT-PCR tests over conventional methods (antigenic tests and viral culture) for detecting influenza viruses in clinical samples including those sent to the laboratory by mail (Boivin, G., I. Hardy, and A. Kress. 2001. J. Clin. Microbiol. 39:730-732, Ellis, J. S., D. M. Fleming, and M. C. Zambon. 1997. 1996. J. Clin. Microbiol. 35:2076-2082, Kehl, S. C., et al. 2001. 39:1696-1701, Steininger, C., et al. 2002. J. Clin. Microbiol. 40:2051-2056, van Elden, L. J., et al. 2001. J. Clin. Microbiol. 39:196-200). It is now common procedure at our institution

to confirm any negative antigenic tests results for influenza A and B by either viral culture or RT-PCR considering the high specificity but relatively poor sensitivity of the former assays.

- 5 For HRSV, the multiplex real-time PCR assay was also found to be more sensitive (by approximately 15%) than the rapid antigenic test when a second RT-PCR assay for the HRSV gG gene was used to resolve the discrepancies. Most of the false-negative antigenic test results could be explained by low amounts of viral RNA in the NPA samples as shown by mean C_T values of 32.7 for discordant results compared to
10 28.6 for concordant positive results. The specificity of the multiplex assay was excellent with only one positive result not confirmed by the second PCR test. In contrast, the multiplex PCR assay missed six cases of HRSV which tested positive in both the antigenic test and the second PCR assay for HRSV gG. Notably, four of those six samples tested positive for influenza A in the multiplex PCR assay. Thus,
15 although our multiplex PCR test has the capability of detecting dual infections (as seen in 6% of our cases), it is possible that high amounts of one virus could inhibit amplification of other pathogens. It is noteworthy that the multiplex PCR assay had the ability to amplify both HRSV genotypes as shown by the detection of 15 B and 11 A genotypes using specific PCR assays aimed at detecting variable regions of the
20 HRSV gG gene (Mazzulli, T., et al, 1999. *J. Infect. Dis.* 180:1686-1689). Although the rapid antigenic test had a relatively good performance (sensitivity: 82%, specificity 95%) for detection of HRSV in young children, the real advantage of PCR probably resides in the adult population where viral titers are lower and where antigenic tests are not recommended with upper respiratory tract samples (Englund, J.
25 A., et al 1996. 34:1649-1653).

There are some limitations to our study which are worth mentioning. First, the absence of circulation of influenza B viruses during the study period prevents adequate validation of our multiplex assay for this pathogen and in particular for its
30 ability to detect mixed (influenza B and HRSV) infections. Second, the performance of our multiplex PCR assay cannot be generalized to other types of samples (throat

swabs, sputum) and to other populations (outpatients, adults) at the present time. Also, the absence of serological testing in our study may have underestimated the rate of viral infections especially for those children who presented late after the onset of symptoms. Finally, although it was relatively easy to discriminate between the different viral pathogens based on their specific T_m values only (Table 14), we sometimes had to confirm viral amplicons by gel electrophoresis, which increases the assay's turnaround time.

In conclusion, we described a rapid and sensitive multiplex real-time PCR assay for detecting influenza viruses and HRSV in children's NPA samples. This new assay is as specific and much more sensitive than currently-available antigen detection tests and could complement the latter in the hospital setting when there is high clinical suspicion despite negative results. Future work is needed to expand the panel of viral pathogens detected by such rapid molecular methods in order to eventually circumvent the need for viral cultures. Also, future evaluation of the multiplex PCR assay is warranted in the adult population with severe ARTI.

Example 10 : Description and Evaluation of the Multiplex Respiratory-1 PCR.

5 Same as example 9, except that hMPV primers (as defined in SEQ. ID. Nos. 95 and 96 or 112 and 114) were added to the multiplex PCR assay (already containing primers of SEQ. ID. Nos. 139+140 for influenza A, 141+142 for influenza B, and 143+144 for hRSV) at a concentration of 0.3 μ M. The cycling conditions included an amplification step of 50 cycles of 15 s at 94°C, 5 s at 58°C, and 28 s at 72°C. The T_m values determined with the LightCycler instrument were 91°C, 85°C, 83°C, 79°C, and 82°C/77°C for the internal control, influenza A, influenza B, hRSV, and hMPV N/L genes, respectively (Fig. 7A for hMPV N primers of SEQ. ID. Nos. 95 and 96 and Fig. 7B for hMPV L primers of SEQ. ID. Nos. 112 and 114). The lower limit of detection of the multiplex respiratory-1 PCR was 10, 50, 100, and 100 copies for influenza A, influenza B, hRSV, and hMPV, respectively, in the presence of 500 copies of an internal control (plasmid flanked by influenza B complementary primer sequences). The multiplex respiratory-1 assay was found to be specific with no amplification of adenoviruses, enteroviruses, rhinoviruses, parainfluenza viruses 1-3, coronaviruses, herpes simplex virus type 1 and 2, varicella-zoster virus, cytomegalovirus, HHV-6, HHV-8, and Epstein-Barr virus.

The multiplex respiratory-1 PCR was evaluated with NPA samples from 248 children ≤ 3 years with acute respiratory tract infections and 108 adults ≥ 50 years with exacerbation of chronic obstructive pulmonary disease or pneumonia requiring hospitalization during the 2002-03 winter/spring period in Québec City, Canada. In children, the detection rate for influenza A, influenza B, hRSV, and hMPV was 9/248 (3.6%), 4/248 (1.6%), 123/248 (49.6%), and 13/248 (5.2%), respectively. Five (2.0%) of the 248 children had a mixed viral infection. None of the NPA samples was found to contain PCR-inhibitory substances as shown by successful amplification of the internal control in all negative samples. In adults, the detection rate for influenza A, influenza B, hRSV, and hMPV was 3/108 (2.8%), 0/108 (0%), 13/108 (12.0%), and

2/108 (1.8%), respectively. One patient had a mixed viral infection (influenza A and hMPV). No samples contained PCR-inhibitory samples.

Example 11: Description and evaluation of the multiplex respiratory-2 PCR.

5

Same as example 9, except that the multiplex PCR assay is composed of the following PCR primers for detection of parainfluenza-1 (SEQ. ID. Nos. 147 and 148), parainfluenza-3 (SEQ. ID. Nos. 151 and 152), human adenoviruses (SEQ. ID. Nos. 153 and 155), and rhinoviruses/enteroviruses (SEQ. ID. Nos. 160 and 161). Primers are added in the PCR reaction mixture at a concentration of 0.2 μ M (SEQ. ID. Nos. 147 and 151), 0.3 μ M (SEQ. ID. Nos. 153 and 155), 0.4 μ M (SEQ. ID. Nos. 148 and 152), and 0.5 μ M (SEQ. ID. Nos. 160 and 161). The cycling conditions included an amplification step of 50 cycles of 15 s at 94°C, 5 s at 58°C, and 26 s at 72°C. The T_m values determined with the LightCycler instrument were 91.0°C, 80.0°C, 77.5°C, 89.0°C, 82.0°C, and 85.0°C for the internal control, parainfluenza-1, parainfluenza-3, adenoviruses, rhinoviruses, and enteroviruses, respectively (Fig. 8). The lower limit of detection of the multiplex respiratory-2 PCR was 50, 100, 10, 50, and 200 copies for parainfluenza-1, parainfluenza-3, adenoviruses, rhinoviruses, and enteroviruses, respectively, in the presence of 500 copies of an internal control (plasmid flanked by rhinovirus/enterovirus complementary primer sequences). The multiplex respiratory-2 assay was found to be specific with no amplification of influenza A, influenza B, hRSV, hMPV, coronavirus, herpes simplex virus type 1 and 2, varicella-zoster virus, cytomegalovirus, HHV-6, HHV-8, and Epstein-Barr virus.

25

Example 12 : Description of real-time PCR assays for the SARS-coronavirus.

30 Same as example 9, except that the PCR assay is composed uniquely of primers (two different possible sets) for the SARS-coronavirus as defined in SEQ. ID. Nos. 156, 157 and 158-159. The concentration of the primers in the PCR reaction mixture is 0.5 μ M. The amplification step included 50 cycles of 15 s at 94°C, 5 s at 58°C, and 20 s at 72°C. The T_m for both PCR products is 83°C (Fig. 12).

Table 1: List of hMPV sequences revealed in the present invention

SEQ ID NO.	Isolate No.	Target gene
2	hMPV-118	Nucleoprotein
3	hMPV-174	Nucleoprotein
4	hMPV-176	Nucleoprotein
5	hMPV-193	Nucleoprotein
6	C-77807	Nucleoprotein
7	C-77748	Nucleoprotein
8	hMPV-217	Nucleoprotein
10	hMPV-163	Nucleoprotein
11	hMPV-174	Nucleoprotein
12	hMPV-184	Nucleoprotein
13	hMPV-185	Nucleoprotein
14	C-76837	Nucleoprotein
15	C-77807	Nucleoprotein
16	C-78123	Nucleoprotein
17	C-78132	Nucleoprotein
18	C-78163	Nucleoprotein
19	C-91205	Nucleoprotein
20	C-91364	Nucleoprotein
21	C-91830	Nucleoprotein
22	hMPV-Q86	Nucleoprotein
23	hMPV-Q97	Nucleoprotein
24	Can 97-83	Nucleoprotein
25	Can 98-75	Nucleoprotein
26	Can 98-75	Fusion type II
27	C-67345	Fusion type I
28	Can 97-83	Fusion type I
29	C-68661	Fusion type I
30	C-73750	Fusion type I
31	C-74549	Fusion type I
32	C-74783	Fusion type I
33	C-76837	Fusion type I
34	C-77748	Fusion type I
35	C-77807	Fusion type I
36	C-78132	Fusion type I
37	C-78163	Fusion type I
38	C-78406	Fusion type I
39	hMPV-174	Fusion type II
40	hMPV-193	Fusion type I
41	hMPV-194	Fusion type I
42	hMPV-198	Fusion type I
43	hMPV-217	Fusion type II
44	hMPV-208	Fusion type I
45	hMPV-223	Fusion type I
46	hMPV-228	Fusion type I

47	C-85885	Fusion type I
48	C-60298	Fusion type I
49	C-63778	Fusion type II
50	C-64199	Fusion type II
51	C-64200	Fusion type II
52	C-64536	Fusion type II
53	C-73769	Fusion type II
54	C-74501	Fusion type II
55	C-78429	Fusion type II
56	C-78562	Fusion type II
57	hMPV-118	Fusion type II
58	hMPV-200	Fusion type I
59	hMPV-176	Fusion type I
60	hMPV-193	Glycoprotein
61	hMPV-228	Glycoprotein
62	C-77748	Glycoprotein
63	C-78132	Glycoprotein
64	C-78406	Glycoprotein
65	C-73750	Glycoprotein
66	C-60298	Glycoprotein
67	C-74783	Glycoprotein
68	C-74549	Glycoprotein
69	C-77807	Glycoprotein
70	C-78163	Glycoprotein
71	C-68661	Glycoprotein
72	C-88448	Glycoprotein
73	C-88470	Glycoprotein
74	C-86316	Glycoprotein
76	hMPV-118	Polymerase
77	hMPV-163	Polymerase
78	hMPV-174	Polymerase
79	hMPV-184	Polymerase
80	hMPV-196	Polymerase
81	C-76837	Polymerase
82	C-77807	Polymerase
83	hMPV-185	Polymerase
84	C-78123	Polymerase
85	C-91205	Polymerase
86	C-91364	Polymerase
87	C-91749	Polymerase
88	hMPV-Q86	Polymerase
89	hMPV-Q97	Polymerase
90	Can 97-83	Polymerase

Table 2: List of hMPV PCR primers developed in the present invention

SEQ ID NO.	Target gene	Originating DNA	
		Position ^a	SEQ ID NO.
91	Nucleoprotein (N)	25	1
92	Nucleoprotein (N)	97	1
93	Nucleoprotein (N)	146 ^b	1
94	Nucleoprotein (N)	1025 ^b	1
95	Nucleoprotein (N)	58	9
96	Nucleoprotein (N)	986 ^b	9
97	Fusion (F)	3052	1
98	Fusion (F)	3810 ^b	1
99	Fusion (F)	4671 ^b	1
100	Matrix (M)	2165	1
101	Matrix (M)	2943 ^b	1
102	Phosphoprotein (P)	1248	1
103	Phosphoprotein (P)	2124 ^b	1
104	Glycoprotein (G)	6231	1
105	Glycoprotein (G)	6247	1
106	Glycoprotein (G)	6957 ^b	1
107	Glycoprotein (G)	6981 ^b	1
108	Glycoprotein (G)	6235	1
109	Glycoprotein (G)	7227 ^b	1
110	RNA polymerase (L)	142	75
111	RNA polymerase (L)	691 ^b	75
112	RNA polymerase (L)	7308	1
113	RNA polymerase (L)	7857 ^b	1
114	RNA polymerase (L)	7616	1

^a Position refers to nucleotide position of 5' end of primer. Oligonucleotides are 17-20 bp in length.

^b Primer is reverse-complement of target sequence.

Table 3: List of hMPV probes developed in the present invention

SEQ ID NO.	Target gene	Originating DNA	
		Position ^a	SEQ ID NO.
115	Nucleoprotein (N)	786	1
116	Nucleoprotein (N)	808	1
117	Fusion (F)	3163	1
118	Fusion (F)	3187	1
119	Matrix (M)	2636	1
120	Matrix (M)	2659	1
121	Phosphoprotein (P)	1492	1
122	Phosphoprotein (P)	1518	1
123	Glycoprotein (G)	6509	1
124	Glycoprotein (G)	6530	1
125	RNA polymerase (L)	7600	1
126	RNA polymerase (L)	7627	1
127	RNA polymerase (L)	7331	1
128	Nucleoprotein (N)	824	9
129	RNA polymerase (L)	434	75

^a Position refers to nucleotide position of 5' end of probe. Oligonucleotides are 21-25 bp in length.

Table 4: Length of amplicons obtained with different hMPV primer pairs which are objects of the present invention

SEQ ID NO.	Target Gene	Length of amplicon
91 + 94	Nucleoprotein (N)	1001 bp
92 + 94	Nucleoprotein (N)	929 bp
91 + 93	Nucleoprotein (N)	122 bp
97 + 99	Fusion (F)	1620 bp
97 + 98	Fusion (F)	759 bp
100 + 101	Matrix (M)	779 bp
102 + 103	Phosphoprotein (P)	877 bp
104 + 107	Glycoprotein (G)	751 bp
105 + 106	Glycoprotein (G)	711 bp
108 + 109	Glycoprotein (G)	993 bp
112 + 113	RNA polymerase (L)	550 bp
112+114	RNA polymerase (L)	308 bp

Table 5: Comparative evaluation of different hMPV primers for detection of hMPV strains

Strains No.	Type of sample	Year	N Primers		M primers		F primers		P primers		L primers	
			SEQ. ID. Nos. 92+94		SEQ. ID. Nos. 100+101		SEQ. ID. Nos. 97+98		SEQ. ID. Nos. 102+103		SEQ. ID. Nos. 112 + 113	
	I or S		+/-	Tm (°C)	+/-	Tm (°C)	+/-	Tm (°C)	+/-	Tm (°C)	+/-	Tm (°C)
C-74501	I	2000	+	82.92	-		+	83.65	-		+	78.14
C-74783	I	2000	+	82.76	+	83.49	-		+	81.51	+	78.20
C-76837	I	2000	+	82.94	+	83.43	+	83.17	+	80.86	-	
C-77719	I	2001	+	83.26	+	84.64	-		-		+	77.87
C-77738	I	2001	+	82.99	-		-		-		+	77.51
C-77748	I	2001	+	83.06	+	82.96	+	83.10	+	81.27	+	77.38
C-77807	I	2001	+	82.99	+	83.26	+	83.25	+	80.65	+	78.34
C-78024	I	2001	+	82.86	+	83.95	-		-		-	
C-78028	I	2001	+	82.98	+	83.13	-		-		+	78.32
C-78123	I	2001	+	82.83	-		-		-		+	78.48
C-85984	I	2002	+	82.59	+	83.21	+	83.51	+	79.99	+	77.97
C-85448	I	2002	+	83.66	+	82.72	-		+	80.31	+	78.88
C-85983	I	2002	+	82.59	+	83.03	+	83.88	+	80.46	+	78.01
C-85988	I	2002	+	82.17	-		+	84.39	-		+	78.06
C-86316	I	2002	+	82.64	+	82.75	+	83.18	+	80.18	+	78.02
C-85126	I	2002	+	81.89	+	82.05	+	82.39	+	80.00	+	78.04
C-85473	I	2002	+	82.39	+	82.57	+	82.91	+	80.74	+	77.82
C-85332	I	2002	+	81.98	-		-		-		+	77.72
C-85596	I	2002	+	82.24	+	82.73	+	83.17	+	80.35	+	77.58
C-85542	I	2002	+	82.22	+	82.72	-		+	80.08	+	77.67
HMPV-118	S	2002	+	82.47	-		-		-		ND	ND
HMPV-174	S	2002	+	82.18	+	82.06	+	83.16	+	80.17	+	78.20
HMPV-176	S	2002	+	81.41	-		+	83.97	-		+	77.81
HMPV-193	S	2002	+	82.22	+	81.89	+	83.00	+	80.58	+	77.94
HMPV-194	S	2002	+	82.24	+	81.32	+	82.98	-		+	77.84
HMPV-198	S	2002	+	82.66	-		-		-		-	
HMPV-200	S	2002	+	82.53	-		+	83.46	-		+	77.62
HMPV-208	S	2002	+	82.11	+	81.81	+	83.33	+	80.06	+	78.40
HMPV-217	S	2002	+	82.13	+	81.58	+	83.01	-		+	77.76

64

HMPV- S	2002	+	81.89	+	82.36	+	83.04	-	+	78.10
223										
Mean			82.63 ± 0.87		82.75 ± 0.80		83.29 ± 0.45		80.48 ± 0.46	77.99 ± 0.33

Note: I = viral isolates; S = clinical specimens; Tm = melting temperature as determined by a LightCycler instrument.

Table 6: Size of the viral fusion (F) gene fragments obtained for different hMPV isolates following enzymatic digestion with restriction endonucleases

SEQ ID NO.	Fragments obtained after digestion with the restriction endonuclease		F genotype ^a
	ApaI	Avr II	
35	532 bp + 227 bp	759 bp	I
58	532 bp + 227 bp	759 bp	I
39	759 bp	447 bp + 312 bp	II
40	532 bp + 227 bp	759 bp	I
41	532 bp + 227 bp	759 bp	I
43	759 bp	447 bp + 312 bp	II
44	532 bp + 227 bp	759 bp	I
59	532 bp + 227 bp	759 bp	I
45	532 bp + 227 bp	759 bp	I

5 ^aAs determined by DNA sequencing and phylogenetic studies.

Table 7. Type of laboratory confirmation by type of infection

Laboratory test	hMPV		hRSV		Influenza A		Adenovirus		PIV 2	
	Tests done	Positive	Tests Done	Positive	Tests done	Positive	Tests done	Positive	Tests done	Positive
PCR	208	12 5.8%	208	106 51.0%	208	45 21.6%	NA	NA	NA	NA
Culture	100	2 2%	100	31 31%	100	14 14%	100	6 6%	100	1 1%
Antigen detection (Immunofluorescence)	NA	NA	NA	NA	NA	NA	81	1 1%	76	1 1.3%
Antigen detection (ELISA)	NA	NA	204	94 46.1%	100	14 14%	NA	NA	NA	NA
Total (+) in at least one test	12 (5.8%)		118 (56.7%)		49 (23.6%)		6 (6%)		2 (2%)	

Delay between onset of
symptoms and NPA,
days

3.0/3.0

6.0/6.5

8.7/5.0

5.2/4.0

6.3/5.0

Mean/median

Note: hMPV, human metapneumovirus; hRSV, human respiratory syncytial virus; PIV, parainfluenza virus; NPA, nasopharyngeal aspirate; NA, not available.

Table 8. Signs and symptoms by type of viral infection

Signs and symptoms	HMPV	hRSV	Influenza A	Single virus	Multiple viruses	No virus detected	Total
	N=12	N=118	N=49	N=141	N=23	N=44	N=208
Fever	8	67	38	85	17	25	127
	67%	57%	78%	60%	74%	57%	61%
Cough	12	117	47	138	23	40	201
	100%	99%	96%	98%	100%	90%	97%
Rhinorrhea	11	107	41	123	22	42	187
	92%	91%	84%	87%	96%	96%	90%
Retractions	11	112	40	125	22	39	186
	92%	95%	82%	89%	96%	89%	89%
Wheezing	10	77	28	83	19	31	133
	83%	65%	57%	59%	83%	71%	64%
Lacrimation	3	37	15	46	6	11	63
	25%	31%	31%	33%	26%	25%	30%
Diarrhea	1	19	13	24	5	10	39

	8%	17%	27%	17%	22%	23%	19%
Vomiting	3	9	5	10	4	1	15
	25%	8%	10%	7%	17%	2%	7%
Other	0	31	9	33	4	9	46
		26%	18%	23%	17%	21%	22%

Note: hMPV, human metapneumovirus; hRSV, human respiratory syncytial virus.

Table 9. Final diagnoses (complications) by type of viral infection

Complications	hMPV	HRSV	Influenza A	Single virus	Multiple viruses	No virus detected	Total
	N=12	N=118	N=49	N=141	N=23	N=44	N=208
Bronchiolitis	8 66.7%	99 83.9%	25 51.0%	98 69.5%	19 82.6%	25 56.8%	142 68.3%
Otitis	6 50.0%	70 59.3%	27 55.1%	78 55.3%	15 65.2%	24 54.6%	117 56.3%
Pneumonia	2 16.7%	30 25.4%	18 36.7%	39 27.7%	7 30.4%	12 27.3%	58 27.9%
Laryngotracheobronchitis	0	10 8.5%	6 12.2%	9 6.4%	4 17.4%	1 2.3%	14 6.7%
Sinusitis	0	3 2.5%	3 6.1%	2 1.4%	2 8.7%	1 2.3%	5 2.4%
Pharyngitis	0	1 0.9%	0	2 1.4%	0	2 4.6%	4 1.9%
Flu syndrome	0	2 1.7%	0	2 1.4%	0	4 9.1%	6 2.9%

Group	0	2	0	2	0	1	3
		1.7%		1.4%		2.3%	1.4%
Other	1	4	3	9	0	5	14
	8.3%	3.4%	6.1%	6.4%		11.4%	6.7%

Note: hMPV, human metapneumovirus; hRSV, human respiratory syncytial virus.

- 72 -

Table 10: List of PCR primers used for amplification of respiratory viruses

Primer SEQ ID NO.	Virus	Target Gene	Originating DNA Position ^a	SEQ ID NO.
139	Influenza A	Matrix	32 / 7	130-131
140	Influenza A	Matrix	276 ^b / 251 ^b	130-131
141	Influenza B	Matrix	82	132
142	Influenza B	Matrix	605 ^b	132
143	RSV	Fusion	1111	133
144	RSV	Fusion	1490 ^b	133
95	hMPV	Nucleocapsid	58	9
96	hMPV	Nucleocapsid	986 ^b	9
110	hMPV	Polymerase	142	75
111	hMPV	Polymerase	691 ^b	75
145	PIV-1	Nucleocapsid	64	134
146	PIV-1	Nucleocapsid	147 ^b	134
149	PIV-3	Nucleocapsid	416	135
150	PIV-3	Nucleocapsid	649 ^b	135
154	Adenovirus	Hexon	154	136
155	Adenovirus	Hexon	368 ^b	136
160	Enterovirus	5'-non coding region	94 / 71	137/138
161	Enterovirus	5'-non coding region / VP2	746 ^b / 603 ^b	137/138
141	IC ^c multiplex 1	DNA polymerase HSV-2	1	170
142	IC ^c multiplex 1	DNA polymerase HSV-2	558 ^b	170
160	IC ^c multiplex 2	DNA polymerase HSV-2	1	171
161	IC ^c multiplex 2	DNA polymerase HSV-2	554 ^b	171
112	hMPV	Polymerase	7308	1
114	hMPV	Polymerase	7616	1
147	PIV-1	Nucleocapsid	822	134
148	PIV-1	Nucleocapsid	1029	134
151	PIV-3	Nucleocapsid	792	135
152	PIV-3	Nucleocapsid	902	135
153	Adenovirus	Hexon	7	136
156	Sars-CoV	nsp9		
157	Sars-CoV	nsp9		
158	Sars-CoV	nsp11		
159	Sars-CoV	nsp11		

^a Position refers to nucleotide position of 5'-end of primer. Oligonucleotides are 16-26 bp in length.

^b Primer is reverse-complement of target sequence.

^c IC refers to the internal control used to monitor the efficiency of the PCR amplification

- 73 -

Table 11: List of viral probes developed in the present invention

Probe SEQ ID NO.	Target	Originating DNA Position ^a	SEQ ID NO.
162	Influenza A	114 ^b / 89 ^b	130/131
163	Influenza B	383	132
164	hRSV	1391 ^b	133
128	hMPV	824	9
129	hMPV	434	75
165	PIV-1	96	134
166	PIV- 3	616 ^b	135
167	Adenovirus	228	136
168	Rhinovirus	467 ^b	138
169	Enterovirus	644 ^b	137
172	Internal Control ^c	321 ^b / 325 ^b	170/171

^aPosition refers to nucleotide position of 5'-end of primer. Oligonucleotides are 20-23 bp in length.

^bProbe is reverse-complement of target sequence.

^cA modified DNA polymerase gene sequence of herpes simplex virus (HSV) type 2 serves as the internal control template.

Table 12: Length of amplicons obtained with the different viral primer pairs

Primer SEQ ID NO.	Virus	Target gene	Length of amplicons
139 + 140	Influenza A	Matrix	245 bp
141 + 142	Influenza B	Matrix	524 bp
143 + 144	hRSV	Fusion	380 bp
95 + 96	hMPV	Nucleocapsid	929 bp
110 + 111	hMPV	Polymerase	550 bp
145 + 146	PIV-1	Nucleocapsid	84 bp
149 + 150	PIV-3	Nucleocapsid	234 bp
154 + 155	Adenoviruses	Hexon	215 bp
160 + 161	Rhinoviruses	5'-non coding region - VP2	533 bp
160 + 161	Enteroviruses	5'-non coding region	653 bp
141 + 142	IC multiplex 1	DNA polymerase HSV-2	558 bp
160 + 161	IC multiplex 2	DNA polymerase HSV-2	554 bp
112 + 114	hMPV	Polymerase	308 bp
147 + 148	PIV-1	Nucleocapsid	208 bp
151 + 152	PIV-3	Nucleocapsid	111 bp
153 + 155	Adenovirus	Hexon	362 bp
156 + 157	Sars-CoV	nsp9	198 bp
158 + 159	Sars-CoV	nsp11	368 bp

- 75 -

Table 13: Selection of primer sets with resulting melting temperature (T_m) values of the corresponding amplicons for each multiplex assay

Primer SEQ ID NO.	Target	Multiplex NO.	T _m (°C)
139 + 140	Influenza A	1	85
141 + 142	Influenza B	1	83
143 + 144	hRSV	1	79
95 + 96 or 112 + 114	hMPV	1	82 or 77
141 + 142	Internal Control	1	91
147 + 148	Parainfluenza 1	2	80.0
151 + 152	Parainfluenza 3	2	77.5
153 + 155	Adenovirus	2	89.0
160 + 161	Rhinovirus	2	82.0
160 + 161	Enterovirus	2	85.0
160 + 161	Internal Control	2	91

- 76 -

Table 14. Evaluation of the multiplex PCR respiratory assay with temporally-different strains of influenza (Flu) and human respiratory syncytial (HRSV) viruses.

Virus	Subtype / Genotype ^a	Year	Type	Strain	T _m (°C)
Flu A	H1	99-00	clinical	-	85.10
Flu A	H1	99-00	clinical	-	85.39
Flu A	H1	00-01	clinical	-	85.12
Flu A	H1	00-01	clinical	-	85.20
Flu A	H1	00-01	clinical	-	85.04
Flu A	H1	01-02	clinical	-	84.62
Flu A	H1	01-02	clinical	-	85.07
Flu A	H1	02-03	clinical	-	85.50
Flu A	H1	02-03	clinical	-	85.29
Flu A	H1	95	vaccine	A/Beijing/262/95	85.06
Flu A	H1	33	vaccine	A/WSN/33	85.25
Mean AH1					85.15±0.22
Flu A	H3	98-99	clinical	-	85.58
Flu A	H3	98-99	clinical	-	85.18
Flu A	H3	98-99	clinical	-	85.35
Flu A	H3	98-99	clinical	-	85.57
Flu A	H3	98-99	clinical	-	85.37
Flu A	H3	01-02	clinical	-	85.07
Flu A	H3	01-02	clinical	-	85.65
Flu A	H3	02-03	clinical	-	84.92
Flu A	H3	99	vaccine	A/Panama/2007/99	85.18
Flu A	H3	97	vaccine	A/Sydney/5/97	85.06
Mean AH3					85.31±0.25
Mean FluA					85.27±0.22
Flu B	-	98-99	clinical	-	83.87
Flu B	-	98-99	clinical	-	83.12
Flu B	-	00-01	clinical	-	83.01
Flu B	-	00-01	clinical	-	83.03
Flu B	-	00-01	clinical	-	82.88
Flu B	-	00-01	clinical	-	83.75
Flu B	-	00-01	clinical	-	83.17
Flu B	-	02-03	clinical	-	83.89
Flu B	-	02-03	clinical	-	83.84
Flu B	-	97	vaccine	B/Harbin/7/97	84.12
Mean FluB					83.47±0.46

- 77 -

Table 14. Evaluation of the multiplex PCR respiratory assay with temporally-different strains of influenza (Flu) and human respiratory syncytial (HRSV) viruses. (Continued).

HRSV	B	99-00	clinical	-	79.32
HRSV	A	99-00	clinical	-	79.83
HRSV	A	00-01	clinical	-	79.06
HRSV	A	00-01	clinical	-	78.85
HRSV	B	01-02	clinical	-	79.34
HRSV	B	01-02	clinical	-	79.52
HRSV	B	01-02	clinical	-	79.98
HRSV	B	01-02	clinical	-	79.52
HRSV	A	01-02	clinical	-	79.84
HRSV	B	01-02	clinical	-	79.42
HRSV	B	01-02	clinical	-	79.49
HRSV	B	01-02	clinical	-	79.48
HRSV	B	01-02	clinical	-	79.55
HRSV	B	01-02	clinical	-	79.32
HRSV	A	01-02	clinical	-	79.77
HRSV	A	01-02	clinical	-	79.92
HRSV	A	01-02	clinical	-	79.40
Mean HRSV-A					79.52±0.43
Mean HRSV-B					79.49±0.19
Mean HRSV					79.51±0.30

^a Subtyping was performed by multiplex PCR for the influenza hemagglutinin gene (2) whereas genotyping was done by conventional PCR for the HRSV G gene (22)

- 78 -

Table 15. Evaluation of the multiplex PCR respiratory assay for detection of influenza A (Flu A) virus.

		Antigenic test (Directigen Flu A+B) (n = 172)		Flu A M2 PCR assay ^a (n = 27)	
		+	-	+	-
Multiplex PCR	+	17	25	22	3
	-	2	128	0	2

5 Sensitivity: 39/39 = 100%
 Specificity: 130/133 = 97.7%
 Positive predictive value: 39/42 = 92.8%
 Negative predictive value: 130/130 = 100%

^a Only performed for samples showing discordant results with the
 10 multiplex PCR assay and the antigenic test.

- 79 -

Table 16: Evaluation of discordant test results for influenza A (Flu A) virus.

Sample No.	Multiplex PCR Flu A results (C _T) ^a	Antigenic test Flu A results	M2 PCR Flu A results	Other PCR- amplified viruses ^b
16	-	+	-	HRSV
23	+(27)	-	+	
24	-	+	-	HRSV
27	+(28)	-	+	HRSV
35	+(28)	-	+	HRSV
36	+(32)	-	+	
40	+(34)	-	+	
43	+(36)	-	+	HRSV
44	+(35)	-	+	
50	+(34)	-	+	
51	+(33)	-	+	HRSV
103	+(35)	-	+	
107	+(35)	-	+	
114	+(37)	-	-	
118	+(38)	-	+	HRSV
120	+(36)	-	+	HRSV
125	+(38)	-	+	
130	+(35)	-	+	HRSV
131	+(36)	-	-	
132	+(24)	-	+	HRSV
134	+(36)	-	-	
141	+(28)	-	+	
152	+(34)	-	+	
158	+(32)	-	+	
160	+(33)	-	+	HRSV
161	+(28)	-	+	HRSV
163	+(32)	-	+	

^a Cycle threshold value as determined by LightCycler.^b Viruses amplified by the multiplex PCR assay i. e. influenza (Flu) A and B as well as the human respiratory syncytial virus (HRSV).

- 80 -

Table 17: Evaluation of the multiplex PCR respiratory assay for detection of human respiratory syncytial virus (HRSV).

		Antigenic test (RSV TestPack) (n = 204)		HRSV gG PCR assays ^a (n = 32)	
		+	-	+	-
Multiplex PCR	+	83	21	20	1
	-	11	89	6	5

5

Sensitivity: 103/109 = 94.5%

Specificity: 94/95 = 98.9%

Positive predictive value: 103/104 = 99.0%

Negative predictive value: 94/100 = 94.0%

10

^a Only performed for samples showing discordant results with the multiplex PCR assay and the antigenic test.

- 81 -

Table 18: Evaluation of discordant test results for human respiratory syncytial virus (HRSV).

Sample No.	Multiplex PCR HRSV results (C _T) ^a	Antigenic test HRSV results	Glycoprotein G PCR HRSV results (genotype)	Other PCR- amplified viruses ^b
16	+(32)	-	+(B)	
17	+(27)	-	+(B)	
26	+(36)	-	+(B)	
34	-	+	-	
35	+(33)	-	+(B)	Flu A
43	+(36)	-	+(A)	Flu A
46	+(34)	-	+(B)	
55	+(34)	-	+(B)	
58	+(33)	-	+(B)	
62	-	+	+(A)	Flu A
70	+(37)	-	+(B)	
71	+(35)	-	+(B)	
72	+(34)	-	+(B)	
73	+(26)	-	+(A)	
79	+(33)	-	+(B)	
80	-	+	-	
91	+(35)	-	+(A)	
95	+(29)	-	+(B)	
100	+(30)	-	+(A)	
112	-	+	-	
129	+(34)	-	+(B)	
130	+(35)	-	+(B)	
134	-	+	+(A)	Flu A
139	-	+	+(A)	Flu A
142	-	+	+(A)	Flu A
144	-	+	+(B)	Flu A
150	+(34)	-	-	
187	+(31)	-	+(A)	
191	+(29)	-	+(A)	

- 82 -

Table 18: Evaluation of discordant test results for human respiratory syncytial virus (HRSV). (Continued).

193	-	+	+(A)
211	-	+	-
212	-	+	-

5

^a Cycle threshold value as determined by Lightcycler.

^b Viruses amplified by the multiplex PCR assay i. e. influenza (Flu) A and B as well as the human respiratory syncytial virus (HRSV).

- 83 -

CLAIMS:

- 1- A method for detecting and/or quantifying human metapneumovirus (hMPV) in a sample said method comprising:
- 5 -providing at least one probe or primer specific for a nucleic acid sequence of said hMPV;
- contacting said at least one probe and/or primer with said sample to allow annealing of said probe and/or primer with said nucleic acid sequence; and
- detecting and/or quantifying said nucleic acid sequence using said annealed probe and/or primer.
- 10 2- The method as claimed in claim 1 wherein said nucleic acid sequence is comprised in a hMPV gene selected from a group consisting of nucleocapsid (N), phosphoprotein (P), matrix (M), fusion (F), membrane (M2), polymerase (L), glycoprotein (G) and small hydrophobic (SH) genes.
- 15 3- The method as claimed in claim 2 wherein said nucleic acid sequence is selected from any one of SEQ ID NO 2-8, 10-74, 76-90 or fragments thereof.
- 4- The method as claimed in claim 3 wherein said probe or primer is at least 10
- 20 nucleotides in length.
- 5- A method for detecting and/or quantifying human metapneumovirus (hMPV) in a sample said method comprising:
- 25 -performing reverse transcription using a template RNA derived from said sample to obtain a nucleic acid product;
- amplifying said nucleic acid product using a pair of oligonucleotide primers wherein said primers are specific for a sequence comprised in a hMPV gene selected from a group consisting of nucleocapsid (N), phosphoprotein (P), matrix (M), fusion

- 84 -

(F), membrane (M2), polymerase (L), glycoprotein (G) and small hydrophobic (SH) genes to produce an amplification product; and

-detecting and/or quantifying said amplification product.

5 6- The method as claimed in claim 5 wherein said oligonucleotide primers are at least 10 nucleotides in length and capable of hybridizing with any one of SEQ ID 2-8, 10-74, 76-90.

7- The method as claimed in claim 5 or 6 wherein said step of performing reverse
10 transcription comprises contacting said template RNA with a primer selected from SEQ ID Nos 91-114 and wherein said oligonucleotide primers for PCR are selected from SEQ ID Nos 91-114.

8- The method as claimed in any one of claim 5-7 wherein said oligonucleotide
15 primers are pairs of primers selected from SEQ ID Nos 91 and 94, 92 and 94, 91 and 93, 97 and 99, 97 and 98, 100 and 101, 102 and 103, 104 and 107, 105 and 106, 108 and 109, 112 and 113 and 112 and 114.

9- The method as claimed in claim 5 wherein said template RNA is contacted
20 with primer selected from SEQ ID NO 91-94 and 112-114 and wherein said oligonucleotide primers are selected from SEQ ID NO 91-94 and 112-114.

10- The method as claimed in any one of claim 5-9 wherein said step of
amplifying is performed using PCR.

25

11- The method as claimed in claim 10 wherein said PCR is RT-PCR.

12- The method as claimed in claim 11 wherein said RT-PCR is real time RT-
PCR.

30

- 85 -

- 13- The method as claimed in claim 11 or 12 wherein said RT-PCR comprises detecting said amplification products by characteristic melting temperature of said amplification products.
- 5 14- The method as claimed in claim 11 or 12 wherein said RT-PCR comprises detecting and/or quantifying said amplification products with probes specific for said products.
- 15- The method as claimed in claim 14 wherein said probes are selected from SEQ ID no 115-129.
- 10 16- A composition for detecting a hMPV said composition comprising a combination of oligonucleotides for performing reverse transcription of a template RNA from said hMPV virus and for an amplification reaction of a product obtained from said reverse transcription wherein said oligonucleotides for said amplification reaction are specific for a sequence comprised in a hMPV gene selected from a group consisting of nucleocapsid (N), phosphoprotein (P), matrix (M), fusion (F), membrane (M2), polymerase (L), glycoprotein (G) and small hydrophobic (SH) genes.
- 20 17- The composition of claim 16 wherein said oligonucleotides for said amplification reaction are primers selected from the group comprising SEQ ID Nos 91-114 and combination thereof.
- 25 18- A kit comprising a combination of oligonucleotides wherein the oligonucleotides are selected from:
SEQ ID NOs: 91-114 and the pairs of SEQ ID Nos 91 and 94, 92 and 94, 91 and 93, 97 and 99, 97 and 98, 100 and 101, 102 and 103, 104 and 107, 105 and 106, 108 and 109, 112 and 113 and 112 and 114.
- 30 19- A method for typing an hMPV strain which comprises the steps of:

- 86 -

-amplifying an hMPV nucleic acid fragment and detecting specific viral sequences;

-digesting said fragment with one or more restriction endonuclease; and

-analysing the restriction fragment length polymorphisms.

5

20- The method as claimed in claim 19 wherein said nucleotide sequences are found in fusion(F) or glycoprotein (G) gene.

10

21- The method as claimed in claim 20 wherein said sequences are selected from SEQ ID NO 26-74.

22- A method for detecting and/or quantifying two or more respiratory viruses in a sample said method comprising:

15 -providing at least two probes and/or primers specific for a nucleic acid sequences in said two or more respiratory viruses;

-contacting said at least two probes and/or primers with said sample to allow annealing of said probes and/or primers with said nucleic acid sequences; and

-detecting and/or quantifying said nucleic acid sequences using said annealed probes and/or primers.

20

23- The method as claimed in claim 22 wherein at least one of said nucleic acid sequences is comprised in a hMPV gene selected from a group consisting of nucleocapsid (N), phosphoprotein (P), matrix (M), fusion (F), membrane (M2), polymerase (L), glycoprotein (G) and small hydrophobic (SH) genes.

25

24- The method as claimed in claim 23 wherein said nucleic acid sequence is selected from any one of SEQ ID NO 2-8, 10-74, 76-90 or fragments thereof.

25- The method as claimed in claim 24 wherein said probes and/or primers are at
30 least 10 nucleotides in length.

- 87 -

26- A method for detecting and/or quantifying two or more respiratory viruses in a sample said method comprising:

- 5 -performing reverse transcription using a template RNA derived from said sample to obtain nucleic acid products for each of said viruses;
 -amplifying said nucleic acid products using two or more pairs of oligonucleotide primers to produce an amplification product; and
 -detecting and/or quantifying said amplification products.

10

27- The method as claimed in claim 26 wherein at least one of said primers is specific for a sequence comprised in a hMPV gene selected from a group consisting of nucleocapsid (N), phosphoprotein (P), matrix (M), fusion (F), membrane (M2), polymerase (L), glycoprotein (G) and small hydrophobic (SH) genes.

15

28- The method as claimed in claim 27 wherein said oligonucleotide primers specific for a sequence comprised in a hMPV gene are capable of hybridizing with any one of SEQ ID 2-8, 10-74, 76-90.

20

29- The method as claimed in claim 28 wherein said oligonucleotide primers are at least 10 nucleotides in length.

30- The method as claimed in claim 29 wherein said oligonucleotide primer
25 specific for a sequence comprised in a hMPV gene are selected from SEQ ID Nos 91-114.

31- The method as claimed in any one of claim 26-30 wherein said at least two
30 respiratory viruses comprise influenza A and B, human respiratory syncytial viruses A and B, parainfluenza viruses (PIV) types 1-4, adenoviruses, rhinoviruses,

- 88 -

enteroviruses and coronaviruses or any combination thereof and wherein said primers and said two or more viruses are selected such that the detection and or quantification is specific for each of said viruses.

5 32- The method as claimed in claim 31 wherein said oligonucleotide primers are at least 10 nucleotides in length and capable of hybridizing with any one of SEQ ID NO 130-138 and 170-171.

10 33- The method as claimed in claim 31 or 32 wherein said at least two viruses are influenza A, human Respiratory syncytial virus, human metapneumovirus and influenza B.

15 34- The method as claimed in claim 31 or 32 wherein said at least two viruses are Parainfluenza 1, Rhinovirus, Adenovirus, Parainfluenza 3, Enterovirus, and coronavirus.

20 35- The method as claimed in claim 31 wherein said pairs of oligonucleotide primers are selected from SEQ ID Nos 139 and 140, 141 and 142, 143 and 144, 92 and 94, 112 and 113, 112 and 114, 145 and 146, 147 and 148, 149 and 150, 151 and 152, 154 and 155, 153 and 155, 156 and 157, 158 and 159, 160 and 161.

25 36- The method as claimed in any one of claim 26-35 wherein said step of amplifying is performed using PCR and said primer are selected such that the products of the amplifications can be distinguished.

37- The method as claimed in claim 36 wherein said PCR is RT-PCR.

38- The method as claimed in claim 37 wherein said RT-PCR is real time RT-PCR.

30

- 89 -

- 39- The method as claimed in claim 37 or 38 wherein said RT-PCR comprises detecting said amplification products by characteristic melting temperature of said amplification products.
- 5 40- The method as claimed in claim 37 or 38 wherein said RT-PCR comprises detecting and/or quantifying said amplification products with probes specific for said products.
- 41- The method as claimed in claim 40 wherein said probes are selected from SEQ
10 ID no 162-169 and 172.
- 42- A composition for detecting at least two respiratory viruses said viruses comprising at least hMPV said composition comprising a combination of oligonucleotides for performing reverse transcription of a template RNA from said at
15 least two respiratory viruses and for an amplification reaction of a product obtained from said reverse transcription wherein said oligonucleotides for said amplification reaction comprise oligonucleotides specific for a sequence comprised in a hMPV gene selected from a group consisting of nucleocapsid (N), phosphoprotein (P), matrix (M), fusion (F), membrane (M2), polymerase (L), glycoprotein (G) and small hydrophobic
20 (SH) genes.
- 43- The composition of claim 42 wherein said oligonucleotides for said amplification reaction are primers selected from the group comprising SEQ ID Nos 91-114 and combination thereof.
- 25 44- A method for simultaneously detecting two or more respiratory tract viruses in a sample, said method comprising:

- 90 -

Selecting primers specific for a nucleic acid sequence in each of said two or more viruses, said primers to be used in an amplification reaction for detection of said nucleic acid sequences;

5 distributing said primers in one or more assay mixture comprising said sample and at least two pairs of primers; and

wherein said selecting and said distributing is based on said detection of said nucleic acid sequence of said two or more viruses being substantially free of overlap and
10 enabling to distinguish between said two or more viruses.

45- The method as claimed in claim 44 wherein said amplification reaction is PCR.
15

46- The method as claimed in claim 45 wherein said PCR is RT-PCR.

47- The method as claimed in claim 45 wherein said RT-PCR is real time RT-PCR.
20

48- The method as claimed in claim 24 wherein said detection is melting temperature.

49- An isolated nucleic acid comprising a sequence that hybridizes under stringent
25 conditions to a hybridization probe the nucleotide sequence of which consists of any one of SEQ ID NO 2-8, 10-74, 76-90 or complements thereof.

50- A kit comprising a nucleic acid probe that is at least 10 nucleotides in length and is selected from a group consisting sequences hybridizable to SEQ ID Nos 2-8, 10-74,
30 76-90 or fragments thereof.

- 91 -

51- A human metapneumovirus (hMPV) deposited with the International Depository Authority of Canada under Accession number IDAC 111203-01 (CAN97-83).

- 5 52- A human metapneumovirus (hMPV) deposited with the International Depository Authority of Canada under Accession number IDAC 111203-02 (CAN98-75).

1/13




FIGURE 1




FIGURE 2

3/13




FIGURE 3

4/13




FIGURE 4

5/13




FIGURE 5

6/13




FIGURE 6

7/13




FIGURE 7

8/13




FIGURE 8

9/13




FIGURE 9




FIGURE 10 A

11/13




FIGURE 10 B

12/13




FIGURE 11

13/13




FIGURE 12

SEQUENCE LISTING

<110> Boivin, Guy

<120> METHOD FOR DETECTING RESPIRATORY VIRUSES

<130> 6013-148PCT

<150> CA 2,411,264

<151> 2002-12-19

<150> CA 2,418,004

<151> 2003-01-24

<160> 172

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 13350

<212> DNA

<213> human metapneumovirus

<220>

<221> gene

<222> (1)...(13450)

<223> human metapneumovirus, strain 00-1
Accession number af371337

<400> 1

gtataaatta	gattccaaaa	aaatatggga	caagtgaaaa	tgtctcttca	agggattcac	60
ctgagtgtt	tatcatacaa	gcattgctata	ttaaaagagt	ctcagtcacac	aataaaaaaga	120
gtgtgtgggta	caacaactgc	agtgcacccc	tcatcattgc	aacaagaaat	aacactgttg	180
tggtggagaaa	ttctgtatgc	taaacatgct	gactacaaat	atgctgcaga	aatagggaata	240
caatatatta	gcacagcttt	aggatcagag	agagtgcagc	agattctgag	gaactcaggc	300
agtgaagtcc	aagtgtgctt	aaccagaacg	tactctctgg	ggaaaaattaa	aaacaataaa	360
ggagaagatt	tacagatggt	agacatacac	ggggtagaga	agagctgggt	agaagagata	420
gacaaagaag	caaggaaaac	aatggcaacc	ttgcttaagg	aatcatcagg	taatatccca	480
caaaatcaga	ggccctcagc	accagacaca	cccataatct	tattatgtgt	aggtgcctta	540
atattcacta	aactagcatc	aaccatagaa	gtgggactag	agaccacagt	cagaagggtc	600
aaccgtgtac	taagtgtatg	actcaagaga	taccctagaa	tggacatacc	aaagattgcc	660
agatccttct	atgacttatt	tgaacaaaaa	gtgtatcaca	gaagtttgtt	cattgagtat	720
ggcaaaagcat	taggtccatc	atctacaggc	agcaaaagcag	aaagtctatt	tgtaaata	780
ttcatgcaag	cttatggggc	cggtcaaaaa	atgctaaggt	ggggggtcat	tgccagggtca	840
tccaacaata	taatgttagg	acatgtatcc	gtccaagctg	agttaaaaaa	ggtcacagaa	900
gtctatgact	tggtgcgaga	aatggggccct	gaatctggac	ttctacattt	aaggcaaaagc	960
ccaaaagctg	gactgttatt	actagccaac	tgtcccaact	ttgcaagtgt	tgctctcggg	1020
aatgcctcag	gcttaggcat	aatcggatat	tatcgaggga	gagtaccaa	cacagaatta	1080
ttttcagcag	ctgaaagtta	tgccaaaagt	ttgaaagaaa	gcaataaaat	aaatttctct	1140
tcattaggac	ttacagatga	agagaaagag	gctgcagaac	atttcttaaa	tgtgagtgc	1200
gacagtcaaa	atgattatga	gtaattaaaa	aaagtgggaca	agtcaaaatg	tcattccctg	1260
aaggaaaaaga	tattcttttc	atgggtaatg	aagcagcaaa	attagcagaa	gctttccaga	1320
aatcattaag	aaaaccaggt	cataaaagat	ctcaatctat	tataggagaa	aaagtgaata	1380
ctgratcaga	aacattggaa	ttacctacta	tcagtagacc	tgcaaaaacca	accataccgt	1440
cagaaccaaaa	gttagcatgg	acagataaag	gtggggcaac	caaaactgaa	ataaagcaag	1500
caatcaaaagt	catggatccc	attgaagaag	aagagtctac	cgagaagaag	gtgtaccctt	1560
ccagtgtatg	gaaaacccct	gcagaaaaga	aactgaaacc	atcaactaac	accaaaaaga	1620
aggttttcat	tacaccaa	gaaccaaggga	aatatacaaa	gttggaaaaa	gatgctctag	1680
atttgctctc	agataatgaa	gaagaagatg	cagaatcttc	aatcttaacc	tttgaagaaa	1740
gagatacttc	atcattaagc	attgaggcca	gattggaatc	aatagaggag	aaattaaagca	1800
tgatattagg	gctattaaga	acactcaaca	ttgctacagc	aggaccaca	gcagcaagag	1860
atgggatcag	agatgcaatg	attggcgtaa	gagagggaat	aatagcagac	ataataaagg	1920
aagctaaagg	gaaagcagca	gaaatgatgg	aagaggaaat	gagtcaacga	tcaaaaatag	1980
gaaatggtag	tgtaaaatta	acagaaaaag	caaaagagct	caacaaaatt	gttgaagatg	2040
aaagcacaag	tgtagaatcc	gaagaagaag	aagaaccaaa	agacacacaa	gaccaatagtc	2100
aagaagatga	catttaccag	ttaattatgt	agtttaataa	aaataaaca	tyggacaagt	2160
aaaaatggag	tcctacctag	tagacaccta	tcaaggcatt	ccttacacag	cagctgttca	2220
agttgatcta	atagaaaagg	acctgttacc	tgcaagccta	acaatatggg	tcctttgtt	2280
tcaggccaac	acaccaccag	cagtgtctgt	cgatcagcta	aaaacctga	caataaccac	2340
tctgtatgct	gcatacaaaa	atggtccaat	actcaagtg	aatgcattcag	ccaagggtgc	2400

2/52

agcaatgtct	gtactttccca	aaaaatttga	agtcaatgcg	actgtagcac	tcgatgaata	2460
tagcaaaactg	gaattttgaca	aactcacagt	ctgtgaagta	aaaacagttt	acttaacaac	2520
catgaaacca	tacgggatgg	tatcaaaatt	tgtgagctca	gccaattcag	ttggcaaaaa	2580
aacacatgat	ctaactcgac	tatgtgattt	tatggatcta	gaaaagaaca	cacctgttac	2640
aataccagca	ttcatcaaat	cagtttcaat	caaagagagt	gagtcagcta	ctgttggaagc	2700
tgctataagc	agtgaagcag	accaagctct	aacacaggcc	aaaattgcac	cttatgctggg	2760
attaattatg	atcatgacta	tgaacaatcc	caaaggcata	ttcaaaaagc	ttggagctgg	2820
gactcaagtc	atagtagaac	taggagcata	tgtccaggct	gaaagcataa	gcaaaaatag	2880
caagacttgg	agccatcaag	ggacaagata	tgtcttgaag	tccagataac	aaccaagcac	2940
cttggccaag	agctactaac	cctatctcat	agatcataaa	gtcaccattc	tagttatata	3000
aaaatcaagt	tagaacaaga	attaaatcaa	tcaagaacgg	gacaaaataa	aatgtcttgg	3060
aaagtgggtga	tcatttttttc	attgttaata	acacctcaac	acgggtctta	agagagctac	3120
ttagaagagt	catgttagcac	tataactgaa	ggatatctca	gtgttctgag	gacaggttgg	3180
tacaccaatg	tttttacact	ggaggtaggc	gatgtagaga	acrttactag	tgccgatgga	3240
cccagcttaa	taaaaaacaga	attagacctg	acccaaagtg	cactaagaga	gctcagaaac	3300
gtttctgctg	atcaactggc	aagagaggag	caaattgaaa	atcccagaca	atctagattc	3360
gttctaggag	caatagcact	cggtgttgca	actgcagctg	cagttacagc	aggtgttgca	3420
attgccaaaa	ccatccggct	tgaagtgtga	gtaacagcaa	ttaagaatgc	cctcaaaaag	3480
accaatgaag	cagtatctac	attgggggaa	ggagttcgtg	tgttggcaac	tgagtgaga	3540
gagctgaaag	attttgtgag	caagaatcta	acacgtgcaa	tcaacaaaaa	caagtgcgac	3600
attgctgacc	tgaanaatggc	cgtagacttc	agtcaattca	acagaagggt	cctaaatgtt	3660
gtgcggcaat	tttcagacaa	cgctgggaat	acacagcaaa	tatcttttga	cttaatgaca	3720
gatgctgaac	tagccagagc	tgtttccaac	atgcccaaat	ctgcaggaca	aataaaactg	3780
atgtrtgaga	accgtgcaat	ggtaagaaga	aaagggttcg	gattcctgat	aggagtttac	3840
ggagctccg	taattttacat	ggtgcaactg	ccaatctttg	gggttataga	cacgccttgc	3900
tggatagtaa	aagcagcccc	ttcttgttca	ggaaaaaagg	gaaactatgc	ttgcctctta	3960
agagaagacc	aaggatggtg	ttgtcaaaat	gcagggtcaa	ctgtttacta	cccaaatgaa	4020
aaagactgtg	aaacaagagg	agaccatgtc	ttttgcgaca	cagcagcagg	aatcaatgtt	4080
gctgagcagt	caaaaggagt	caacataaat	atatctacta	ctaattaccc	atgcaaatgt	4140
agcacaggaa	gacatcctat	cagtattggt	gcactatctc	ctcttggggc	tttggttgct	4200
tgctacaagg	gagtggactg	ttccattggc	agcaacagag	tagggatcat	caagcaactg	4260
aacaaggct	gctcttata	aaccaaccaa	gacgcagaca	cagtgaacat	agacaacact	4320
gtataccagg	taagcaaatg	tgaaggcgaa	cagcatgtta	taaaagggaag	gccagtgta	4380
agcagcttgg	accagctcaa	gtttcctgaa	gatcaattca	atgttgcaat	tgaccaaggt	4440
ttcgagagca	ttgagaacag	tcaggccctg	gtggatcaat	caaacagaa	cctaagcagt	4500
gcagagaaag	gaaacactgg	cttcacatct	gtaataattc	taattgtctg	ccttggtctt	4560
accatgattc	tttgtagtgt	ttttatcata	ataaagaaaa	caaaagaaac	cacaggagca	4620
cctccagagc	tgagtgggtg	cacaaacaat	ggcttcatac	cacataatta	gttaattaaa	4680
aataaagtaa	attaaaaata	attaaaaata	aaaaataaaa	tttgggacaa	atcataatgt	4740
ctcgcaaggc	tccgtgcaaa	tatgaagtgc	ggggcaaatg	caatagagga	agtgaagtgc	4800
agttaacca	caattactgg	agttggccag	atagataact	attaataaga	tcaaatattt	4860
tattaaatca	acttttaagg	aacactgata	gagctgatgg	cttatcaata	atatcaggag	4920
caggcagaga	agataggaca	caagattttg	tcctaggttc	caccaatgtg	gttcaagggt	4980
ataattgagt	taaccaaagc	ataacaaaag	ctgcagcctg	ttacagctca	cataatataa	5040
tcaacaact	acaaggaagt	gaagttaggc	aggctagaga	taacaaacta	tctgacagca	5100
aacatgragc	acttcacaac	ttagtccrat	cttatattgga	gatgagcaaa	actcctgcat	5160
ctttaatcaa	caatrtcaag	agactgcccga	gagagaaaat	gaaaaaatta	gcaaaagctca	5220
taattgactt	atcagcaggt	gctgaaaatg	actcttcata	tgcccttgcaa	gacagtgaac	5280
gcactaatca	agtgcagtga	gcatgggtcca	gttttcatta	ctatagaggt	tgatgacatg	5340
atatggactc	acaaggactt	aaaagaagct	ttatctgatg	ggatagtgaa	gtctcactac	5400
aacattttaca	attgtttatt	agaaaacata	gaaaattatat	atgtcaaggc	ttactttaagt	5460
tagtaaaaac	acatcagagt	gggataaatg	acaatgataa	cattagatgt	cattaaaagt	5520
gatgggtctt	caaaaaacatg	tactcacctc	aaaaaaataa	ttaaagacca	ctctggtaaa	5580
gtgcttattg	tactttaagt	aatattagct	ttactaacat	ttctcacagt	aacaatcacc	5640
atcaattata	taaaagtggg	aaacaactctg	caaataatg	agtcacaaac	tgaatcagac	5700
aaaaaggact	catcatcaaa	taccacatca	gtcacacaac	agactactct	aatcatgat	5760
atcacacagt	atttttaaaag	tttgattcaa	aggtatacaa	actctgcaat	aaacagtgc	5820
acatgctgga	aaataaacag	aatcaatg	acaaatataa	caacatacaa	atttttatgt	5880
tttaaatctg	aagacacaaa	aaccaacaat	tgtgataaac	tgacagattt	atgcagaaac	5940
aaaccaaacc	cagcagttgg	agtgatcac	atagtagaat	gccattgtat	atacacagtt	6000
aaatgggaag	gctatcatta	cccaaccgat	gaaaccfaat	cctaaatgtt	aacaccagat	6060
taggatccat	ccaagtctgt	tagttcaaca	atttagttat	ttaaaaatat	tttgaaaaac	6120
agtaagtttc	tatgatactt	cataataata	agtaataatt	aatgtcttaa	tcatcatcac	6180
aacattatrc	gaaaccataa	ctattcaatt	taaaaagtaa	aaaacaataa	catgggacaa	6240
gtagttatgg	agggtgaaagt	ggagaacatt	cgaacaaatg	atatgtctca	agcaagagta	6300
aaaaatcgtg	tggcagcgag	caaatgcttt	aaaaatgctt	ctttggtcct	cataggaata	6360
actacattga	gtattgccct	caatatctat	ctgatcataa	actataaaat	gcaaaaaaac	6420
acatctgaat	cagaacatca	caccagctca	tcacccatgg	aatccagcag	agaaactcca	6480
acgggtcccca	cagacaaactc	agacaccaac	tcaagcccac	agcatccaac	tcaacagtc	6540
acagaagggt	ccacactcta	ctttgcagcc	tcagcaagct	caccagagac	agaaccaaca	6600
tcaacaccag	atacaacaaa	ccgcccgcct	ttcgtcgaca	cacacacaac	accaccaagc	6660
gcaagcagaa	caaagacaag	tcgggcagtc	cacacaaaaa	acaacccaag	gacaagctct	6720

3/52

agaacacatt	ctccaccacg	ggcaacgaca	aggacggcac	gcagaaccac	cactctccgc	6780
acaagcagca	caagaaagag	accgtccaca	gcatcagtc	aacctgacat	cagcgcaaca	6840
accacacaaa	acgaagaagc	aagtcacagc	agcccaaaaa	catctgcaag	cacaaacaga	6900
atacaaaagg	aaagcgtgga	ggccaacaca	tcaacaacat	acaaccaaac	tagttaacaa	6960
aaaatacaaa	ataactctaa	gataaacctat	gcagacacca	acaatggaga	agccaaaaga	7020
caattcacaa	tctccccaaa	aaggcaacaa	caccatatta	gctctgcccc	aatctctccg	7080
gaaaaaacac	tgcgccatat	accaaaaata	ccacaaccac	cccaagaaaa	aaactgggca	7140
aaacaacacc	caagagacaa	ataacaattg	atcctctcaa	tgaatccact	gttaattgtct	7200
atcttctctga	ctcatatctt	aaaggagtg	tttcttttag	tgagactaat	gcaattggrr	7260
catgtctctt	aaaaagacct	tacctaaaaa	atgacaacac	tgcaaaagtt	gccatagaga	7320
atcctgttat	cgagcatgrr	agactcaaaa	atgcagtcac	ttctaagatg	aaaatacag	7380
attacaagat	agtagagcca	gtaaacatgc	aacatgaaat	tatgaagaat	gtacacagtt	7440
gtgagctcac	attatataaa	cagtttttaa	caaggagtaa	aaatattagc	actctcaaat	7500
taaatatgat	atgtgattgg	ctgcagtrta	agctctacac	agatgatacc	tcaatcctaa	7560
gttttataga	tgtagaattt	atacctagct	gggtaagcaa	ttggtttagt	aatgggtaca	7620
atctcaacaa	gttgattctt	gaattcagga	aagaagaagt	ataagaact	ggttcaatct	7680
tgtgtagggt	attgggtaaa	ttagtttttg	ttgtatcatc	atatggatgt	atagtcaaga	7740
gcaacaaaag	caaaagagtg	agcttcttca	catacaatca	actgttaaca	tggaaagatg	7800
tgtgtttaa	tagattcaat	gcaaatrrtt	gtatatgggt	aagcaacagt	ctgaatgaaa	7860
atcaagaagg	gctagggttg	agaagtaatc	tgcaaggcat	attaactaat	aagctatatg	7920
aaactgtaga	ttatatgctt	agtttatgtt	gcaatgaagg	tttctcactt	gtgaaagagt	7980
tcgaaggctt	tattatgagt	gaaattctta	ggattactga	acatgctcaa	ttcagtacta	8040
gatttagaaa	tactttatta	aatggattaa	ctgatcaatt	aaaaaatta	aaaaataaaa	8100
acagactcag	agttcatggg	accgtgttag	aaaataatga	ttatccaatg	tacgaagrrg	8160
tacttaagtt	attaggagat	actttgagat	gtattaaatt	attaatcaat	aaaaacttag	8220
agaatgctgc	tgaattatac	tatatattta	gaattattcg	tcaccaatg	gtagatgaaa	8280
gagatgcaat	gpatgctgtc	aaattaaaca	atgaaatcac	aaaaatcctt	aggtgggaga	8340
gcttgacaga	actaagaggg	gcattcatat	taaggattat	caaaaggattt	gtagacacaa	8400
acaaaagagt	gcccacaaatt	aaaaacttaa	aagtgttag	taagagatgg	actatgtact	8460
tcgaagcaaa	agtttaccct	agtcacactg	aattaaagca	acaagatttt	rtagagcttg	8520
ctgcaatata	gtttgaacaa	gagttttctg	tccctgaaaa	aaccaacctt	gagatgggtat	8580
taaatgataa	agctatatca	cctcctaaaa	gattaatattg	gtctgtgtat	ccaaaaaatt	8640
acttaccata	gaaaataaaa	aatcgatatc	tagaagagac	tttcaatgca	agtgtatgtc	8700
tcaaaacazg	aagagtacta	gagtactatt	tgaagataaa	taaatctgac	caaaaagaac	8760
ctaaaagttt	tgtgtttaaa	caagaatatt	taaatgataa	ggatcatatt	gtctctgcaa	8820
ttgaaaagaa	aagagaaatt	agtgtaggta	gaatgtttgc	tatgcaacca	ggaaaacagc	8880
gacaaatata	aatattgggt	gaaaaattgt	tagctgataa	tattgtacct	tttttccag	8940
aaactttaac	aaagtattgt	gatctagatc	ttcagagaat	aatggaaatc	aaatcggaac	9000
tttcttctat	taaaactaga	agaaatgata	gttataataa	ttacattgca	agagcatcca	9060
tagtaacaga	tttaagtaag	ttcaaccaag	cctttaggta	tgaactaca	gcgatctgtg	9120
cggatgtagc	agatgaacta	catgggaacac	aaagcctatt	cigtgtggtta	catcttaicg	9180
tccctatgac	aaatagata	tgtgcttata	gacatgcacc	accagaaaca	aaaggtgaat	9240
atgatataga	taagatagaa	gagcaaaagt	gtttatatag	atatcatatg	gggtgtattg	9300
aaggatgggt	tcgaaaaact	tggacaatgg	aagctatatc	tctattagat	gttgtatctg	9360
taaaaacacg	atgtcaaatg	acatctttat	taaacgggtga	caaccaatca	atagatgtaa	9420
gtaaaaccagt	taagtatatc	gagggtttag	atgaaagtga	agcagattat	agcttggctg	9480
taaaaatggt	aaagagaata	agagatgcat	acagaaatat	agggcataaa	cttaagaag	9540
gggaaacata	tatatcaaga	gatcttcagt	ttataagtaa	gggtgattcaa	tctgaaggag	9600
taatgcatcc	tacccttata	aaaaagatct	taagagtggg	accatggata	aacacaatat	9660
tagatgacat	taaaaaccagt	gcagagrtcaa	tagggagtct	atgtcaggaa	ttagaattta	9720
gggggggaaag	cataatagtt	agtcgtgat	taaggaattt	ttggctgtat	aatttataca	9780
tgcattgaatc	aaagcaacac	cccctagcag	ggaagcagtt	attcaaacaa	ctaaataaaa	9840
cattaacatc	agtgacagaa	ttttttgaaa	taaaaaagga	aaatgaagta	gtagatctat	9900
ggatgaacat	accaatgcag	tttgaggagg	gagatccagt	agtccttctat	agatctttct	9960
atagaaggac	ccctgatttt	ttactgaag	caatcagtc	tgtggatatt	cigttaagaa	10020
tatcagccaa	cataagaat	gaagcgaaaa	taagtttctt	caaaagcrrta	ctgtcaatag	10080
aaaaaaatga	acgtgctaca	ctgacaacac	taatgagaga	tcctcaagct	gttggctcag	10140
agcgacaagc	aaaagtaaca	agtgatatca	atagaacagc	agttaccagc	atcttaagtc	10200
tttctccaaa	tcaacttttc	agcgatagtg	ctatacacta	cagtagaaat	gaagaagagg	10260
tcggaatcat	tgtgcacaa	ataacacctg	tttatcctca	tggactgaga	gttttgtatg	10320
aatcattacc	ttttcatata	gctgaaaaag	ttgtgaatat	gatatcagga	acgaaatcca	10380
taaccaactt	attacagaga	acatctgcta	ttaatgggtga	agatattgac	agagctgtat	10440
ccatgatgct	ggagaaccta	ggattattat	ctagaatatt	gtcagtagtt	gtttagatga	10500
tagaaattcc	aaccaaatct	aatggtaggc	tgtatgtttg	tcagatatct	agaaccctaa	10560
gggagacatc	atggaaataat	atggaaatag	ttggagtaac	atcccttagc	atcactacat	10620
gcattgagat	catatatgca	actagctctc	atttgaaagg	gataatcatt	gaaaagttca	10680
gtactgacag	aactacaaga	ggtcaaagag	gtccaaagag	cccttgggta	gggtcgagca	10740
ctcaagagaa	aaaattagtt	cctgtttata	acagacaaat	tctttcaaaa	caacaagag	10800
aacagctaga	agcaattgga	aaaaatgagat	gggtatatata	agggacacca	ggtttaagac	10860
gattactcaa	taagatttgt	cttggaggtt	taggcattag	ttacaaatgt	gttaaacctt	10920
tattacctag	gtttatgagt	gtaaatttcc	tacacaggtt	atctgtcagt	agtagacctc	10980
tggaattccc	agcatcagrr	ccagcttata	gaacaacaaa	ttaccatttt	gacactagtc	11040

4/52

ctattaatca	agcactaagt	gagagatttg	ggaatgaaga	tattaatttg	gtcttccaaa	11100
atgcaatcag	ctgtggaatt	agcataatga	gtgtagtaga	acaattaact	ggtaggagtc	11160
caaaacagtt	agttttaata	cctcaattag	aagaaataga	cattatgccca	ccaccagtgt	11220
ttcaaggga	attcaattat	aagctagtag	ataagataac	ttctgatcaa	catatcttca	11280
gtccagacaa	aatagatarg	ttaacactgg	ggaaaatgct	catgccact	ataaaaggct	11340
agaaaacaga	tcagttcctg	aacaagagag	agaattat	ccatgggaat	aatctttatg	11400
agtctttgtc	agcagcgtaa	gcatgtcatt	gggtgtggg	atnaacagag	caatgtatag	11460
aaaaataaat	tttcaagaaa	gactgggggt	acgggttcac	atcggatcat	gcttttatgg	11520
acttcaaaat	attcctatgt	gtctttaaaa	ctaaactttt	atgtagttag	gggtcccaag	11580
ggaaaaacat	taaaagatga	gatatagtag	atgaatcaat	agataaactg	ttaaggattg	11640
ataatacttt	ttggagaatg	ttcagcaagg	ttatgtttga	atcaaaagggt	aagaaaagga	11700
taattgttata	tgatgtaaaa	tttctatcat	tagtaggtta	tatagggttt	aagaattggg	11760
ttatagaaca	gttgagatca	gctgagttgc	atgaggtacc	ttggattgtc	aatgccgaag	11820
gtgatctggt	tgagatcaag	tcaattaaaa	tctattttga	actgatagag	caaagtttat	11880
ttttaagaat	aactgttttt	aactatacag	atattggcaca	tgctctcaca	agattaatca	11940
gaaagaagtt	gatgtgtgat	aatgcactat	taactccgat	tccatcccca	atggttaatt	12000
taactcaagt	tattgatcct	acagaacaat	tagcttattt	ccctaagata	acatttgaaa	12060
ggctaaaaaa	ttatgacact	agtttcaaat	atgctaagg	aaagctaaac	aggaattaca	12120
tgatactgtt	gccatggcaa	catgttaata	gatataactt	tgctcttagt	ttactggat	12180
gtaaagttag	tctaaaaaca	tgcatgtgaa	aacttatgaa	agatctaaac	cctaaagttc	12240
tgtactttat	tggaagaagg	gcaggaaatt	ggatggccag	aacagcatgt	gaatatcctg	12300
acatcaaat	tgatacaga	agttttaaag	atgacctga	tcactcattat	cctttggaa	12360
accagagagt	tataggagaa	ttaagcagga	taatagatag	cggtgaagg	ctttcaatgg	12420
aaacaacaga	tgcaactcaa	aaaactcatt	gggatttgat	acacagagta	agcaaaagtg	12480
ctttattaat	aactttatgt	gatgcagaat	ttaaggacag	agatgatttt	tttaagatgg	12540
taattctatg	gaggaaacat	gtattatcat	cgagaatttg	cactacttat	gggacagacc	12600
tctattttat	cgcaaaagtat	catgctaaag	actgcaatgt	aaaattacct	ttttttgtga	12660
gatcagtagc	cacttttatt	atgcaaggta	gtaaaactgt	aggctcagaa	tgctacatac	12720
tcttaaacat	agggcaccac	aacaatttac	cctgccatgg	agaaatacaa	aattctaaag	12780
tgaaaatagc	agtggtgta	gatttttatg	ctgcaaaaaa	acttgacaat	aaatctattg	12840
aagccaactg	taaatcactt	ttatcagggc	taagaatacc	gataaataag	aaagaattaa	12900
atagacagag	aaggttatta	acactacaac	gcaaccattc	ttctgtagca	acagttggag	12960
gtagcaaggt	catagagttc	aaatggttaa	caaacagagg	aaacacaata	attgattggg	13020
tagaacatat	tttaaatctt	ccaaaagggt	aattaaatta	tgattttttt	gaagcattag	13080
aaaatactta	ccctaataat	attaaactaa	tagataatct	aggggaatga	gagataaaaa	13140
aactgatcaa	agtaacttga	tatatgcttg	taagtaaaaa	atgaaaaatg	ataaaaaatga	13200
taaaataggt	gacaacttca	tactattcca	aagtaatcat	ttgattatgc	aattatgtaa	13260
tagttaatta	aaaactaaaa	atcaaaaggt	agaaactaac	aactgtcatt	aagtttatta	13320
aaaataagaa	attataattg	gatgtatagc				13350<210> 2

<211> 782

<212> DNA

<213> human metapneumovirus

<220>

<221> gene

<222> (1)...(782)

<223> human metapneumovirus, strain Quebec isolate No hmpv-118

<400> 2

atgtaggcac	cacaactgca	gtgacacctt	catcattgca	gcaagagata	acacttttgt	60
gtggagagat	tctttacact	aaacatactg	attacaaata	tgctgcagag	atagggatac	120
aatatatttg	cacggctcta	ggatcagaaa	gagtacaata	gattttaaga	aattcaggca	180
gtgaagtcca	gggtgttcta	accaagacat	actcrttagg	gaaaggtaaa	aattagtaag	240
gggaagagtt	gcaaatgtta	gatatacatg	gagtggaaaa	gagttgggta	gaagaaatag	300
acaaagaggg	aagaaaaaca	atggtgactt	tgctaaagga	atcatcaggt	aacatccac	360
aaaaccagag	gccttcagca	ccagacacac	caataatttt	atratgtgta	gggtctttaa	420
tattactaaa	actagcatca	acaatagaag	ttggactaga	gactacagtt	agaagagcta	480
acagagtgtc	aagtgtatgc	actcaaagat	accctagggt	agataataca	aagattgcta	540
gactcttcta	tgaactattt	gagcagaag	tgtattacag	gagtcatttc	attgagtatg	600
ggaaagcttt	aggtctatct	tgcacagga	gcaaaagcaga	aagtttggtt	gtaaatatat	660
ttatgccagc	ttatggagcc	gggtcaacaa	tgctaaagggt	gggtgtcatt	gccagatcat	720
ctaataatac	attgctaggg	catgtatctg	tgcaacctgg	atttgaagca	agtcacagag	780
gt						782

<210> 3

<211> 878

<212> DNA

<213> human metapneumovirus

<220>

<221> gene

5/52

<222> (1)...(878)

<223> human metapneumovirus, strain Quebec Isolate No hmpv-174

<400> 3

atgtgggtac	caccactgca	gtgacaccct	catcattgca	acaagaaata	acgctgttgt	60
gtggagaaat	tctgtatgct	aaacatgctg	attacaaata	tgctgcagaa	ataggaatac	120
aatatattag	cacagcttta	ggatcagaga	gagtgacaga	gattctgagg	aactcaggca	180
gtgaagtcca	agtggcttta	accagaacgt	actctctggg	gaaagttaaa	aacaataaag	240
gagaagattt	acagatgtta	gacatacacg	gggtagagaa	gagctgggta	gaagagatag	300
acaaagaagc	aaggaaaaca	atggcaacct	tgcttaaggga	atcatcaggt	aatatcccg	360
aaaatcagag	gccctcagca	ccagacacac	ccataatctt	attatgtgta	gggtccttaa	420
tatttactaa	actagcatca	accatagaag	tgggactaga	gaccacagtc	agaagggcta	480
accgtgtact	aagtgatgca	ctcaagagat	accctagaat	ggacatccca	aaaattgcca	540
gattccttcta	tgacttattt	gaacaaaaag	tgatcacacg	aagtttggtc	attgagtatg	600
gcaaagcatt	aggctcatca	tctacaggca	gcaaagcaga	aagtcctattt	gttaatatat	660
tcatgcaagc	ttatggagcc	ggtaaaacaa	tgctaagggtg	gggggtcatt	gccaggtcat	720
ccaacaatat	aatgttatga	catgtatccg	tccaagctga	gttaaacaca	ggtcacagaa	780
ctctatgact	tggtgcgaga	aatgggtcct	gaatctggac	ttctacattt	aaggcaaagc	840
ccaaaagctg	gactgtatca	ctagccaact	tcccaact			878

<210> 4

<211> 876

<212> DNA

<213> human metapneumovirus

<220>

<221> gene

<222> (1)...(876)

<223> human metapneumovirus, strain Quebec Isolate No hmpv-176

<400> 4

atgtaggccc	cacaactgca	gtgacacctt	catcattgca	gcaagagata	acacttttgt	60
gtggagagat	tctttacact	aaacatactg	attacaaata	tgctgcagag	atagggatac	120
aatatatttg	cacggctcta	ggatcagaaa	gagtacaaca	gattttaaga	aattcaggta	180
gtgaagttca	gggtggcttta	accagaacat	actctttagg	gaaaggtaaa	aatagtaaaag	240
gggaagagrt	gcaaatgtta	gatatacatg	gagtggaaaa	gagttgggta	gaagaataag	300
acaaagaggg	aagaaagaca	atgggtgactt	tgctaaaggga	atcatcaggt	aacatccac	360
aaaacagag	gccctcagca	ccagacacac	caataatctt	attatgtgta	gggtcgttaa	420
tattcactaa	actagcatca	acaatagaag	ttggactaga	gactacagtt	agaagagcta	480
acagagtgtc	aagtgatgca	ctcaaaagat	accctagggt	agatatacca	aagattgcta	540
gattctttta	tgaaactattt	gagcagaaag	tgattacacg	gagtcctattc	attgagtatg	600
ggaaagcttt	aggctcatct	tcaacaggaa	gcaaagcaga	aagtttggtt	gttaatatat	660
ttatgcaagc	ttatggagcc	ggtaaaacaa	tgctaagggtg	gggtgtcatt	gccagatcat	720
ctaacaacat	aatgttaggg	catgtatctg	tgcaagctga	attgaaacaa	gttacagagg	780
tttatgattt	gggtgagaaa	atgggtcctg	aatctgggct	tttactctta	agaacaagtc	840
caaaggcagg	actgttatcg	tggctaattgc	cccaat			876

<210> 5

<211> 869

<212> DNA

<213> human metapneumovirus

<220>

<221> gene

<222> (1)...(869)

<223> human metapneumovirus, strain Quebec Isolate No hmpv-193

<400> 5

atgtgggtac	aaacaactgca	gtgacaccct	catcattgca	acaagaaata	acgctgttgt	60
gtggagaaat	tctgtatgct	aaacatgctg	attacaaata	tgctgcagaa	ataggaatac	120
aatatattag	cacagcttta	ggatcagaga	gagtgacaga	gattctgagg	aactcaggta	180
gtgaagtcca	agtggcttta	accagaacgt	actctctggg	gaaagttaaa	aacaataaag	240
gagaagattt	acagatgtta	gacatacacg	gggtagagaa	gagctgggta	gaagagatag	300
acaaagaagc	aaggaaaaca	atggcaacct	tgcttaaggga	atcatcaggt	aatatccac	360
aaaatcagag	gccctcagca	ccagacacac	ccataatctt	attatgtgta	gggtccttaa	420
tatttactaa	gctagcatca	accatagaag	tgggactaga	gaccacagtc	agaagggcta	480
accgtgtact	aagtgatgca	ctcaagagat	accctagaat	ggacatccca	aaaattgcca	540
gattccttcta	tgacttattt	gaacaaaaag	tgatcacacg	aagtttggtc	attgagtatg	600
gtaaagcatt	aggatcatca	tctacaggca	gcaaagcaga	aagtcctattt	gttaatatat	660

6/52

tcattgcaagc	ttatggagcc	gggtcaaacaa	tgctaagggtg	gggggtcatt	gccaggtcat	720
ccaacaatat	aatgttagga	catgtatccg	tccaaggctg	agttaaaaa	ggtcacagaa	780
gtctatgact	tggtgcgaga	aatgggtcct	gaatctggac	ttctacattt	aaggcaaaagc	840
ccaaaagctg	gactgttatc	actagccaa				869

<210> 6
 <211> 848
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(848)
 <223> human metapneumovirus, strain Quebec Isolate No C-77807

<400> 6						
atgtaggcac	cacaactgca	gtgacacctt	catcattgca	acaagaaata	acacttttgt	60
gtggggaaat	tctttacact	aaacacactg	attacaaata	tgctgctgag	ataggaatgc	120
aatatatttg	cacagctcta	ggatcagaaa	gagtacaaca	gattttgaga	aactcaggta	180
gtgaagtcca	gggtgtttta	accaaaacat	actccttagg	gaaaggcaaa	aacagtaaag	240
gggaagagct	gcagatgcta	gatatacatg	gagtggaaaa	gagttgggta	gaagaaatag	300
acaaagaggg	aagaaagaca	atggtaacct	tgcttaagga	gtcatcaggt	aacatccac	360
aaaaccagag	accttcagca	ccagacacac	caataatttt	attatgtgta	ggtgccctaa	420
tattcactaa	actagcatca	acaatagaag	ttggattaga	gactacagtt	agaagagcta	480
atagagtgtc	aagtgtatga	ctcaaaagat	acctagggtt	agatatacca	aagattgcta	540
gatcttttta	tgaactattt	gaacaaaaag	tgtactacag	aagttttatt	attgagtacg	600
gaaaagcttt	aggctcatct	ccaacaggaa	gcaaaagcaga	aagtttggtt	gtaaatatat	660
ttatgcaagc	ttatggagct	gggtcaaacac	tgctaagggtg	gggtgtcatt	gccagatcat	720
ccaacaacat	aatgctaggg	catgtatctg	tgcaatctga	attgaagcaa	ttcacagagg	780
tttatgactt	gggtgagagaa	atgggtcctg	aatctgggct	tttacctcta	agacaaagtc	840
caaaaggca						848

<210> 7
 <211> 894
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(894)
 <223> human metapneumovirus, strain Quebec Isolate No C-77748

<400> 7						
atgtgggtac	aacaactgca	gtgacaccct	catcattgca	acaagaaata	acgctgttgt	60
gtggagaaat	tctgtatgct	aaacatgctg	attacaaata	tgctgcagaa	ataggaatac	120
aatatattag	cacagcttta	ggatcagaga	gagtgacgca	garrctgagg	aactcaggca	180
gtgaagtcca	agtgttctta	accagaacgt	actctctggg	gaaagttaaa	aacaataaag	240
gagaagatttt	acagatgrra	gacatacacg	gggtagagaa	gagctgggta	gaagagatag	300
acaaagaagc	aaggaaaaca	atggcaacct	tgcttaagga	atcatcaggt	aatatccac	360
aaaatcagag	gccctcagca	ccagacacac	ccataatctt	attatgtgta	ggtgccctaa	420
tatttactaa	gctagcatca	accatagaag	tgggactaga	gaccacagtc	agaagggcta	480
accgtgtact	aagtgtatga	cctaagagat	accctagaat	ggacatccca	aaaattgcca	540
gatccttcta	tgacttattt	gaacaaaaag	tgtatcacag	aagtttggtc	attgagtatg	600
gcaaagcatt	aggctcatca	tctacaggca	gcaaacgaga	aagtctattt	gcttatatat	660
tcattgcgagc	ttatggagcc	gggtcaaacaa	tgctaagggtg	gggggtcatt	gccagatcat	720
ccaacaatat	aatgttagga	catgtatctg	ttcaagctga	atttaaacaa	gacacagaag	780
ttcatgactt	gggtgtagaa	atggggcctg	aatctggact	ttctacttta	aggcaaaagcc	840
caaaagctgg	actgtttaca	ctagccaact	gtcccaactt	tgcaagtgtt	gttc	894

<210> 8
 <211> 850
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(850)
 <223> human metapneumovirus, strain Quebec Isolate No HMPV-217

7/52

```

<400> 8
atgtgggtac aacaactgca gtgacaccct catcattgca acaagaaata acgctgttgt 60
gtggagaaat tctgtatgct aaacatgctg attacaaata tgctgcagaa ataggaatac 120
aatatattag cacagcttta ggatcagaga gagtgcagca gattctgagg aactcaggta 180
gtgaagtcca agtgggtctta accagaaact actctctggg gaaagttaaa aacaataaag 240
gagaagatttt acagatgtta gacatacacg gggtagagaa gagctgggta gaagagatag 300
acaaagaagc aagggaaaaca atggcaacct tgcctaaagg atcatcagggt aatatccac 360
aaaattcagag gccctcagca ccagacacac ccataatctt attatgtgta ggtgccttaa 420
tatttactaa gctagcatca accatagaag tgggactaga gaccacagtc agaagggcta 480
accgtgtact aagtgtatgca ctcaagagat accctagaat ggacatccca aaaattgccca 540
gatccttcta tgacttattt gaacaaaag tgtatcacag aagtgtgttc attgagtatg 600
gtaaagcatt aggatcatca tctacaggca gcaaaagcaga aagtctattt gttaatatat 660
tcatgcaagc ttatggagcc ggtcaaaaca tgctaagggt ggggggtcatt gccaaagtcatt 720
ccaacaatat aatgttagga catgtatccg tccaagctga attaaaaaca ggtcccagaa 780
ctccatgact tgggtgcaga aatggggcct gaatctggac ttctactttt aaggcaaagc 840
ccaaaagctg                                     850

```

```

<210> 9
<211> 1185
<212> DNA
<213> human metapneumovirus

```

```

<220>
<221> gene
<222> (1)...(1185)
<223> human metapneumovirus, strain 00-1, accession
number af371337

```

```

<400> 9
atgtctcttc aagggattca cctgagtgat ttatcataca agcatgctat attaaaagag 60
tctcagtaca caataaaaag agatgtgggt acaacaactg cagtgacacc ctcatcattg 120
caacaagaaa taacactgtt gtgtggagaa attctgtatg ctaaacatgc tgactacaaa 180
tatgtctgcag aaataggaaat acaatatatt agcacagctt taggatcaga gagagtgcag 240
cagattctga ggaactcagg cagtgaagtc caagtggctt taaccagaac gtactctctg 300
gggaaaatta aaaacaataa aggagaagat ttacagatgt tagacataca cggggtagag 360
aagagctggg tagaagagat agacaaagaa gcaaggaaaa caatggcaac ctigtctaa 420
gaatcatcag gtaatatccc acaaaatcag aggccctcag caccagacac acccataatc 480
ttattatgtg taggtgcctt aatatttact aaactagcat caaccataga agtgggacta 540
gagaccacag tcagaagggc taacctgtga ctaagtgtat cactcaagag ataccctaga 600
atggacatac caaagattgc cagatccttc tatgacttat ttgaacaaaa agtgtatcac 660
agaagtgtgt tcattgagta tggcaaaagca ttaggtctcat catctacagg cagcaaaagca 720
gaaagtctat ttgttaatat attcatgcaa gcttatgggg ccggtcaaac aatgctaagg 780
tgggggggtca ttgccagggt atccaaacaat ataattgttag gacatgtatc cgtccaagct 840
gagttaaaac aggtcacaga agtctatgac ttgggtcgag aaatggggcc tgaatctgga 900
cttctacatt taaggcaaaag cccaaaagct ggactgttat cactagccaa ctgtrcccaac 960
tttgcaagtg ttgttctcgg aaatgcctca ggcttaggca taatcggtat gtatcgaggg 1020
agagtaccaa acacagaatt attttcagca gctgaaagtt atgcccagaa ttgaaagaa 1080
agcaataaaa taaatttctc ttcattagga ctacagatg aagagaaga ggtgcagaa 1140
catttcttaa atgtgagtga cgacagtcaa aatgattatg agtaa 1185

```

```

<210> 10
<211> 700
<212> DNA
<213> human metapneumovirus

```

```

<220>
<221> gene
<222> (1)...(700)
<223> human metapneumovirus, strain Quebec Isolate No
hMPV-163

```

```

<400> 10
tgcagaaata ggaatacaat atattagcac agctttagga tcagagagag tgcagcagat 60
tctgaggaac tcaggcagtg aagtccaagt ggtcttaacc agaactgact ctctggggaa 120
agttaaaaac aataaaggag aagatttaca gatgttagac atacacgggg tagagaagag 180
ctgggttagaa gagatagaca aagaagcaag gaaaacaatg gcaaccttgc ttaagggaatc 240
atcaggtaat atcccaaaa atcagaggcc ctacagacca gacacacca taatcttatt 300
atgtgtaggt gccttaatat ttactaaact agcatcaacc atagaagtgg gactagagac 360
cacagtcaaa agggccaacc gtgtactaag tgatgcactc aagagatacc ctagaatgga 420
catcccaaaa attgccagat ccttctatga ctattttgaa caaaaagtgt atcacagaag 480
tttgttcatt gagtattggc aagcattagg ctcatcatct acaggcagca aagcagaag 540
tctatttggt aatatattca tgcaagctta tggagccggt caaacaatgc taagggtggg 600

```

8/52

ggtaattgcc aggtcatcca acaatataat gttaggacat gtatccgtcc aagctgagtt 660
 aaaaacaggtc acagaagtct atgacttggt gcgagaaatg 700

<210> 11
 <211> 705
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(705)
 <223> human metapneumovirus, strain Quebec Isolate No
 hMPV-174

<400> 11
 tattagcaca gctttaggat cagagagagt gcagcagatt ctgaggaact caggcagtgga 60
 agtccaagtg gtcttaacca gaacgtactc tctggggaaa gttaaaaaca ataaaggaga 120
 agattttacag atgttagaca tacacggggg agagaagagc tgggtagaag agatagacaa 180
 agaagcaagg aaaaacaatgg caaccttgct taaggaaatca tcaggtaata tcccccaaaa 240
 tcagaggccc tcagcaccag acacacccat aatcttatta tgtgtaggtg ccttaatat 300
 tactaaacta gcatcaacca tagaagtggg actagagacc acagtcagaa gggctaaccg 360
 tgtactaagt gatgcactca agagataccc tagaatggac atcccaaaaa ttgccagatc 420
 cttctatgac ttatttgaac aaaaagtgtg tcacagaagt ttgttcattg agtatggcaa 480
 agcattaggc tcatcatcta caggcagcaa agcagaaagt gtatttgtaa atatatcat 540
 gcaagcttat ggagccgggt aaacaatgct gaggtggggg gtcattgccaa ggtcatccaa 600
 caatataatg ttaggacatg tatcctgctt agctgaagct aaaccgggtc cagaagtcta 660
 tgacttggtg cgagaaatga ttcctgaatc tngacttcta catta 705

<210> 12
 <211> 700
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(700)
 <223> human metapneumovirus, strain Quebec Isolate No
 hMPV-184

<400> 12
 aaatatgctg cagaaatagg aatacaatat attagcacag ctttaggacg agagagagtg 60
 cagcagattc tgaggaaactc aggcagtgaa gtccaagtgg tcttaaccag aacgtactct 120
 ctgggggaaag ttaaaaaaca taaaggagaa gatttacaga tgttagacat acacggggga 180
 gagaagagct gggtagaaga gatagacaaa gaagcaagga aaacaatggc aaccttgcct 240
 aaggaatcat caggtaatat cccacaaaat cagaggccct cagcaccaga cacaccata 300
 atcttattat gtgtagggtg ctttaatat 360
 ctgagagacca cagtcagaag ggccaaccgt gtactaagtg atgcactcaa gagataccct 420
 agaattggaca tccccaaaat tgccagatcc ttctatgact tatttgaaca aaaagtgtat 480
 cacagaagtt tgttcattga gtatggcaaa gcattaggct catcatctac aggcagcaaa 540
 gcagaaaagtc tatttgrtaa tatattcatg caagcttatg gagccgggtc aacaatgcta 600
 aggtgggggg taattgccag atcatccaac aatataatgt taggacatgt atccgtccaa 660
 gctgagttaa aacagggtcac agaagtctat gacttagtgc 700

<210> 13
 <211> 650
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(650)
 <223> human metapneumovirus, strain Quebec Isolate No
 hMPV-185

<400> 13
 taggaatata atatattagc acagctctag gatcagagag agtacagcag attctaagaa 60
 actcaggcag tgaagtccaa gtggttttaa ccagaacgta ctcttgggg aaagttaaaa 120
 acaacaaagg agaagattta cagatgttag acatacacgg agtagagaaa agctgggtgg 180
 aagagataga caaagaagca agaaaaacaa tggcaacttt gcttaaaaga tcatcaggca 240
 atattccaca aaatcagagg ccttcagcac cagacacacc tataatccta ttatgtgtag 300
 gtgccctaat atttaccaa ctagcatcaa ctatagaagt gggattagag accacagtca 360
 gaagagctaa ccgtgtacta agtgatgcac tcaaaagata ccctaggatg gacataccaa 420

9/52
 aaatcgctag atcttttctat gactttatttg aacaaaaagt gtattacaga agctttgttca 480
 ttgagtattg caaagcatta ggctcatcct ctacaggcag caaagcagaa agttttattcg 540
 ttaatatatt catgcaagct tacgggtgctg gtcaaacat gctgaggtag ggagtcattg 600
 ccaggctcatc taacaatata atgttaggac atgtatctgt ccaagctgag 650

<210> 14
 <211> 650
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(650)
 <223> human metapneumovirus, strain Quebec Isolate No
 C-76837

<400> 14
 acaaatatgc atcataaata ggaatacaat atattagcac agcttttagag atcagagaga 60
 gtgcagcaga ttctaaggaa ctacaggcag gaagttccaag tgggtcttaac cagaacgtac 120
 tctctgggga aagtttaaaaa caataaaggga gaagatttac agatgttaga catacacggg 180
 gtagagaaga gctgggtaga agagatagac aaagaagcaa ggaaaaacaat ggcaaccttg 240
 cttaaggaat catcaggtaa tatcccacaa aatcagaggg cctcagcacc agacacacccc 300
 ataattttat tatgtgtagg tgcccttaata ttactaaac tagcatcaac catagaagtg 360
 ggactagaga ccacagtcag aagggtctaac cgtgtactaa gtgatgcact caagagatag 420
 cctagaatgg acatcccaaa aattgcccaga tccctctatg acttatttga acaaaaagt 480
 tatcacagaa gtttgttcat tgagtatggc aaagcattag gctcatcatc tacaggcagc 540
 aaagcagaaa gtctatttgt taatatattc atgcaagctt atggagccgg tcaaaccaatg 600
 ctaagggtggg ggggtcattgc cagggtcatcc aacaatataa tgttaggata 650

<210> 15
 <211> 650
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(650)
 <223> human metapneumovirus, strain Quebec Isolate No
 C-77807

<400> 15
 gtatgctaaa catgctgatt acaaatatgc tgcagaaata ggaatacaat atattagcac 60
 agcttttagga tcagagagag tgcagcagat tctgaggaaac tcaggcagtg aagttccaagt 120
 ggtcttaacc agaacgtact ctctggggaa agtttaaaac aataaaaggga gaagatttac 180
 agatgttaga catacacggg gtagagaaga gctgggtaga agagatagac aaagaagcaa 240
 ggaaaaacaat ggcaaccttg cttaagggaat catcaggtaa tatcccacaa aatcagaggg 300
 cctcagcacc agacacacccc ataattttat tatgtgtagg tgcccttaata ttactaagc 360
 tagcatcaac catagaagtg ggactagaga ccacagtcag aagggtctaac cgtgtactaa 420
 gtgatgcact caagagatag cctagaatgg acatcccaaa aattgcccaga tccctctatg 480
 acttatttga acaaaaagtg tatcacagaa gtttgttcat tgagtatggc aaagcattag 540
 gctcatcatc tacaggcagc aaagcagaaa gtctatttgt taatatattc atgcaagctt 600
 atggagccgg tcaaaccaatg ctaagggtggg ggggtcattgc cagggtcatcc 650

<210> 16
 <211> 650
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(650)
 <223> human metapneumovirus, strain Quebec Isolate No
 hMPV-C-78123

<400> 16
 ttaggatcag agagagtgcg gcagattcta aggaactcag gcagtgaagt ccaagtggtc 60
 ttaaccagaa cgtactctct ggggaaagt aaaaacaata aaggagaaga tttacagatg 120
 ttagacatac acggggtaga gaagagctgg gtagaagaga tagacaaaga agcaaggaaa 180
 acaatggcaa ccttgcctaa ggaatcatca ggtaatatcc cacaaaatca gaggccctca 240
 gcaccagaca caccataat cttattatgt gtagggtcct taatatttcc taaactagca 300
 tcaaccatag aagtgggact agagaccaca gtcagaaggg ctaactcgtg actaagtgat 360
 gcactcaaga gataccctag aatggacatc ccaaaaattg ccagatcctt ctatgactta 420

10/52

tttgaacaaa	aagtgtatca	cagaagtttg	ttcattgagt	atggcacaagc	attaggctca	480
tcattctacag	gcagcaaaagc	agaaagtcta	tttgtaata	tattcatgca	agcttatgga	540
gccgggtcaaa	caatgctaag	gtgggggggtc	attgccaggt	catccaacaa	tataatgtta	600
ggacatgtat	ccgtccaagc	tgagttaaaa	caggtcacag	aagtcctatga		650

<210> 17
 <211> 650
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(700)
 <223> human metapneumovirus, strain Quebec Isolate No C-78132

<400> 17						
cagaaagagt	acaacagatt	ttgagaaact	caggtagtga	agttcaggtg	gttttaacca	60
aaacatactc	cttagggaaa	ggcaaaaaca	gtaaagggga	agagctgcag	atgttagata	120
taacatggagt	ggaaaaagagt	tggttagaag	aaatagacaa	agaggcaaga	aagacaatgg	180
taactttgct	taaggagtc	tcaggtaaca	tcccacaaaa	ccagagacct	tcagcaccag	240
acacaccaat	aattttatta	tgtgtagggt	ccctaattatt	cactaaacta	gcattctaca	300
tagaagrtgg	attagagact	acagtttaga	gagctaata	agtgttaagt	gatgcactca	360
aaagataccc	tagggtagat	ataccaaaga	ttgttagatc	tttttatgaa	ctatttgaac	420
aaaaagtgta	ctacagaagt	ttattcattg	agtacggaaa	agcttttaggc	tcattcttcaa	480
caggaagcaa	agcagaaagt	ttgtttgtaa	atataattat	gcaagcttat	ggagctgggtc	540
aaacactgct	aaggtgggggt	gtcattgcca	gatcatccaa	caacataatg	ctagggcatg	600
tatctgtgca	atctgaattg	aagcaagtta	cagagggtta	tgacttggtg		650

<210> 18
 <211> 650
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(650)
 <223> human metapneumovirus, strain Quebec Isolate No C-78163

<400> 18						
ggatcagaaa	gagtacaaca	gattttgaga	aactcaggta	gtgaagttca	ggtgggttta	60
accaaaacat	actccttagg	gaaaggcaaa	aacagttaag	gggaagagct	gcagatgtta	120
gatatacatg	gagtgggaaa	gagttgggta	gaagaaatag	acaaagaggc	aagaaaagaca	180
atggtaactt	tgcttaagga	gtcatcaggt	aacatccac	aaaaccagag	accttcagca	240
ccagacacac	caataatttt	attatgtgta	gggtgccctaa	tattcactaa	actagcatca	300
acaatagaag	ttggattaga	gactacagtt	agaagagcta	atagagtgtt	aagtgatgca	360
ctcaaaagat	accctagggt	agatatacca	aagattgcta	gatcttttta	tgaactatct	420
gaacaaaaag	tgtactacag	aagtttatcc	attgagtacg	gaaaagcttt	aggctcatct	480
tcaacaggaa	gcaaaagcaga	aagtttggtt	gtaaaatat	ttatgcaagc	ttatggagct	540
ggtcaaacac	tgctaagggt	gggtgtcatt	gccagatcat	ccaacaacat	aatgctaggg	600
catgtatctg	tgcaatctga	attgaagcaa	gttacagagg	tttatgactt		650

<210> 19
 <211> 600
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(600)
 <223> human metapneumovirus, strain Quebec Isolate No C-91205

<400> 19						
atattagcac	agctctaggg	atcagagaga	gtacagcaga	ttctaagaaa	ctcaggcagt	60
gaagttccaag	tggttttaac	cagaacgtac	tccttggggg	aagttaaaaa	caacaaagga	120
gaagattttac	agatgttaga	catcacggga	gtagagaaaa	gctgggtgga	agagatagac	180
aaagaagcaa	gaaaaacaat	ggcaactttg	cttaaagaat	catcaggcaa	tattccacaa	240
aatcagaggg	cttcagcacc	agacacacct	ataatcttat	tatgtgtagg	tgctttaata	300
tttaccacaa	tagcatcaac	tatagaagtg	ggattagaga	ccacagtcag	aagagctaac	360
cgtgtactaa	gtgatgcact	caaaagatac	cctaggatgg	acataccaaa	aatcgctaga	420

11/52

tctttctatg	acttatttga	acaaaaagt	tattacagaa	gcttgttc	tgagtatggc	480
aaagcattag	gctcatcctc	tacaggcagc	aaagcagaaa	gtttattcgt	taatatattc	540
atgcaagctt	acgggtgctg	tcaaacatg	ctgagggtgg	gagtcattgc	cagggtcatct	600

<210> 20
 <211> 700
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(700)
 <223> human metapneumovirus, strain Quebec Isolate No C-91364

<400> 20						
gattacaat	atgctgctga	gataggaatg	caatatattt	gcacagctct	aggatcagaa	60
agagtacaac	agattttgag	aaactcaggt	agtgaagttc	agggtggttct	aaccaaaaaca	120
tacttccttag	ggaaaaggcaa	aaacagttaa	ggggaagagc	tgcatagttt	agatatcat	180
ggagtggaaa	agagtgggtg	agaagaaaata	gacaaaagg	caagaaaagac	aatggtaact	240
ttgcttaagg	agtcattcagg	taacatccca	caaaaaccaga	gaccttcagc	accagacaca	300
ccaataattt	tattatgtgt	agggtgcccta	atattcacta	aactagcatc	aacaatagaa	360
gttggattag	agactacagt	tagaagagct	aatagagtgc	taagtgtatg	actcaaaaga	420
taccttaggg	tagatatacc	aaagattgct	agatctttt	atgaactatt	tgaacaaaaa	480
gtgtactaca	gaagtttatt	cattgagtac	ggaaaagctt	taggctcatc	ttcaacagga	540
agcaaaagcag	aaagtttggt	tgtaaatata	tttatgcaag	cttatggagc	tggtcaaaaca	600
ctgctaaggt	ggggtgtcat	tgccagatca	tccaacacaca	taatgctagg	gcattgtatct	660
gtgcaatctg	aattgaagca	agttacagag	gtttatgact			700

<210> 21
 <211> 600
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(600)
 <223> human metapneumovirus, strain quebec Isolate No C-91830

<400> 21						
cagctctagg	atcagaaaga	gtacaacaga	ttttgagaaa	ctcaggtagt	gaagttcagg	60
tggttctaac	caaaacatac	tccttaggga	aaggcaaaaa	cagttaaagg	gaagagctgc	120
agatgttaga	tatacatgga	gtggaaaaga	gttgggtaga	agaaatagac	aaagaggcaa	180
gaaagacaat	ggtaactttg	cttaaggagt	catcaggtaa	catcccacaa	aaccagagac	240
cttcagcacc	agacacacca	ataattttat	tatgtgtagg	tgcccttaata	ttcactaaac	300
tagcatcaac	aataagaagt	ggattagaga	ctacagttag	aagagctaatt	agagtgtctaa	360
gtgatgcact	caaaaagatac	cctagggttag	atataccaaa	gattgtctaga	tctttttatg	420
aactatttga	acaaaaagt	tactacagaa	gcttattcat	tgagtacgga	aaagcttttag	480
gtrcatcttc	aacaggaagc	aaagcagaga	gtttgtttgt	aaatatattt	atgcaagctt	540
atggagctgg	tcaaacactg	ctaagggtgg	gtgtcattgc	cagatcatcc	aacaacataa	600

<210> 22
 <211> 650
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(650)
 <223> human metapneumovirus, strain Quebec Isolate No hMPV-Q86

<400> 22						
atgctgatta	caaatatgct	gcagaaaatg	gaatacaata	tattagcaca	gctctagggt	60
cagagaaagt	acagcagatt	ctaagaaact	caggcagtga	agttccaagcg	gttttaacca	120
gaacgtacrc	rrtggggaaa	gttaaaaaaca	ataaaggaga	agattctacag	atgttagaca	180
tacacggagt	agaaaaaagc	tgggtggaag	agatagacaa	agaagcaaga	aaaacaatgg	240
caactttact	taaaagaatca	tcagggttaata	ttccacaaaa	tcagaggcct	tcagcaccag	300
acacacctat	aatcttatta	tgtgtagggt	ccttaatat	caccaaaacta	gcatacaacta	360
tagaagtggg	attagagacc	acagtcagaa	gagctaaccg	tgtaactaagt	gatgacttca	420
aaagataccc	tagaatggac	ataccaaaaa	ttgctagatc	cttctatgac	ttatttgaac	480

12/52

aaaaagtgtg tccacagaagt ttgttcattg agtatgggca aagcattagg ctcatcctct 540
 acaggcagca aagcagaaaag ttatttcgtc aatatattca tgcaagctta tgggtgctgg 600
 caaacaaatgc tgaggtg999 ggggttatcgc cagggtcatct aacaatataa 650

<210> 23
 <211> 650
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(650)
 <223> human metapneumovirus, strain Quebec Isolate No
 hMPV-Q97

<400> 23
 tagcacagct ctaggatcag agagagtaca gcagattcta agaaactcag gcagtgaagt 60
 ccaagtgggt ttaaccagaa cgtactcctt ggggaaagt aaaaacaaca aaggagaaga 120
 ttacagatg tttagacatac acggagtaga gaaaagctgg gtggaagaga tagacaaaga 180
 agcaagaaaa acaatggcaa ctttgcctaa agaatcatca ggcaatattc cacaaaatca 240
 gagggccttca gcaccagaca cacctataat cttattatgt gtagggtgcct taatatttac 300
 caaactagca tcaactatag aagtgggatt agagaccaca gtcagaagag ctaaccgtgt 360
 actaagtgtat gcactcaaaa gataccctag gatggacata ccaaaaatcg ctatgctttt 420
 ctatgactta tttgaacaaa aagtgtatta cagaagcttg ttcattgagt atggcaaagc 480
 attaggttca tccctctacag gcagcaaagc agaaagtgtt attcgttaat atattcatgc 540
 aagcttacgg tgctggtcaa acaatgtcga ggtggggagt cattgcccag tcattctaaca 600
 atataatgtt aggacatgta tctgtccaag ctgagttaaa acaagtcacg 650

<210> 24
 <211> 741
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(741)
 <223> human metapneumovirus, strain Can 97-83

<400> 24
 agtgacaccc tcatcattgc aacaagaaat aacactattg tgtggagaaa ttctatatgc 60
 taagcatgct gattacaaat atgctgcaga aataggaata caatatatta gcacagctct 120
 aggatcagag agagtacagc agattctaag aaactcaggc agtgaagtcc aagtgggttt 180
 aaccagaacg tactccttgg ggaaggttaa aaacaacaaa ggagaagatt tacagatgtt 240
 agacatacac ggagttaga aagctgggt ggaagagata gacaaagaag caagaaaaac 300
 aatggcaact ttgctraaag aatcatcagg caatattcca caaatcaga ggccttcagc 360
 accagacaca cctataatct tattatgtgt aggtgcctta atatttacca aactagcatc 420
 aactatagaa gtgggattag agaccacagt cagaagagct aaccgtgtac taagtgtatgc 480
 actcaaaaaga tacccttaga tggacatacc aaaaatcgct agatctttct atgatttatt 540
 tgaacaaaaa gtgtattaca gaagtgtgt cattgagat ggcaaaagcat taggctcatc 600
 ctctacaggc agcaaagcag aaagtgttatt cgttaatatata ttcatgcaag cttacgggtgc 660
 tgggtcaaaa atgctgaggt ggggagtcac tggcagggtca tctaacaata taatgttagg 720
 acatgtatct gtccaagctg a 741

<210> 25
 <211> 650
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(650)
 <223> human metapneumovirus, strain Can 98-75

<400> 25
 caatatattt gcacggctct aggatcagaa agagtacaac agattttaag aaattcaggc 60
 agtgaagttc aggtgggtct aaccaagaca tactcttttag ggaaaggtaa aaatagtaaa 120
 ggggaagagt tgcaaatgtt agatatacat ggagtggaaa agagtgggt agaagaata 180
 gacaaagagg caagaaaaac aatgggtgact ttgctaaagg aatcatcagg taacatccca 240
 caaaaccaga ggccttcagc accagacaca ccaataattt tattatgtgt aggtgcttta 300
 atattcacta aactagcatc aacaatagaa gttggactag agactacagt tagaagagct 360
 aacagagtcg taagtgtatgc gctcaaaaga taccctaggg tagatatacc gaagattgct 420
 agatctttct atgaactatt tgagcagaaa gtgtattaca ggagtctatt cattgagtat 480

13/52

gggaaagcct	taggctcctc	ttcaacagga	agcaaagcag	aaagtttggt	tgtaaata	540
tttatgcaag	cttatggagc	cggctcaaca	atgctaaggt	ggggtgtcat	tgccagatca	600
tctaacaaca	taatgctagg	acatgtgtct	gtgcaagctg	aattgaagca		650

<210> 26
 <211> 759
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(759)
 <223> human metapneumovirus, strain Can 98-75

<400> 26						
atgtcttggg	aagtgggtgat	tatcatttcg	ttactcataa	cacctcagca	cggactaaaa	60
gaaagtattt	tagaagaatc	atgtagtact	ataactgaag	gatattctcag	tgttttaaga	120
acagggttgg	acaccaatgt	ctttacatta	gaagttgggt	atgttgaaaa	tcttacatgt	180
ctgatgggac	ctagcttaat	caaaacagaa	cttgacctaa	ccaaaagtgc	tctaagagaa	240
ctcaaaaacag	tttctgctga	tcagttagcg	agagaagaac	aaattgaaaa	tcccagacaa	300
tcaagggtttg	tcctagggtgc	aatagctctt	ggtgttgcca	cagcagcagc	agtcacagca	360
ggcattgcga	tagccaaaac	cataaggcct	gagagtgaag	tgaatgcaat	caaagggtgt	420
ctcaaaaacaa	ccaacgaggg	agtatccaca	ctaggaaatg	gagtgcgagt	cctagccacc	480
gcagtaagag	agctgaaaaga	atttgtgagc	aaaaacctga	ctagtgcagt	taacaagaac	540
aaatgtgaca	ttgctgacct	gaagatggct	gtcagcttca	gtcaattcaa	cagaagattc	600
ctaaatgttg	tgcggcgagt	ttcagacaat	gcagggataa	caccagcaat	atcattggac	660
ctaatgactg	atgctgagct	ggccagagct	gtatcataca	tgccaacatc	tgaggagaca	720
ataaaactaa	tgttagagaa	ccgtgcaatg	gtaagaaga			759

<210> 27
 <211> 759
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(759)
 <223> human metapneumovirus, strain Quebec Isolate No C-67345

<400> 27						
atgtcttggg	aagtgggtgat	cattttttca	ttgctaataa	cacctcaaca	cggctcttaaa	60
gagagctacc	tagaagaatc	atgtatcact	ataactgagg	gatattcttag	tgttctgaga	120
acagggttgg	ataccaacgt	ttttacatta	gaggtgggtg	atgtagaaaa	ccttacatgt	180
ttctgatggg	ctagcctaatt	aaaaacagaa	ttagatctga	ccaaaagtgc	actaagagag	240
ctcaaaaacag	tttctgctga	ccaattggca	agagaggaac	aaattgagaa	tcccagacaa	300
tctagggtttg	tttctgggagc	aatagcactc	ggtgttgcaa	cagcagctgc	agtcacagca	360
ggtgttgcaa	ttgccaacaa	catccggctt	gagagtgaag	tcacagcaat	taagaatgcc	420
ctcaaaaacga	ccaatgaagc	agtatctaca	ttggggaatg	gagttcgagt	gttggcaact	480
gcagtggagag	agctgaaaaga	ctttgtgagc	aagaatttaa	ctcgtgcaat	caacaaaaac	540
aagtgcgaca	ttgatgacct	aaaaatggcc	gttagcttca	gtcaattcaa	cagaagggtt	600
ctaaatgttg	tgcggcgaatt	ttcagacaat	gctggataaa	caccagcaat	atctttggac	660
ttaattgacag	atgctgaact	agctaggggc	gtttccaaca	tgccgacatc	tgaggagaca	720
ataaaaattga	tggtggagaa	ccgtgcgatg	gtaagaaga			759

<210> 28
 <211> 759
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(759)
 <223> human metapneumovirus, strain Can 97-83

<400> 28						
ataaaaatgt	cttggaaagt	ggtgatcatt	ttttcattgc	taataacacc	tcaacacggg	60
cttaaaagaga	gctacctaaga	agaatcatgt	agcaactataa	ctgagggata	tcttagtggt	120
ctgaggacag	gttggatatac	caacgttttt	acattagagg	tggttgatgt	agaaaacctt	180
acatgtttctg	atgggacctag	cctaataaaa	acagaattag	atctgaccaa	aagtgcacta	240
agagagctca	aaacagctctc	tgctgaccaa	ttggcaagag	aggaacaaat	tgagaatccc	300
agacaatcta	ggtttggttct	aggagcaata	gcactcgggtg	ttgcaacagc	agctgcagtc	360

14/52

acagcagggtg	ttgcaattgc	caaaaccatc	cggcttgaga	gtgaagtcac	agcaattaag	420
aatgccctca	aaacgaccaa	tgaagcagta	tctacattgg	gggaatggagt	tcgagtgttg	480
gcaactgcag	tgagagagct	gaaagacttt	gtgagcaaga	atttaactcg	tgcaatcaac	540
aaaaacaagt	gcgacattga	tgacctaaaa	atggccgtta	gcttcagtc	attcaacaga	600
aggtttctaa	atgttggtgc	gcaattttca	gacaatgctg	gaataacacc	agcaatatct	660
ttggacttaa	tgacagatgc	tgaactagcc	agggccgttt	ctaacatgcc	gacatctgca	720
ggacaataaz	aattgatgtt	ggagaaccgt	gcgatgggtg			759

<210> 29
 <211> 759
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(759)
 <223> human metapneumovirus, strain quebec Isolate No C-68661

<400> 29						
atgtcttggg	aagtgggtgat	cattttttca	ttgttaataa	cacctcaaca	cggctcttaa	60
gagagctatt	tagaagagtc	atgtagcact	ataactgaag	gatattctcag	tggtctgagg	120
acaggttggt	ataccaacgt	ttttacactg	gaggtagggtg	atgtagagaa	ccttacatgt	180
gctgatggac	ctagcttaaat	aaaaacagaa	ttagacctga	ccaaaagtgc	actaagagag	240
ctcagaacag	tttctgctga	tcaactggca	agagaggagc	aaattgagaa	tcccagacaa	300
tctagatttg	ttctaggagc	aatagcactc	ggtgttgcaa	cagcagctgc	agttacagca	360
ggtgttgcaa	ttgccaaaac	catccggctt	gaaagtgaag	taacagcaat	taagaatgcc	420
ctcaaaaaga	ccaatgaagc	agtatctaca	ttgggggaatg	gagttcgagt	gttggcaact	480
gcagtgaagg	agctgaaaga	ttttgtgagc	aagaatctaa	cacgtgcaat	caacaaaaac	540
aagtgcgaca	ttgctgacct	gaaaatggcc	gttagcttca	gtcaattcaa	cagaagggtt	600
ctaaatgttg	tgccggcaatt	ttcagacaat	gctggaataa	caccagcaat	atccttggac	660
ttaatgacag	atgctgaact	agccagagct	gtttccaaca	tgccaacatc	tgccaggacaa	720
ataaaactga	tgcttgagaa	ccgtgcaatg	gtaagaaga			759

<210> 30
 <211> 759
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(759)
 <223> human metapneumovirus, strain Quebec Isolate No C-73750

<400> 30						
atgtcttggg	aagtgggtgat	cattttttca	ttgttaataa	cacctcaaca	cggctcttaa	60
gagagctatt	tagaagagtc	atgtagcact	ataactgaag	gatattctcag	tggtctgagg	120
acaggttggt	ataccaacgt	ttttacactg	gaggtagggtg	atgtagagaa	ccttacatgt	180
gctgatggac	ctagcttaaat	aaaaacagaa	ttagacctga	ccaaaagtgc	actaagagag	240
ctcagaacag	tttctgctga	tcaactggca	agagaggagc	aaattgagaa	tcccagacaa	300
tctagatttg	ttctaggagc	aatagcactc	ggtgttgcaa	cagcagctgc	agttacagca	360
ggtgttgcaa	ttgccaaaac	catccggctt	gaaagtgaag	taacagcaat	taagaatgcc	420
ctcaaaaaga	ccaatgaagc	agtatctaca	ttgggggaatg	gagttcgagt	gttggcaact	480
gcagtgaagg	aactgaaaga	ttttgtgagc	aagaatctaa	cacgtgcaat	caacaaaaac	540
aagtgcgaca	ttgctgacct	gaaaatggcc	gttagcttca	gtcaattcaa	cagaagggtt	600
ctaaatgttg	tgccggcaatt	ttcagacaat	gctggaataa	caccagcaat	atccttggac	660
ttaatgacag	atgctgaact	agccagagct	gtttccaaca	tgccaacatc	tgccaggacaa	720
ataaaactga	tgcttgagaa	ccgtgcaatg	gtaagaaga			759

<210> 31
 <211> 759
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(759)
 <223> human metapneumovirus, strain Quebec Isolate No C-74549

<400> 31

15/52

atgtcttggg	aagtgggtgat	catttttttca	ttgctaataa	cacctcaaca	cggtctttaa	60
gagagctacc	tagaagaatc	atgttagcact	ataactgagg	gatattcttag	tggtctgagg	120
acagggttgg	ataccaacgt	ttttacatta	gaggtgggtg	atgtagaaaa	ccttacatgt	180
tctgatggac	ctagcctaata	aaaaacagaa	ttagatctga	caaaaagtgc	actaagagag	240
ctcaaaaacag	ttcttgcctga	ccaattggca	agagagggaac	aaattgagaa	tcccagacaa	300
tctagggtttg	ttctaggagc	aatagcactc	ggtgttgcaa	cagcagctgc	agtcacagca	360
ggtgttgcaa	ttgccaaaac	catccggctt	gagagtgaag	tcacagcaat	taagaatgcc	420
ctcaaaaacga	ccaatgaagc	agtattctaca	ttggggaatg	gagttcgagt	gttggcaact	480
gcagtgaagag	agctgaaaga	ctttgtgagc	aagaatttaa	ctcgtgcaat	caacaaaaac	540
aagtgcgaca	ttgatgacct	aaaaatggcc	gttagcttca	gtcaattcaa	cagaagggtt	600
ctaaatgttg	tgcggcaatt	ttcagacaat	gctggaataa	caccagcaat	atctttggac	660
ttaatgacag	atgctgaact	agccagggcc	gtttctaaca	tgccgacatc	tgcaggacaa	720
ataaaaattga	tggtggagaa	ccgcgcgatg	gtaagaaga			759

<210> 32
 <211> 759
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(759)
 <223> human metapneumovirus, strain Quebec Isolate No
 C-74783

<400> 32

atgtcttggg	aagtgggtgat	catttttttca	ttgctaataa	cacctcaaca	cggtctttaa	60
gagagctacc	tagaagaatc	atgttagcact	ataactgagg	gatattcttag	tggtctgagg	120
acagggttgg	ataccaacgt	ttttacatta	gaggtgggtg	atgtagaaaa	ccttacatgt	180
tctgatggac	ctagcctaata	aaaaacagaa	ttagatctga	caaaaagtgc	actaagagag	240
ctcaaaaacag	ttcttgcctga	ccaattggca	agagagggaac	aaattgagaa	tcccagacaa	300
tctagggtttg	ttctaggagc	aatagcactc	ggtgttgcaa	cagcagctgc	agtcacagca	360
ggtgttgcaa	ttgccaaaac	catccggctt	gagagtgaag	tcacagcaat	taagaatgcc	420
ctcaaaaacga	ccaatgaagc	agtattctaca	ttggggaatg	gagttcgagt	gttggcaact	480
gcagtgaagag	agctgaaaga	ctttgtgagc	aagaatttaa	ctcgtgcaat	caacaaaaac	540
aagtgcgaca	ttgatgacct	aaaaatggcc	gttagcttca	gtcaattcaa	cagaagggtt	600
ctaaatgttg	tgcggcaatt	ttcagacaat	gctggaataa	caccagcaat	atctttggac	660
ttaatgacag	atgctgaact	agccagggcc	gtttctaaca	tgccgacatc	tgcaggacaa	720
ataaaaattga	tggtggagaa	ccgcgcgatg	gtaagaaga			759

<210> 33
 <211> 759
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(759)
 <223> human metapneumovirus, strain Quebec Isolate No
 C-76837

<400> 33

atgtcttggg	aagtgggtgat	catttttttca	ttgttaataa	cacctcaaca	cggtctttaa	60
gagagctatt	tagaagagtc	atgttagcact	ataactgaag	gatattctcag	tggtctgagg	120
acagggttgg	ataccaacgt	ttttacactg	gaggttaggtg	atgtagagaa	ccttacatgt	180
gctgatggac	ctagcctaata	aaaaacagaa	ttagatctga	caaaaagtgc	actaagagag	240
ctcagaacag	ttcttgcctga	tcaactggca	agagaggagc	aaattgagaa	tcccagacaa	300
tctagatttg	ttctaggagc	aatagcactc	ggtgttgcaa	cagcagctgc	agttacagca	360
ggtgttgcaa	ttgccaaaac	catccggctt	gaaagtgaag	taacagcaat	taagaatgcc	420
ctcaaaaaga	ccaatgaagc	agtattctaca	ttggggaatg	gagttcgagt	gttggcaact	480
gcagtgaagg	aactgaagaa	ttttgtgagc	aagaattctaa	cacgtgcaat	caacaaaaac	540
aagtgcgaca	ttgctgacct	gaaaaatggcc	gttagcttca	gtcaattcaa	cagaagggtt	600
ctaaatgttg	tgcggcaatt	ttcagacaat	gctggaataa	caccacaat	atccttggac	660
ttaatgacag	atgctgaact	agccagagct	gtttccaaca	tgccaacatc	tgcaggacaa	720
ataaaaactga	tggtggagaa	ccgtgcaatg	gtaagaaga			759

<210> 34
 <211> 759
 <212> DNA
 <213> human metapneumovirus

<220>

16/52

<221> gene
 <222> (1)...(759)
 <223> human metapneumovirus, strain Quebec Isolate No
 C-77748

```

<400> 34
atgtcttggg aagtggtgat catTTTTTca ttgttaataa cacttcaaca cggctcttaa 60
gagagctatt tagaagagtc atgtagcact ataactgaag gatattctag tgttctgagg 120
acagggttgg ataccaacgt ttttacctg aaggtaggtg atgtagagaa ccttacatgt 180
gctgatggac ctactttaat aaaaacagaa tttagactga ccaaaagtgc actaagagaa 240
ctcagaacag tttctgctga tcaactggca agagaggagc aaattgagaa tcccagacaa 300
tctagatttg ttctaggagc aatagcactc ggtgttgcaa cagcagctgc agttacagca 360
ggtgttgcaa ttgccaaaac catccggctt gaaagtgaag taacagcaat taagaatgcc 420
ctcaaaaaga ccaatgaagc agtatctaca ttggggaatg gagttcaggt gttggcaact 480
gcagtgaggg agctgaaaga ttttgtgagc aagaatctaa cacgtgcaat caacaaaaac 540
aagtgcgaca ttgctgacct gaaaatggcc gttagcttca gtcaattcaa cagaagggtt 600
ctaaatgttg tgcggcaatt tttagacaat gctggaataa caccagcaat atccttggac 660
ttaatgacag atgtggaact agccagagct gtttccaaca tgccaacatc tgcaggacaa 720
ataaaactga tgttgagaaa ccgtgcaatg gtaagaaga 759
  
```

<210> 35
 <211> 759
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(759)
 <223> human metapneumovirus, strain Quebec Isolate No
 C-77807

```

<400> 35
atgtcttggg aagtggtgat catTTTTTca ttgttaataa cacttcaaca cggctcttaa 60
gagagctatt tagaagagtc atgtagcact ataactgaag gatattctag tgttctgagg 120
acagggttgg ataccaacgt ttttacctg aaggtaggtg atgtagagaa ccttacatgt 180
gctgatggac ctactttaat aaaaacagaa tttagactga ccaaaagtgc actaagagag 240
ctcagaacag tttctgctga tcaactggca agagaggagc aaattgagaa tcccagacaa 300
tctagatttg ttctaggagc aatagcactc ggtgttgcaa cagcagctgc agttacagca 360
ggtgttgcaa ttgccaaaac catccggctt gaaagtgaag taacagcaat taagaatgcc 420
ctcaaaaaga ccaatgaagc agtatctaca ttggggaatg gagttcaggt gttggcaact 480
gcagtgaggg aactgaaaga ttttgtgagc aagaatctaa cacgtgcaat caacaaaaac 540
aagtgcgaca ttgctgacct gaaaatggcc gttagcttca gtcaattcaa cagaagggtt 600
ctaaatgttg tgcggcaatt tttagacaat gctggaataa caccagcaat atccttggac 660
ttaatgacag atgtggaact agccagagct gtttccaaca tgccaacatc tgcaggacaa 720
ataaaactga tgttgagaaa ccgtgcaatg gtaagaaga 759
  
```

<210> 36
 <211> 759
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(759)
 <223> human metapneumovirus, strain Quebec Isolate No
 C-78132

```

<400> 36
atgtcttggg aagtggtgat catTTTTTca ttgttaataa cacttcaaca cggctcttaa 60
gagagctatt tagaagagtc atgtagcact ataactgaag gatattctag tgttctgagg 120
acagggttgg ataccaacgt ttttacctg aaggtaggtg atgtagagaa ccttacatgt 180
gctgatggac ctactttaat aaaaacagaa tttagactga ccaaaagtgc actaagagag 240
ctcagaacag tttctgctga tcaactggca agagaggagc aaattgagaa tcccagacaa 300
tctagatttg ttctaggagc aatagcactc ggtgttgcaa cagcagctgc agttacagca 360
ggtgttgcaa ttgccaaaac catccggctt gaaagtgaag taacagcaat taagaatgcc 420
ctcaaaaaga ccaatgaagc agtatctaca ttggggaatg gagttcaggt gttggcaact 480
gcagtgaggg aactgaaaga ttttgtgagc aagaatctaa cacgtgcaat caacaaaaac 540
aagtgcgaca ttgctgacct gaaaatggcc gttagcttca gtcaattcaa cagaagggtt 600
ctaaatgttg tgcggcaatt tttagacaat gctggaataa caccagcaat atccttggac 660
ttaatgacag atgtggaact agccagagct gtttccaaca tgccaacatc tgcaggacaa 720
ataaaactga tgttgagaaa ccgtgcaatg gtaagaaga 759
  
```


18/52

gcagtgcagag	agctgaaaga	ttttgtgagc	aagaatctaa	cacgtgcaat	caacaaaaac	540
aagtgcgaca	ttgtcgacct	gaaaatggcc	gttagcttca	gtcaattcaa	cagaagggtt	600
ctaaatgttg	tgccggcaatt	ttcagacaat	gctggaataa	caccagcaat	atccttggac	660
ttaatgacag	atgctgaact	agccagagct	gtttccaaca	tgccaacatc	tgccaggacaa	720
ataaaaactga	tgttggagaa	ccgtgcaatg	gtaagaaga			759

<210> 40
 <211> 759
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(759)
 <223> human metapneumovirus, strain Quebec Isolate No
 hMPV-193

<400> 40						
atgtcttggg	aagtgggtgat	cattttttca	ttgttaataa	cacctcaaca	cggtctttaa	60
gagagctatt	tagaagagtc	atgtagcact	ataactgaag	gatatctcag	tgttctgagg	120
acagggttgg	ataccaacgt	ttttacactg	gaggtagggtg	atgtagagaa	ccttacatgt	180
gctgatggac	ctagcttaat	aaaaacagaa	ttagacctga	ccaaaagtgc	actaagagag	240
ctcagaacag	tttctgctga	tcaactggca	agagaggagc	aaattgagaa	tcccagacaa	300
tctagatttg	ttctaggagc	aatagcactc	ggtgttgcaa	cagcagctgc	agttacagca	360
ggtgttgcaa	ttgccaaaac	catccggctt	gaaagtgaag	taacagcaat	taagaatgcc	420
ctcaaaaaga	ccaatgaagc	agtatctaca	ttgggggaatg	gagttcgagt	gttggcgaact	480
gcagtgcagag	agctgaaaga	ttttgtgagc	aagaatctaa	cacgtgcaat	caacaaaaac	540
aagtgcgaca	ttgtcgacct	gaaaatggcc	gttagcttca	gtcaattcaa	cagaagggtt	600
ctaaatgttg	tgccggcaatt	ttcagacaat	gctggaataa	caccagcaat	atccttggac	660
ttaatgacag	atgctgaact	agccagagct	gtttccaaca	tgccaacatc	tgccaggacaa	720
ataaaaactga	tgttggagaa	ccgtgcaatg	gtaagaaga			759

<210> 41
 <211> 759
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(759)
 <223> human metapneumovirus, strain Quebec Isolate No
 hMPV-194

<400> 41						
atgtcttggg	aagtgggtgat	cattttttca	ttgttaataa	cacctcaaca	cggtttttaa	60
gagagctatt	tagaagagtc	atgtagcact	ataactgaag	gatatctcag	tgttctgagg	120
acagggttgg	ataccaacgt	ttttacactg	gaggtagggtg	atgtagagaa	ccttacatgt	180
gctgatggac	ctagcttaat	aaaaacagaa	ttagacctga	ccaaaagtgc	actaagagag	240
ctcagaacag	tttctgctga	tcaactggca	agagaggagc	aaattgagaa	tcccagacaa	300
tctagatttg	ttctaggagc	aatagcactc	ggtgttgcaa	cagcagctgc	agttacagca	360
ggtgttgcaa	ttgccaaaac	catccggctt	gaaagtgaag	taacagcaat	taagaatgcc	420
ctcaaaaaga	ccaatgaagc	agtatctaca	ttgggggaatg	gagttcgagt	gttggcgaact	480
gcagtgcagag	agctgaaaga	ttttgtgagc	aagaatctaa	cacgtgcaat	caacaaaaac	540
aagtgcgaca	ttgtcgacct	gaaaatggcc	gttagcttca	gtcaattcaa	cagaagggtt	600
ctaaatgttg	tgccggcaatt	ttcagacaat	gctggaataa	caccagcaat	atccttggac	660
ttaatgacag	atgctgaact	agccagagct	gtttccaaca	tgccaacatc	tgccaggacaa	720
ataaaaactga	tgttggagaa	ccgtgcaatg	gtaagaaga			759

<210> 42
 <211> 759
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(759)
 <223> human metapneumovirus, strain Quebec Isolate No
 hMPV-198

<400> 42						
atgtcttggg	aagtgggtgat	cattttttca	ttgttaataa	cacctcaaca	cggtctttaa	60
gagagctatt	tagaagagtc	atgtagcact	ataactgaag	gatatctcag	tgttctgagg	120

19/52

acagggttggt	ataccaacgt	ttttacactg	gaggtaggtg	atgtagagaa	ccttacatgt	180
gctgatggac	ctagcttaat	aaaaacagaa	ttagacctga	ccaaaagtgc	actaagagag	240
ctcagaacag	tttctgctga	tcaactggca	agagaggagc	aaattgagaa	tcccagacaa	300
tctagatttg	ttctaggagc	aatagcactc	ggtgttgcaa	cagcagctgc	agttacagca	360
ggtgttgcaa	ttgccaaaac	catccggctt	gaaagtgaag	taacagcaat	taagaatgcc	420
ctcaaaaaga	ccaatgaagc	agtatctaca	ttggggaatg	gagttcgagt	gttggcaact	480
gcagtggagag	agctgaaaaga	ttttgtgagc	aagaatctaa	cacgtgcaat	caacaaaaaac	540
aagtgcgaca	ttgctgacct	gaaaatggcc	gttagcrtca	gtcaattcaa	cagaagggtt	600
ctaaatgttg	tgcggaatt	ttcagacaat	gctggaataa	caccagcaat	atccttggac	660
ttaatgacag	atgctgaact	agccagagct	gtttccaaca	tgccaacatc	tcaggacaa	720
ataaaaactga	tggtggagaa	ccgtgcaatg	gtaagaaga			759

<210> 43
 <211> 759
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(759)
 <223> human metapneumovirus, strain Quebec Isolate No
 hMPV-217

<400> 43	atgtcttggg	aagtgggtgat	cattttttca	ttgttaataa	cacctcaaca	cggctcttaaa	60
	gagagctatt	tagaagagtc	atgtagcact	ataactgaag	gatatctcag	tggtctgagg	120
	acagggttggt	ataccaacgt	ttttacactg	gaggtaggtg	atgtagagaa	ccttacatgt	180
	gctgatggac	ctagcttaat	aaaaacagaa	ttagacctga	ccaaaagtgc	actaagagag	240
	ctcagaacag	tttctgctga	tcaactggca	agagaggagc	aaattgagaa	tcccagacaa	300
	tctagatttg	ttctaggagc	aatagcactc	ggtgttgcaa	cagcagctgc	agttacagca	360
	ggtgttgcaa	ttgccaaaac	catccggctt	gaaagtgaag	taacagcaat	taagaatgcc	420
	ctcaaaaaga	ccaatgaagc	agtatctaca	ttggggaatg	gagttcgagt	gttggcaact	480
	gcagtggagag	agctgaaaaga	ttttgtgagc	aagaatctaa	cacgtgcaat	caacaaaaaac	540
	aagtgcgaca	ttgctgacct	gaaaatggcc	gttagcrtca	gtcaattcaa	cagaagggtt	600
	ctaaatgttg	tgcggaatt	ttcagacaat	gctggaataa	caccagcaat	atccttggac	660
	ttaatgacag	atgctgaact	agccagagct	gtttccaaca	tgccaacatc	tcaggacaa	720
	ataaaaactga	tggtggagaa	ccgtgcaatg	gtaagaaga			759

<210> 44
 <211> 759
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(759)
 <223> human metapneumovirus, strain Quebec Isolate No
 hMPV-208

<400> 44	atgtcttggg	aagtgggtgat	cattttttca	ttgttaataa	cacctcaaca	cggctcttaaa	60
	gagagctatt	tagaagagtc	atgtagcact	ataactgaag	gatatctcag	tggtctgagg	120
	acagggttggt	ataccaacgt	ttttacactg	gaggtaggtg	atgtagagaa	ccttacatgt	180
	gctgatggac	ctagcttaat	aaaaacagaa	ttagacctga	ccaaaagtgc	actaagagag	240
	ctcagaacag	tttctgctga	tcaactggca	agagaggagc	aaattgagaa	tcccagacaa	300
	tctagatttg	ttctaggagc	aatagcactc	ggtgttgcaa	cagcagctgc	agttacagca	360
	ggtgttgcaa	ttgccaaaac	catccggctt	gaaagtgaag	taacagcaat	taagaatgcc	420
	ctcaaaaaga	ccaatgaagc	agtatctaca	ttggggaatg	gagttcgagt	gttggcaact	480
	gcagtggagag	agctgaaaaga	ttttgtgagc	aagaatctaa	cacgtgcaat	caacaaaaaac	540
	aagtgcgaca	ttgctgacct	gaaaatggcc	gttagcrtca	gtcaattcaa	cagaagggtt	600
	ctaaatgttg	tgcggaatt	ttcagacaat	gctggaataa	caccagcaat	atccttggac	660
	ttaatgacag	atgctgaatt	agccagagct	gtttccaaca	tgccaacatc	tcaggacaa	720
	ataaaaactga	tggtggagaa	ccgtgcaatg	gtaagaaga			759

<210> 45
 <211> 759
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(759)

20/52

<223> human metapneumovirus, strain Quebec Isolate No
hmpv-223

<400> 45

atgtcttggg	aagtgggtgat	catttttttca	ttgttaataa	cacctcaaca	cggctcttaaa	60
gagagctatt	tagaagagtc	atgttagcact	ataactgaag	gatatctcag	tggtctgagg	120
acagggttgg	ataccaacgt	ttttacactg	gaggtaggtg	atgttagagaa	ccttacatgt	180
gctgatggac	ctagcttaat	aaaaacagaa	ttagacctga	ccaaaagtgc	actaagagag	240
ctcagaacag	tttctgctga	tcaactggca	agagaggagc	aaattgagaa	tcccagacaa	300
tctagatttg	ttctaggagc	aatagcactc	ggtgttgcaa	cagcagctgc	agttacagca	360
ggtgttgcaa	ttgccaaaac	catccggctt	gaaagtgaag	taacagcaat	taagaatgcc	420
ctcaaaaaga	ccaatgaagc	agtatctaca	ttggggaatg	gagttcgagt	gttggcaact	480
gcagtggagag	agctgaaaga	ttttgtgagc	aagaatctaa	cacgtgcaat	caacaaaaac	540
aagtgcgaca	ttgctgacct	gaaaatggcc	gttagcttca	gtcaattcaa	cagaagggtt	600
ctaaatgttg	tgcggaattt	ttcagacaat	gctggaataa	caccagcaat	atccttggac	660
ttaatgacag	atgctgaact	agccagagct	gtttccaaca	tgccaacatc	tgaggacaa	720
ataaaaactga	tggtggagaa	ccgtgcaatg	gtaagaaga			759

<210> 46

<211> 759

<212> DNA

<213> human metapneumovirus

<220>

<221> gene

<222> (1)...(759)

<223> human metapneumovirus, strain Quebec Isolate No
hmpv-228

<400> 46

atgtcttggg	aagtgggtgat	catttttttca	ttgttaataa	cacctcaaca	cggctcttaaa	60
gagagctatt	tagaagagtc	atgttagcact	ataactgaag	gatatctcag	tggtctgagg	120
acagggttgg	ataccaacgt	ttttacactg	gaggtaggtg	atgttagagaa	ccttacatgt	180
gctgatggac	ctagcttaat	aaaaacagaa	ttagacctga	ccaaaagtgc	actaagagag	240
ctcagaacag	tttctgctga	tcaactggca	agagaggagc	aaattgagaa	tcccagacaa	300
tctagatttg	ttctaggagc	aatagcactc	ggtgttgcaa	cagcagctgc	agttacagca	360
ggtgttgcaa	ttgccaaaac	catccggctt	gaaagtgaag	taacagcaat	taagaatgcc	420
ctcaaaaaga	ccaatgaagc	agtatctaca	ttggggaatg	gagttcgagt	gttggcaact	480
gcagtggagag	agctgaaaga	ttttgtgagc	aagaatctaa	cacgtgcaat	caacaaaaac	540
aagtgcgaca	ttgctgacct	gaaaatggcc	gttagcttca	gtcaattcaa	cagaagggtt	600
ctaaatgttg	tgcggaattt	ttcagacaat	gctggaataa	caccagcaat	atccttggac	660
ttaatgacag	atgctgaact	agccagagct	gtttccaaca	tgccaacatc	tgaggacaa	720
ataaaaactga	tggtggagaa	ccgtgcaatg	gtaagaaga			759

<210> 47

<211> 759

<212> DNA

<213> human metapneumovirus

<220>

<221> gene

<222> (1)...(759)

<223> human metapneumovirus, strain Quebec Isolate No
C-85885

<400> 47

atgtcttggg	aagtgggtgat	catttttttca	ttgttaataa	cacctcaaca	cggctcttaaa	60
gagagctatt	tagaagagtc	atgttagcact	ataactgaag	gatatctcag	tggtctgagg	120
acagggttgg	ataccaacgt	ttttacactg	gaggtaggtg	atgttagagaa	ccttacatgt	180
gctgatggac	ctagcttaat	aaaaacagaa	ttagacctga	ccaaaagtgc	actaagagag	240
ctcagaacag	tttctgctga	tcaactggca	agagaggagc	aaattgagaa	tcccagacaa	300
tctagatttg	ttctaggagc	aatagcactc	ggtgttgcaa	cagcagctgc	agttacagca	360
ggtgttgcaa	ttgccaaaac	catccggctt	gaaagtgaag	taacagcaat	taagaatgcc	420
ctcaaaaaga	ccaatgaagc	agtatctaca	ttggggaatg	gagttcgagt	gttggcaact	480
gcagtggagag	agctgaaaga	ttttgtgagc	aagaatctaa	cacgtgcaat	caacaaaaac	540
aagtgcgaca	ttgctgacct	gaaaatggcc	gttagcttca	gtcaattcaa	cagaagggtt	600
ctaaatgttg	tgcggaattt	ttcagacaat	gctggaataa	caccagcaat	atccttggac	660
ttaatgacag	atgctgaact	agccagagct	gtttccaaca	tgccaacatc	tgaggacaa	720
ataaaaactga	tggtggagaa	ccgtgcaatg	gtaagaaga			759

<210> 48

<211> 759

21/52

<212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(759)
 <223> human metapneumovirus, strain Quebec Isolate No
 C-60298

```

<400> 48
atgtcttggga aagtgggtgat ctttttttca ttgttaataa cacctcaaca cggctcttaaa 60
gagagctatt tagaagagtc atgtagcact ataactgaag gatattctcag tgttctgagg 120
acaggttgggt ataccaacgt ttttacctg gaggtagggt atgtagagaa ccttacatgt 180
gctgatggac ctatgcttaat aaaaacagaa ttatgcttga ccaaaagtgc actaagagag 240
ctcagaacag tttctgctga tcaactggca agagaggagc aaattgagaa tcccagacaa 300
tctagatttg tttctaggagc aatagcactc ggtgttgcaa cagcagctgc agttacagca 360
ggtgttgcaa ttgccaaaac catccggctt gaaagtgaag taacagcaat taagaatgcc 420
ctcaaaaaga ccaatgaagc agtatctaca ttggggaatg gagttcgagt gttggcaact 480
gcagtgaagg aactgaaaga ttttgtgagc aagaatctaa cagtgcaat caacaaaaac 540
aagtgcgaca ttgctgacct gaaaatggcc gttagcttca gtcaattcaa cagaagggtt 600
ctaaatgttg tgcggcaatt ttacagacaat gctggaataa caccagcaat atccttggac 660
ttaatgacag atgttgaact agccagagct gtttccaaca tgccaacatc tgcaggacaa 720
ataaaactga tgttggagaa ccgtgcaatg gtaagaaga 759
  
```

<210> 49
 <211> 759
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(759)
 <223> human metapneumovirus, strain Quebec Isolate No
 C-63778

```

<400> 49
atgtcttggga aagtgggtgat tatcatttcg ttactcataa cacctcagca cggactaaag 60
gaaagttaatt tagaagaatc atgtagtact ataactgaag gatattctcag tgttttaaga 120
acaggttgggt acaccaatgt ctttacatta gaagtgggtg atgttgaaaa tcttacatgt 180
actgatggac ctatgcttaat caaaacagaa cttgacctaa ccaaaagtgc tctaaagagaa 240
ctcaaaacag tttctgctga tcagttagcg agagaagaac aaattgaaaa tcccagacaa 300
tcaagggtttg tcttaggtgc aatagctctt ggtgttgcca cagcagcagc agtcacagca 360
ggcatttgcga tagccaaaac cataaggctt gagagtgaag tgaatgcaat caaagggtgct 420
ctcaaaacaa ccaacgaggc agtatccaca ctaggaaatg gagtgcgagt cctagccacc 480
gcagtaagag agctgaaaga atttgtgagc aaaaacctga ctagtgcatt taacaagaac 540
aaatgtgaca ttgctgatct gaagatggct gtcagcttca gtcaattcaa cagaagattc 600
ctaaatgttg tgcggcagtt ttacagacaat gcagggataa caccagcaat atcattggac 660
ctaatgactg atgtctgagct ggccagaact gtatcatata tgccaacatt tgcaggacag 720
ataaaactaa tgttagagaa ccgtgcaatg gtaagaaga 759
  
```

<210> 50
 <211> 759
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(759)
 <223> human metapneumovirus, strain Quebec Isolate No
 C-64199

```

<400> 50
atgtcttggga aagtgggtgat tatcatttcg ttactcataa cacttcagca cggactaaaa 60
gaaagttaatt tagaagaatc atgtagtact ataactgaag gatattctcag tgttttaaga 120
acaggttgggt acaccaatgt ctttacatta gaagtgggtg atgttgaaaa tcttacatgt 180
actgatggac ctatgcttaat caaaacagaa cttgacctaa ccaaaagtgc tctaaagagaa 240
ctcaaaacag tttctgctga tcagttagcg agagaagaac aaattgaaaa tcccagacaa 300
tcaagggtttg tcttaggtgc aatagctctt ggtgttgcca cagcagcagc agtcacagca 360
ggcatttgcga tagccaaaac cataaggctt gagagtgaag tgaatgcaat caaagatgct 420
ctcaaaacaa ccaacgaggc agtatccaca ctaggaaatg gagtgcgagt cctagccacc 480
gcagtaagag agctgaaaga atttgtgagc aaaaacctga ctagtgcatt taacaagaac 540
aaatgtgaca ttgctgatct gaagatggct gtcagcttca gtcaattcaa cagaagattc 600
  
```

22/52

ctaaatgttg	tgcggcagtt	ttcagacaat	gcagggataa	caccagcaat	atcattggac	660
ctaattgactg	atgctgagct	ggccagagct	gtatcatata	tgccaacatc	tcaggagacag	720
ataaaaactaa	tgtttagagaa	ccgtgcaatg	gtaagaaga			759

<210> 51
 <211> 759
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(759)
 <223> human metapneumovirus, strain Quebec Isolate No C-64200

<400> 51						
atgtcttgga	aagtgggtgat	tatcatttcg	ttactcataa	cacctcagca	cggactaaaa	60
gaaagttatt	tagaagaatc	atgtagtact	ataactgaag	gatattctcag	tgttttaaga	120
acagggttgg	acaccaatgt	ctttacatta	gaagttgggtg	atgttgaaaa	tcttacatgt	180
actgatggac	ctagcttaat	caaaacagaa	cttgacctaa	ccaaaagtgc	tctaagagaa	240
ctcaaaacag	tttctgctga	tcagtttagcg	agagaagaac	aaattgaaaa	tcccagacaa	300
tcaaggtttg	tcctaggtgc	aatagtctct	gggtttgcca	cagcagcagc	agtcacagca	360
ggcattgcga	tagccaaaac	cataaggctt	gagagtgaag	tgaatgcaat	caaagggtgct	420
ctcaaaacaa	ccaatcagggc	agtatccaca	ctaggaaatg	gagtgcgagt	cctagccacc	480
gcagtaagag	agctgaaaga	atttgtgagc	aaaaacctga	ctagtgcgaat	taacaagaac	540
aaatgtgaca	ttgctgatct	gaagatggct	gtcagcttca	gtcaattcaa	cagaagattc	600
ctaaatgttg	tgcggcagtt	ttcagacaat	gcagggataa	caccagcaat	atcattggac	660
ctaattgactg	atgctgagct	ggccagagct	gtatcatata	tgccaacatc	tcaggagacag	720
ataaaaactaa	tgtttagagaa	ccgtgcaatg	gtaagaaga			759

<210> 52
 <211> 759
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(759)
 <223> human metapneumovirus, strain Quebec Isolate No C-64536

<400> 52						
atgtcttgga	aagtgggtgat	tatcatttcg	ttactcataa	cacctcagca	cggactaaaa	60
gaaagttatt	tagaagaatc	atgtagtact	ataactgaag	gatattctcag	tgttttaaga	120
acagggttgg	acaccaatgt	ctttacatta	gaagttgggtg	atgttgaaaa	tcttacatgt	180
actgatggac	ctagcttaat	caaaacagaa	cttgacctaa	ccaaaagtgc	tctaagagaa	240
ctcaaaacag	tttctgctga	tcagtttagcg	agagaagaac	aaattgaaaa	tcccagacaa	300
tcaaggtttg	tcctaggtgc	aatagtctct	gggtttgcca	cagcagcagc	agtcacagca	360
ggcattgcga	tagccaaaac	cataaggctt	gagagtgaag	tgaatgcaat	caaagggtgct	420
ctcaaaacaa	ccaatcagggc	agtatccaca	ctaggaaatg	gagtgcgagt	cctagccacc	480
gcagtaagag	agctgaaaga	atttgtgagc	aaaaacctga	ctagtgcgaat	taacaagaac	540
aaatgtgaca	ttgctgatct	gaagatggct	gtcagcttca	gtcaattcaa	cagaagattc	600
ctaaatgttg	tgcggcagtt	ttcagacaat	gcagggataa	caccagcaat	atcattggac	660
ctaattgactg	atgctgagct	ggccagagct	gtatcatata	tgccaacatc	tcaggagacag	720
ataaaaactaa	tgtttagagaa	ccgtgcaatg	gtaagaaga			759

<210> 53
 <211> 759
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(759)
 <223> human metapneumovirus, strain Quebec Isolate No C-73769

<400> 53						
atgtcttgga	aagtgggtgat	tatcatttcg	ttactcatat	cacttcagca	cggactaaaa	60
gaaagttatt	tagaagaatc	atgtagtact	ataactgaag	gatattctcag	tgttttaaga	120
ccagggttgg	acaccaatgt	ctttacatta	gaagttgggtg	atgttgaaaa	tcttacatgt	180
actgatggac	ctagcttaat	caaaacagaa	cttgacctaa	ccaaaagtgc	tctaagagaa	240

23/52

ctcaaaaacag	tttctgctga	tcagtttagcg	agagaagaac	aaattgaaaa	tcccagacaa	300
tcaaggtttg	tccttaggtgc	aatagctctt	ggtgttgcca	cagcagcagc	agtcacagca	360
ggcattgcca	tagccaaaac	cataaggctt	gagagtgaag	tgaatgcaat	caaagggtgt	420
ctcaaaaacaa	ccaacgaggc	agtatccaca	ctagggaaatg	gagtgctgagt	cctagccacc	480
gcagtaagag	agttgaaaga	atttgtgagc	aaaaacctga	ctagtgcgaat	taacaagaac	540
aaatgtgaca	ttgctgatct	gaagatggct	gtcagcttca	gtcaattcaa	cagaagattc	600
ctaaatgttg	tgccggcagtt	ttcagacaat	gcagggataa	caccagcaat	atcattagac	660
ctaattgactg	atgctgagct	ggccagagct	gtatcataca	tgccaacatc	tgccaggacag	720
ataaaactaa	tgtttagagaa	ccgtgcaatg	gtaagaaga			759

<210> 54
 <211> 759
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(759)
 <223> human metapneumovirus, strain Quebec Isolate No C-74501

<400> 54

atgtcttggg	aagtgggtgat	tatcatttcg	ttactcataa	cacttcagca	cggactaaaa	60
gaaagttatt	tagaagaatc	atgtagtact	ataactgaag	gatattctag	tgttttaaga	120
acaggttggt	acaccaatgt	ctttacatta	gaagttgggt	atgttgaaaa	tcttacatgt	180
actgatggac	ctagcttaat	caaaaacagaa	cttgacctaa	ccaaaagtgc	tctaagagaa	240
ctcaaaaacag	tttctgctga	tcagtttagcg	agagaagaac	aaattgaaaa	tcccagacaa	300
tcaaggtttg	tccttaggtgc	aatagctctt	ggtgttgcca	cagcagcagc	agtcacagca	360
ggcattgcca	tagccaaaac	cataaggctt	gagagtgaag	tgaatgcaat	caaagggtgt	420
ctcaaaaacaa	ccaacgaggc	agtatccaca	ctagggaaatg	gagtgcgagt	cctagccact	480
gcagtaagag	agctgaaaga	atttgtgagc	aaaaacctga	ctagtgcgaat	taacaagaac	540
aaatgtgaca	ttgctgatct	gaagatggct	gtcagcttca	gtcaattcaa	cagaagattc	600
ctaaatgttg	tgccggcagtt	ttcagacaat	gcagggataa	caccagcaat	atcattagac	660
ctaattgactg	atgctgagct	ggccagagct	gtatcataca	tgccaacatc	tgccaggacag	720
ataaaactaa	tgtttagagaa	ccgtgcaatg	gtaagaaga			759

<210> 55
 <211> 759
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(759)
 <223> human metapneumovirus, strain Quebec Isolate No C-78429

<400> 55

atgtcttggg	aagtgggtgtt	catcatttcg	ttactcataa	caccccagca	cgggctaaag	60
gagagttatt	tggaagaatc	atgcagtagt	ataactgagg	gatacctcag	tgttttaaga	120
acaggttggt	acattaatgt	cttcacatta	gaagttgggt	atgttgaaaa	tcttacatgt	180
actgatggac	ctagcttaat	caaaaacagaa	cttgacctaa	caaaaagtgc	tttaagggaa	240
ctcaaaaacag	tctctgctga	tcagtttagcg	agagaggagc	aaattgaaaa	tcccagacaa	300
tcaagatttg	tccttaggtgc	aatagctctt	ggagtgtgta	cagcagcagc	agtcacagca	360
ggcattgcaa	tagccaaaac	cataaggctt	gagagtgaag	tgaatgcaat	taaagggtgt	420
ctcaaaaacaa	ctaattgaagc	agtatccaca	ttagggaaatg	gtgtgctgggt	cctagccact	480
gcagtgagag	agctaaaaga	atttgtgagc	aaaaatctga	ctagtgcgaat	caacagggaac	540
aaatgtgaca	ttgctgatct	gaagatggct	gtcagcttca	gtcaattcaa	cagaagattt	600
ctcaatgttg	tgccggcagtt	ttcagacaat	gcagggataa	caccagcaat	atcattggac	660
ctaattgactg	atgctgaatt	ggccagagct	gtatcataca	tgccaacatc	tgccaggacag	720
ataaaactga	tgttggagaa	ccgtgcaatg	gtaagaaga			759

<210> 56
 <211> 759
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(759)
 <223> human metapneumovirus, strain Quebec Isolate No C-78652

24/52

```

<400> 56
atgtcttggg aagtgggtgat catcatttcg ttactcataa caccctcagca cgggctaaga 60
gagagttatt tggagaatc atgcagtact ataactgagg gatacctcag tgttttaaga 120
acgggttggt acaccaatgt cttcacatta gaagttgggt atgttgaaaa tcttacatgt 180
actgatggac ctactttaat caaaacagaa ctgaccta aaagtgcc ttaaggga 240
ctcaaaacag tctctgctga tcagttaacg agagaggagc aaattgaaaa tcccagacaa 300
tcaagatttg tcttaggtgc aatagctctc ggagttgcta cagcagcagc agtcacagca 360
ggcattgcga tagccaaaac cataaggctt gagagtgagg tgaatgcaat taaagggtgct 420
ctcaaacaaa ctaatgaagc agtatccaca ttaggaaatg gtgtgcgggt cctagccact 480
gcagtggagag agctaaaaga atttgtgagc aaaaatctga ctagtgcagt caacagggaac 540
aaatgtgaca ttgctgatct gaagatggct gtcagcttca gtcaattcaa cagaagattt 600
ctaaatgttg tgcggcagtt ttccagacaat gcagggataa caccagcaat atcattggac 660
ctaattgactg atgctgaatt ggccagagct gtatcatata tgccaacatc tgcaggacag 720
ataaaactga tgttgagaa ccgtgcaatg gtaagaaga 759

```

```

<210> 57
<211> 759
<212> DNA
<213> human metapneumovirus

```

```

<220>
<221> gene
<222> (1)...(759)
<223> human metapneumovirus, strain Quebec Isolate No
hmpv-118

```

```

<400> 57
atgtcttggg aaggggtgat tatcatttcg ttactcataa caccctcagca cggactaaaa 60
gaaagtatt tagaagaatc atgtagtact ataactgaag gatattctcag tgttttaaga 120
acaggttggt acaccaatgt ctttacatta gaagttgggt atgttgaaaa tcttacatgt 180
actgatggac ctactttaat caaaacagaa ctgaccta aaagtgcc tctgagagaa 240
ctcaaaacag tttctgctga tcagttaacg agagaagaac aaattgaaaa tcccagacaa 300
tcaagggttg tcttaggtgc aatagctctt ggtgttgcca cagcagcagc agtcacagca 360
ggcattgcga tagccaaaac cataaggctt gagagtgaag tgaatgcaat caaagggtgct 420
ctcaaaacaa ccaacgaggc agtatccaca ctaggaaatg gagtgcgagt cctagccacc 480
gcagtaagag agctgaaga atttgtgagc aaaaacctga ccagtgcagt taacaagaac 540
aaatgtgaca ttgctgatct gaagatggct gtcagcttca gtcaattcaa cagaagattc 600
ctaaatgttg tgcggcagtt ttccagacaat gcagggataa caccagcaat atcattagac 660
ctaattgactg atgctgagct ggccagagct gtatcatata tgccaacatc tgcagggcag 720
ataaaactaa tgttagagaa ccgtgcaatg gtaagaaga 759

```

```

<210> 58
<211> 759
<212> DNA
<213> human metapneumovirus

```

```

<220>
<221> gene
<222> (1)...(759)
<223> human metapneumovirus, strain Quebec Isolate No
hmpv-200

```

```

<400> 58
atgtcttggg aagtgggtgat ctttttttcg ttactcataa caccctcagca cggactaaaa 60
gaaagtatt tagaagaatc atgtagtact ataactgaag gatattctcag tgttttaaga 120
acaggttggt acaccaatgt ctttacatta gaagttgggt atgttgaaaa tcttacatgt 180
actgatggac ctactttaat caaaacagaa ctgaccta aaagtgcc tctaagagaa 240
ctcaaaacag tttctgctga tcagttaacg agagaagaac aaattgaaaa tcccagacaa 300
tcaagggttg tcttaggtgc aatagctctt ggtgttgcca cagcagcagc agtcacagca 360
ggcattgcga tagccaaaac cataaggctt gagagtgaag tgaatgcaat caaagggtgct 420
ctcaaaacaa ccaacgaggc agtatccaca ctaggaaatg gagtgcgagt cctagccacc 480
gcagtaagag agctgaaga atttgtgagc aaaaacctga ccagtgcagt taacaagaac 540
aaatgtgaca ttgctgatct gaagatggct gtcagcttca gtcaattcaa cagaagattc 600
ctaaatgttg tgcggcagtt ttccagacaat gcagggataa caccagcaat atcattagac 660
ctaattgactg atgctgagct ggccagagct gtatcatata tgccaacatc tgcagggcag 720
ataaaactaa tgttagagaa ccgtgcaatg gtaagaaga 759

```

```

<210> 59
<211> 759
<212> DNA
<213> human metapneumovirus

```

25/52

<220>
 <221> gene
 <222> (1)...(759)
 <223> human metapneumovirus, strain Quebec Isolate No
 hMPV-176

<400> 59
 atgtcttggg aagtgggtgat tatcatttcg ttactcataa caccctcagca cggactaaaa 60
 gaaagttatt tagaagaatc atgtagtact ataactgaag gatattctcag tgttctaaga 120
 acagggttgg acaccaatgt ctttacatta gaagttgggt atgttgaaaa tcttacatgt 180
 actgatggac ctagcttaat caaaacagaa cttgacctaa ccaaaagtgc ttttaagagaa 240
 ctcaaaaacag tttctgctga tcagtttagcg agagaagaac aaattgaaaa tcccagacaa 300
 tcaaggtttg tcctagggtgc aatagctctc ggagttggca cagcagcagc agtcacagca 360
 ggcatgtgcaa tagccaaaac tataaggcct gagagtgaag tgaatgcaat caaaggtgct 420
 ctcaaaacaa ccaatgaggc agtatcaaca ctaggaaatg gagtgcggt cctagccact 480
 gcagtaagag agctgaaaaga atttgtgagc aaaaacctga ctagtgcgat caacaagaac 540
 aaatgtgaca ttgtctgattt gaagatggct gtcagcttca gtcagttcaa cagaagattc 600
 ctaaatgttg tgccgagctg ttcagacaat gcagggataa caccagcaat atcattggac 660
 ctgatgactg atgtctgagct ggccagagct gtatcataca tgccaacatc tgaggagacg 720
 ataaaactaa tgrtagagaa ccgtgcaatg gtaagaaga 759

<210> 60
 <211> 711
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(711)
 <223> human metapneumovirus, strain Quebec Isolate No
 hMPV-193

<400> 60
 atggaggtga aagtggagaa cattcgaaca atagatatgc tcaaagcaag agtgaaaaat 60
 cgtgtggcac gcagcaaatg ctttaaaaaat gcccttttga tcctaataagg aataactaca 120
 ttgagtatag ccctcaatat ctatctgac ataaactata caatgcaaga aaacacatcc 180
 gaatcagaac atcacaccag ctcatcacc atggaatcca gcagggaac tccaacgggtc 240
 cccatggact acccagacac caatccaggc tcacagtatc caactcaaca gtccacagaa 300
 ggctccacac tctactttgc agcctcagca agctcaccag agacagaacc aacatcaaca 360
 ccaaacacaa caagccgccc gcccttcgtc gacacacaca caacaccacc aagtgcagc 420
 agaacaaaga caagtccggc agtccacaca aaaaacaatc caaggataag cctcagaaca 480
 cattccccac catgggcaat gacaaggacg gtcccgaggaa ccaccactct ccgcacaagc 540
 agcacaagaa aaagaccgtc tacagcatca gtccaacctg acagcagcgc aacaacccac 600
 aaacacgaag aagcaagccc agtgagcccg caaacatctg caagcacagc aagaccacaa 660
 aggaaggtca tggaggccag cacatcaaca acatacaatc aaactagtta a 711

<210> 61
 <211> 711
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(711)
 <223> human metapneumovirus, strain Quebec Isolate No
 hMPV-228

<400> 61
 atggaggtga aagtggagaa cattcgaaca atagatatgc tcaaagcaag agtgaaaaat 60
 cgtgtggcac gcagcaaatg ctttaaaaaat gcccttttga tcctaataagg aataactaca 120
 ttgagtatag ccctcaatat ctatctgac ataaactata caatgcaaga aaacacatcc 180
 gaatcagaac atcacaccag ctcatcacc atggaatcca gcagggaac tccaacgggtc 240
 cccatggact acccagacac caatccaggc tcacagtatc caactcaaca gtccacagaa 300
 ggctccacac tctactttgc agcctcagca agctcaccag agacagaacc aacatcaaca 360
 ccaaacacaa caagccgccc gcccttcgtc gacacacaca caacaccacc aagtgcagc 420
 agaacaaaga caagtccggc agtccacaca aaaaacaatc caaggataag cctcagaaca 480
 cattccccac catgggcaat gacaaggacg gtcccgaggaa ccaccactct ccgcacaagc 540
 agcacaagaa aaagaccgtc tacagcatca gtccaacctg acagcagcgc aacaacccac 600
 aaacacgaag aagcaagccc agtgagcccg caaacatctg caagcacagc aagaccacaa 660
 aggaaggtca tggaggccag cacatcaaca acatacaatc aaactagtta a 711

26/52

<210> 62
 <211> 711
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(711)
 <223> human metapneumovirus, strain Quebec Isolate No
 C-77748

<400> 62							
atggagggtga	aagtggagaa	cattcgaaca	atagatatgc	tcaaagcaag	agtgaaaaat	60	
cgtgtggcac	gcagcaaatg	ctttaaaaaat	gcctctttga	tcctaataagg	aataactaca	120	
ttgagtataag	ccctcaaatat	ctatctaatc	ataaactata	caatgcaaga	aaacacatcc	180	
gaatcagaac	atcacaccag	ctcatcacc	atggaatcca	gcagggaac	tccaacagtc	240	
cctatggaca	actcagacac	caatccaggc	tcacagtatc	caactcaaca	gtccacagaa	300	
ggctccacac	tctactttgc	agcctcagca	agctcaccag	agacagaacc	aacatcaaca	360	
ccagacacaa	caagccgccc	gcccttcgtc	gacacacaca	caacaccacc	aagtgcagc	420	
agaacaagga	caagtccggc	agtcacaca	aaaaacaatc	caaggacaag	ccccagaaca	480	
cattccccac	catgggcaat	gacaaggacg	gtccgtggaa	ccaccactct	ccgcacaagc	540	
agcacaagaa	aaagaccgtc	tacagcatca	gtccaacctg	acagcagcgc	aacaaccac	600	
aaacacgaag	aagcaagccc	agtgagcccg	caaacatctg	cgagcacagc	aagaccacaa	660	
aggaagggca	tggaggccag	cacatcaaca	acatacaacc	aaactagtta	a	711	

<210> 63
 <211> 711
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(711)
 <223> human metapneumovirus, strain Quebec Isolate No
 C-78132

<400> 63							
atggagggtga	aagtggagaa	cattcgaaca	atagatatgc	tcaaagcaag	agtgaaaaat	60	
cgtgtggcac	gcagcaaatg	ctttaaaaaat	gcctctttga	tcctaataagg	aataactaca	120	
ttgagtataag	ccctcaaatat	ctatctaatc	ataaactata	caatgcaaga	aaacacatcc	180	
gaatcagaac	atcacaccag	ctcatcacc	atggaatcca	gcagggaac	tccaacggtc	240	
cctatagaca	actcagacac	caatccaggc	tcacagtatc	caactcaaca	gtccacagaa	300	
ggctccacac	tccactttgc	agcctcagca	agctcaccag	agacagaacc	aacatcaaca	360	
ccagacacaa	caagccgccc	gcccttcgtc	gacacacaca	caacaccacc	aagtgcagc	420	
agaacaagga	caagtccggc	agtcacaca	aaaaacaatc	taagataag	ccccagaata	480	
cattccccac	catgggcaat	gacaaggacg	gtccgtggaa	ccaccactct	ccgcacaagc	540	
agcacaagaa	aaagaccgtc	tacagcatca	gtccaacctg	acagcagcac	aacaactcac	600	
aaacacgaag	aagcaagccc	agtgagccca	caaacatctg	caagcacagc	aagaccacaa	660	
aggaagggca	tggaggccag	cacatcaaca	acatacaacc	aaactagtta	a	711	

<210> 64
 <211> 711
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(711)
 <223> human metapneumovirus, strain Quebec Isolate No
 C-78406

<400> 64							
atggagggtga	aagtggagaa	cattcgaaca	atagatatgc	tcaaagcaag	agtgaaaaat	60	
cgtgtggcac	gcagcaaatg	ctttaaaaaat	gcctctttga	tcctaataagg	aataactaca	120	
ttgagtataag	ccctcaaatat	ctatctaatc	ataaactata	caatgcaaga	aaacacatcc	180	
gaatcagaac	atcacaccag	ctcatcacc	atggaatcca	gcagggaac	tccaacggtc	240	
cctatagaca	actcagacac	caatccaggc	tcacagtatc	caactcaaca	gtccacagaa	300	
ggctccacac	tccactttgc	agcctcagca	agctcaccag	agacagaacc	aacatcaaca	360	
ccagacacaa	caagccgccc	gcccttcgtc	gacacacaca	caacaccacc	aagtgcagc	420	
agaacaagga	caagtccggc	agtcacaca	aaaaacaatc	taagataag	ccccagaata	480	
cattccccac	catgggcaat	gacaaggacg	gtccgtggaa	ccaccactct	ccgcacaagc	540	
agcacaagaa	aaagaccgtc	tacagcatca	gtccaacctg	acagcagcac	aacaactcac	600	

27/52

aaacacgaag aagcaagccc agtgagccca caaacatctg caagcacagc aagaccacaa 660
 aggaagggca tggaggccag cacatcaaca acatacaacc aaactagtta a 711

<210> 65
 <211> 711
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(711)
 <223> human metapneumovirus, strain Quebec Isolate No
 C-73750

<400> 65
 atggagggtga aagtggagaa cattcgaaca atagatatgc tcaaagcaag agtgaaaaat 60
 cgtgtggcac gtagcaaatg ctttaaaaaat gcttctttga tcctaatagg aataactaca 120
 ttgagtatag ccttcaacat ctatctgac ataaactata caatgcaaga aaacacatcc 180
 gaatcagaac atcacaccag ctcatcacc atggaatcca gcagggaac tccaacggtc 240
 cctatagaca actcagacac caatccaggc tcacagtatc caactcaaca gtccacagaa 300
 ggctccacac tccaacttgc agcctcagca agctcaccag agacagaacc aacatcaaca 360
 ccagacacaa caagccgccc gcccttcgtc gacacacaca caacaccacc aagtgaagc 420
 agaacaagga caagtccggt agtccacaca aaaaacaatc taaagataag cccagaaaca 480
 cattccccac catgggcaat gacaaggagc gtccgtggaa ccaccactct ccgcacaagc 540
 agcataagaa aaagaccgtc cacagcatca gtccaacctg acagcagcat aacaaccac 600
 aaacacgaag aagcaagccc agtgagccca caaacatctg caagcacagc aagaccacaa 660
 aggaagggca tggaggccag cacatcaaca acatacaacc aaactagtta a 711

<210> 66
 <211> 660
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(660)
 <223> human metapneumovirus, strain Quebec Isolate No
 C-60298

<400> 66
 atggagggtga aagtggagaa cattcgaaga atagacatgc tcaaagcaag agtgaaaaat 60
 cgtgtggcac gtagcaaatg ctttaaaaaat gcttctttta tcctaatagg aataactaca 120
 ctgagtatag ctctcaatat ctatctgac ataaactata caatacaaaa aacctcatct 180
 gaatcagaac accacaccag ctacccaccc acagaatcca acaagggaagc ttcaacaatc 240
 tccacagaca acccagacat caatccaaac tcacagcatc caactcaaca gtccacagaa 300
 aacccacac tcaaccccggt agcatcagtg agcccatcag aaacagaacc agcatcaaca 360
 ccagacacaa caaacccgct gtctccgta gacaggtcca cagcacaacc aagtgaagc 420
 agaacaagga caaaaccgac agtccacaca agaaacaacc caagcacagc ttccagtaca 480
 caatccccac cacgggcaac aacgaaggca atccgcagag ccaccacttt ccgcatagac 540
 agcacaggaa aaagaccaac cacaacatca gtccagtccg acagcagcat cacaaccaca 600
 aatcatgaag aaacagggttc agcgaaccca caggcatctg taagcacaat gcaaaactag 660

<210> 67
 <211> 654
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(654)
 <223> human metapneumovirus, strain Quebec Isolate No
 C-74783

<400> 67
 atggagggtga aagtggagaa cattcgaaga atagacatgc tcaaagcaag agtgaaaaat 60
 cgtgtggcac gtagcaaatg ctttaaaaaat gcttctttta tcctaatagg aataactaca 120
 ctgagtatag ctctcaatat ctatctgac ataaaccaca caatacaaaa aaccacatct 180
 gaatcagaac accacaccag ctacccaccc acagaatcca acaagggaagc ttcaacaatc 240
 tccacagaca acccagacat caatccaaac tcacagcatc caactcaaca gtctacagaa 300
 aacccacac tcaaccccggt agtatcaaca agcccatcag aaacagaacc aacatcaaca 360
 ccagacacaa caaacccgct gtctccgta gacaggtcca cagcacaacc aagtgaagc 420
 agaacaagga caaaatcgac agtccacaca agaaacaacc caagcacagc ttccagcaca 480

28/52

caatccccac	cacgggcaac	aacgaaggca	atccgcagag	ccaccacttt	ccgcatgagc	540
agcacagaaa	aaagaccaac	cacaacacta	gtccagtacg	acagcagcac	cacaacccaa	600
aatcatgaag	aaacagggtc	agcgaacca	caggcatctg	caagcacaat	gtaa	654

<210> 68
 <211> 660
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(660)
 <223> human metapneumovirus, strain Quebec Isolate No C-74549

<400> 68						
atggagggtga	aagtggagaa	cattcgagca	atagacatgc	tcaaagcaag	agtgaaaaat	60
cgtgtggcac	gtagcaaatg	cttcaaaaat	gcttcccaa	tcctcacagg	aataaccaca	120
ctgagcatag	ctctcaatat	ccacctgac	ataaactaca	caatacaaaa	aaccacatct	180
gaatcagaac	accacaccag	ctcaccaccc	acagaatcta	acaagggaagc	ttcaacaatc	240
tccacagaca	accagacat	caatccaaac	tcacagcatc	caactcaaca	gtctacagaa	300
aacccacac	tcaacccgc	agtatcaaca	agccatcag	aaacagaacc	aacatcaaca	360
ccagacacaa	caaacccgct	gtcctccgta	gacagggtcca	cagcacaacc	aagtgaagc	420
agaacaaaga	caaaatcgac	agtccacaca	agaaacaacc	caagcacagc	ttccagcaca	480
caatccccac	cacgggcaac	aacgaaggca	atccgcagag	ccaccacttt	ccgcatgagc	540
agcacagaaa	aaagaccaac	cacaacatta	gtccagtacg	acagcagcac	cacaacccaa	600
aatcatgaag	aaacagggtc	agcgaacca	caggcatctg	taagcacaat	gtaaaactag	660

<210> 69
 <211> 711
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(711)
 <223> human metapneumovirus, strain Quebec Isolate No C-77807

<400> 69						
atggagggtga	aagtggagaa	cattcgaaaca	atagatatgc	tcaaagcaag	agtgaaaaat	60
cgtgtggcac	gcagcaaatg	ctttaaaaat	gcttctttga	tcctaatagg	aataacgaca	120
ttgagtatag	ccctcaacat	ctatctgac	ataaactata	caatgcaaga	aaacacatcc	180
gaatcagaac	atcacaccag	ctcatcacc	atggaatcca	gcagggaaac	tccaacgggtc	240
cctatagaca	actcagacac	caatccaggc	tcacagtatc	caactcaaca	gtccacagaa	300
ggctccacac	tccactttgc	agcctcagca	agctcaccag	agacagaacc	aacatcaaca	360
ccagacacaa	caagccgccc	gcccttcgct	gacacacaca	caacaccacc	aagtgcagc	420
agaacaagga	caagtccggc	agtcacacaca	aaaaacaatc	taaagataag	ccccagaata	480
cattccccac	catgggcaat	gacaaggacg	gtccgtggaa	ccaccactct	ccgcacaagc	540
agcacagaag	aaagaccgtc	tacagcatca	gtccaaacctg	acagcagcac	aacaactcac	600
aaacacgaag	aagcaagccc	agtgaagccc	caaacatctg	caagcacagc	aagaccacaa	660
aggaagggtga	tggaggccag	cacatcaaca	acatacaacc	aaactagtta	a	711

<210> 70
 <211> 711
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(711)
 <223> human metapneumovirus, strain Quebec Isolate No C-78163

<400> 70						
atggagggtga	aagtggagaa	cattcgaaaca	atagatatgc	tcaaagcaag	agtgaaaaat	60
cgtgtggcac	gcagcaaatg	ctttaaaaat	gcttctttga	tcctaatagg	aataactaca	120
ttgagtatag	ccctcaacat	ctatctgac	ataaactata	caatgcaaga	aaacacatcc	180
gaatcagaac	atcacaccag	ctcatcacc	atggaatcca	gcagggaaac	tccaacgggtc	240
cctatagaca	actcagacac	caatccaggc	tcacagtatc	caactcaaca	gtccacagaa	300
ggctccacac	tccactttgc	agcctcagca	agctcaccag	agacagaacc	aacatcaaca	360
ccagacacaa	caagccgccc	gcccttcgct	gacacacaca	caacaccacc	aagtgcagc	420

29/52

```

agaacaagga caagtccggc agtccacaca aaaaacaatc taaagataag ccccagaata 480
cattcccccac catggggcaat gacaaggacg gtccgtggaa ccaccactct ccgcacaagc 540
agcacaaagaa aaagaccggtc tacagcatca gtccaacctg acagcagcac aacaactcac 600
aaacacgaag aagcaagccc agtgagccca caaacatctg caagcacagc aagaccacaa 660
aggaagggca tggaggccag cacatcaaca acatacaacc aaactagtta a 711

```

<210> 71
 <211> 711
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(711)
 <223> human metapneumovirus, strain Quebec Isolate No C-68661

```

<400> 71
atggagggtga aagtggagaa cattcgaaca atagatagcg tcaaagcaag agtgaaaaat 60
cgtgtggcac gcagcaaatg ctttaaaaaat gcctctttga tcctaataagg aataactaca 120
ttgagtataag ccctcaatat ctatctgacg ataaactata caatgcaaga aaacacatcc 180
aaatcagaac atcacaccag ctcatcaccg atggaatcca gcagggaaac tccaacgggtc 240
cctatagaca actcagacac caatccaggc tcacagtatc caactcaaca gtccacagaa 300
ggctccacac tccactttgc agctcagca agctcaccag agacagaacc aacatcaaca 360
ccagacacaa caagccgccc gcccttcgtc gacacacaca caacaccacc aagtgaagc 420
agaacaagga caagtccggc agtccacaca aaaaacaatc caaggataag ccccagaaca 480
cattcccccac catggggcaat gacaaggacg gtccgtggaa ccaccactct ccgcacaagc 540
agcacaaagaa aaagaccggtc cacagcatca gtccaacctg acagcagcgc aacaacccac 600
aaacacgaag aagcaagccc agtgagccca caaacatctg caagcacagc aagaccacaa 660
aggaagggca tggaggccag cacatcaaca acatacaacc aaactagtta a 711

```

<210> 72
 <211> 711
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(711)
 <223> human metapneumovirus, strain Quebec Isolate No C-88448

```

<400> 72
atggagggtga aagtggagaa cattcgaaca atagatatgc tcaaagcaag agtgaaaaat 60
cgtgtggcac gcagcaaatg ctttaaaaaat gcctctttga tcctaataagg aataactaca 120
ttgagtataag ccctcaatat ctatctaata ataaactata caatgcaaga aaacacatcc 180
gaatcagaac atcacaccag ctcatcaccg atggaatcca gcagggaaac tccaacagtc 240
cctatggaca actcagacac caatccaggc tcacagtatc taactcaaca gtccacagaa 300
ggctccacac tctactttgc agctcagca agctcaccag agacagaacc aacatcaaca 360
ccagacacaa caagccgccc gcccttcgtc gacacacaca caacaccacc aagtgaagc 420
agaacaagga caagtccggc agtccacaca aaaaacaatc caaggacaag ccccagaaca 480
cattcccccac catggggcaat gacaaggacg gtccgtggaa ccaccactct ccgcacaagc 540
agcacaaagaa aaagaccggtc cacagcatca gtccaacctg acagcagcgc aacaacccac 600
aaacacgaag aagcaagccc agtgagcccg caaacatctg cgagcacagc aagaccacaa 660
aggaagggca tggaggccag cacatcaaca acatacaacc aaactagtta a 711

```

<210> 73
 <211> 711
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(711)
 <223> human metapneumovirus, strain Quebec Isolate No C-88470

```

<400> 73
atggagggtga aagtggagaa cattcgaaca atagatatgc tcaaagcaag agtgaaaaat 60
cgtgtggcac gcagcaaatg ctttaaaaaat gcctctttga tcctaataagg aataactaca 120
ttgagtataag ccctcaatat ctatctgacg ataaactata caatgcaaga aaacacatcc 180
gaatcagaac atcacaccag ctcatcaccg atggaatcca gcagggaaac tccaacgggtc 240

```

30/52

.ccatggact	acccagacac	caatccaggc	tcacagcatc	caactcaaca	gtccacagaa	300
ggctccacac	tctactttgc	agcctcagca	agctcaccag	agacagaacc	aacatcaaca	360
-caaacacaa	caagccgccc	gccttcgctc	gacacacaca	caacaccacc	aagtgcgaagc	420
agaacaaaga	caagtcgggc	gtccacacac	aaaaacaatc	caaggataag	cctcagaaca	480
cattccccac	catgggcaat	gacaaggacg	gtccgcgga	ccaccactct	ccgcacaagc	540
agcacagaag	aaagaccgtc	tacagcatca	gtccaacctg	acagcagcgc	aacaaccac	600
aaacacgaag	aagcaagccc	agtgagcccg	caaacatctg	caagcacagc	aagaccacaa	660
aggaagggtca	tggaggccag	cacatcaaca	acatacaacc	aaactagtta	a	711

<210> 74
 <211> 711
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(711)
 <223> human metapneumovirus, strain Quebec Isolate No C-86316

<400> 74	atggagggtga	aagtggagaa	cattcgaaca	atagatatgc	tcaaagcaag	agtgaataat	60
	cggtgtggcac	gcagcaaatg	ctttaaaaat	gcctctttga	tcctaataagg	aataactaca	120
	ttgagtatag	ccctcaatat	ctatctaatc	ataaactata	caatgcaaga	aaacacatcc	180
	gaatcagaac	atcacaccag	ctcatcacc	atggaatcca	gcaaggaaac	tccaacagtc	240
	cctatggaca	actcagacac	caatccaggc	tcacagtatc	caactcaaca	gtccacagaa	300
	ggctccacac	tctactttgc	agcctcagca	agctcaccag	agacagaacc	aacatcaaca	360
	ccagacacaa	caagccgccc	gccttcgctc	gacacacaca	caacaccacc	aagtgcgaagc	420
	agaacaagga	caagtcgggc	agtccacaca	aaaaacaatc	caaggacaag	cctcagaaca	480
	cattccccac	catgggcaat	gacaaggacg	gtccgtggaa	ccaccactct	ccgcacaagc	540
	agcacagaag	aaagaccgtc	cacagcatca	gtccaacctg	acagcagcgc	aacaaccac	600
	aaacacgaag	aagcaagccc	agtgagcccg	caaacatctg	cgagcacagc	aagaccacaa	660
	aggaagggtca	tggaggccag	cacatcaaca	acatacaacc	aaactagtta	a	711

<210> 75
 <211> 6017
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(6017)
 <223> human metapneumovirus, strain 00-1
 accession number af371337

<400> 75	atggatcttc	tcaatgaatc	cactgttaat	gtctatcttc	ctgactcata	tcttaaagga	60
	gtgattttct	ttagtggagc	taatgcaatt	ggttcatgtc	tcttaaaaag	accttaccta	120
	aaaaatgaca	acactgcaaa	agttgccata	gagaatcctg	ttatcgagca	tgtagactc	180
	aaaaatgcag	tcaattctaa	gatgaaaata	tcagattaca	agatagtaga	gccagtaaac	240
	atgcaacatg	aaattatgaa	gaatgtacac	agttgtgagc	tcacattatt	aaaacagttt	300
	ttacaagga	gtaaaaatat	tagcactctc	aaattaaata	tgatatgtga	ttggctgcag	360
	ttaaagtcta	catcagatga	tacctcaatc	ctaagtttta	tagatgtaga	atttatacct	420
	agctgggtaa	gcaattgggt	tagtaattgg	tacaattctc	acaagttgat	tctggaattc	480
	aggaagaag	aagtaataag	aaactggttc	atctgtgtga	ggctattggg	ttaattagtt	540
	tttgtgtgat	catcatatgg	atgtatagtc	aagagcaaca	aaagcaaaag	agtgcgcttc	600
	ttcacatata	atcaactggt	aaactggaaa	gatgtgatgt	taagtagart	caatgcaaat	660
	ttttgtatat	gggtaagcaa	cagtcctgaat	gaaaatcaag	aagggtcagg	gttgagaagt	720
	aatctgcaag	gcataattaac	taataagcta	tatgaaactg	tagattatat	gcttagttta	780
	tggtgcaatg	aaggtttctc	actgtgaaa	gagttcgaag	gctttattat	gagtgaattt	840
	cttaggatta	ctgaacatgc	tcaattcagt	actagattta	gaaatacttt	attaaatgga	900
	ttactgtatc	aattaaacaaa	atrraaaaat	aaaaacagac	tcagagttca	tggtaccgtg	960
	ttagaaaata	atgattatcc	aatgtacgaa	gttgtactta	agttattagg	agatactttg	1020
	agatgtatta	aattattaat	caataaaaaac	ttagagaatg	ctgctgaatt	atactatata	1080
	tttagaatat	tcggtcacc	aatggttagat	gaaagagatg	caatggatgc	tgtcaaatata	1140
	aacaatgaaa	tcacaaaaat	ccttaggtgg	gagagcttga	cagaactaag	aggggcattc	1200
	atattaagga	ttatcaaaag	atttgtagac	aacaacaaaa	gatggcccaa	aattaaaaac	1260
	ttaaaagtgc	ttagtaagag	atggactatg	tacttcaaa	caaaaagtta	ccccagtcaa	1320
	cttgaattaa	gcgaacaaga	tttttttagag	cttgcgtgaa	tacagtttga	acaagagttt	1380
	tctgtccctg	aaaaaaccaa	ccttgagatg	gtattaaatg	ataaagctat	atcacctcct	1440
	aaaagattaa	tatggtctgt	gtatccaaaa	aattactttac	ctgagaaaat	aaaaaatcga	1500
	tatctagaag	agactttcaa	tgcaagtgtat	agtttcaaaa	caagaagagt	actagagtac	1560

31/52

tattttgaaag	ataataaattt	cgacacaaaa	gaactttaaaa	gttatgttgt	taaacagaa	1620
tattttaaatg	ataaggatca	tattgtctcg	ctaactggaa	aagaaagaga	attaagtgt	1680
ggtagaatgt	ttgctatgca	accaggaaaa	cagcgacaaa	tacaaatatt	ggctgaaaa	1740
ttgttagctg	ataatattgt	accttttttc	ccagaaaacct	taacaaagta	tggtagctta	1800
gatcttcaga	gaataatgga	aatcaaatcg	gaactttctt	ctattaaac	tagaagaaat	1860
gatagttata	ataattacat	tgcaagagca	tccatagtaa	cagatrrtaag	taagttcaac	1920
caagccttta	ggtagaaac	tacagcgatc	tgtgaggatg	tagcagatga	actacatgga	1980
acacaaagcc	tattctgttg	gttacatctt	atcgctccct	tgacaacaat	gatattgtgcc	2040
tatagacatg	caccaccaga	aacaaaaggt	gaatatgata	tagataagat	agaagagcaa	2100
agrggtrtat	atagatatca	tatgggtggg	attgaaggat	gggtgtcaaaa	actctggaca	2160
atggaaagcta	tatctctatt	agatgttgta	tctgtaaaaa	cacgatgtca	aatgacatct	2220
ttattaaacg	gtgacaacca	atcaatagat	gtaagttaac	cagttaaagt	atctgagggt	2280
ttagatgaag	tgaaagcaga	ttatagcttg	gctgtaaaaa	tgtaaaaga	aataagagat	2340
gcatacagaa	ataataggcca	taaacttaaa	gaaggggaaa	catatatatc	aagagatctt	2400
cagtttataa	gtaagggtgat	tcaatctgaa	ggagtaatgc	atctaccctc	tataaaaaag	2460
atcttaagag	tgggaccatg	gataaacaca	atattagatg	acattaaac	cagtgacagag	2520
tcaatagggg	gtctatgtca	ggaattagaa	tttagggggg	aaagcataat	agttagtctg	2580
atattaaagga	gtattttggct	gtataattta	tacatgcatg	aatcaagca	acacccctta	2640
gcaggggaagc	agttatttcaa	acaactaaat	aaaacattaa	catcagtgca	gagatttttt	2700
gaaataaaaa	aggaataatga	agtagtagat	ctatggatga	acataccaat	gcagtttgga	2760
ggaggagatc	cagtagtctt	ctatagatct	ttctatagaa	ggaccctga	ttttttaact	2820
gaagcaatca	gtcatgtgga	tattctgtta	agaatatcag	ccaacataag	aatgaagcg	2880
aaaataagtt	tcttcaagc	cttactgtca	atagaaaaa	atgaacgtgc	tacactgaca	2940
acactaatga	gagatcctca	agctgttggc	tcagagcgac	aagcaaaagt	aacaagtgat	3000
atcaatagaa	cagcagrtac	cagcatctta	agctcttctc	caaatacaact	tttcagcgat	3060
agtgtctatc	actacagtac	aaatgaagaa	gaggtcggaa	tcattgtctga	caacataaca	3120
ccgtgttatc	ctcatggact	gagagtittg	tatgaatcat	taccttttca	taaagctgaa	3180
aaagtgtgta	atatgatatc	aggaacgaaa	tccataacca	acttattaca	gagaacatct	3240
gctattaatg	gtgaagatat	tgacagagct	gtatccatga	tgctggagaa	cctaggatta	3300
ttatctagaa	tattgtcagt	agttgttgat	agtatagaaa	ttccaaccaa	atctaagtgt	3360
aggctgatat	tttgtcagat	atctagaacc	ctaagggaga	catcatggaa	taatatggaa	3420
atagtggag	gaatctccct	tagcatcact	acatgcatgg	atgtcatata	tgcaactagc	3480
tctcatttga	aagggataat	cartgaaaa	ttcagcactg	acagaactac	aagaggtcaa	3540
agaggtccaa	agagcccttg	ggtagggtcg	agcactcaag	agaaaaaatt	agttcctgrr	3600
tataacagac	aaattctttc	aaaaacaaca	agagaacagc	tagaagcaat	tggaaaaatg	3660
agatgggtat	ataaaggga	accaggttta	agacgattac	tcaataagat	tigtcttgga	3720
agtttaggca	ttagttacaa	atgtgtaaaa	cctttattac	ctaggtrtat	gagtgtaaat	3780
ttcctacaca	ggttatctgt	cagtagtaga	cctatggaa	tcccagcatc	agttccagct	3840
tatagaacaa	caaattacca	ttttgacact	agtcctatta	atcaagcact	aagtggagga	3900
tttgggaatg	ttgtgtcttc	ttgtgtcttc	caaaaatgcaa	tcagctgtgg	aattagcata	3960
atgagtgtat	tagaacaatt	aactggtagg	agtcacaaac	agttagttrt	aataccctcaa	4020
ttagaagaaa	tagacattat	gccaccacca	gtgtttcaag	ggaaattcaa	ttataagcta	4080
gtagataaga	taacttttga	tcaacatata	ttcagtcacg	acaaaataga	tatgttaaca	4140
ctgggggaaaa	tgctcatgct	cactataaaa	ggtcagaaaa	cagatcagtt	cctgaacaa	4200
agagagaatt	atttccatgg	gaataatctt	attgagctct	tgtagcagc	gttagcatgt	4260
cartgggtgtg	ggatatatac	agagcaatgt	atagaaaaata	atattttcaa	gaaagactgg	4320
ggtagcgggt	tcatatcgga	tcatgttttt	atggacttca	aaatatttct	atgtgtcttt	4380
aaaactaaac	ttttatgtag	ttgggggtcc	caagggaaaa	acattaaaga	tgaagatata	4440
gtagatgaat	caatagataa	actgttaagg	attgataata	ctttttggag	aatgttcagc	4500
aaggttatgt	ttgaattcaa	ggtttaagaa	aggataatgt	tatatgatgt	aaaatttcta	4560
tcattagttag	gtttatagag	gttttaagaat	tggtttatag	aacagtggga	tcagctgagt	4620
tgcatgaggt	accttggaat	gtcaatgccg	aaggtgatct	gggtgagatc	aagtcaatta	4680
aaatctattt	gcaactgata	gagcaaggtt	tatttttaag	aataactgtt	ttgaactata	4740
cagatatggc	acatgctctc	acaagattaa	tcagaaaagaa	gttgatgtgt	gataatgcac	4800
tattaaactcc	gattccatcc	ccaatgggtta	atttaactca	agttattgat	cctacagaac	4860
aatttagctta	tttccctaag	ataacatttg	aaaggctaaa	aaattatgac	actagtctca	4920
attatgctaa	aggaaagcta	acaaggaatt	acatgatact	gttgccatgg	caacatgtra	4980
atagatatata	ctttgtcttt	agttctactg	gatgtaaagt	tagtctaaaa	acatgcattg	5040
gaaaactttat	gaaagatcta	aaacctaaag	ttctgtactt	tattggagaa	ggggcaggaa	5100
attggatggc	cagaacagca	tgtgaatatc	ctgacatcaa	atttgtatac	agaaagtttaa	5160
aagatgacct	tgatcatcat	tatcttttgg	aataccagag	agttatagga	gaattaaagca	5220
ggataataga	tagcgggtgaa	gggctttcaa	tggaacaaac	agatgcaact	caaaaaactc	5280
attgggatttt	gatacacaga	gtaagcaaa	atgcttttat	aaataacttta	tgtgatgcag	5340
aatttaagga	cagagatgat	ttttttaaga	tggttaattct	atggaggaaa	catgtattat	5400
catgcagaat	ttgcactact	tatgggacag	acctctattt	attcgcaaa	tatcargcta	5460
aagactgcaa	tgtaaaatta	cctttttttg	tgagatcagt	agccaccttt	attatgcaag	5520
gtagttaaact	gtcagggtcca	gaatgctaca	tactcttaac	actaggccac	cacaacaatt	5580
tacctgtcca	tggaagaaata	caaaattcta	agatgaaaat	agcagttgtg	aatgattttt	5640
atgctgcaaa	aaaacttgac	ataaaatcta	ttgaagccaa	ctgtaaatca	cttttatcag	5700
ggctaagaat	accgataaat	aagaaagaat	taaatagaca	gagaaggtta	ttaacactac	5760
aaagcaacca	ttcttctgta	gcaacagttg	gaggtagcaa	gggtcatagag	tctaaatggt	5820
taacaaacaa	ggcaaacaca	ataattgatt	ggttagaaca	tattttaaat	tctccaaaag	5880

32/52

gtgaattaaa ttatgatttt tttgaagcat tagaaaaatc ttaccctaata atgattaaac 5940
 taatagataa tctagggaat gcagagataa aaaaactgat caaagtaact ggatatatgc 6000
 ttgtaagtaa aaaatga 6017<210> 76
 <211> 450
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(450)
 <223> human metapneumovirus, strain Quebec Isolate No
 hMPV-118

<400> 76
 taaaatgaaa atatcagatt acaaggtagt agaaccagta aacatgcaac atgaaataat 60
 gaagaatgta cacagctgtg agcacacact attgaaacag tttttaacaa ggagtaaaaa 120
 cattagcact ctcaaatata atatgatatt tgattggctg caattaaaaat ctacatcaga 180
 tggtaacctca atcctaagtt ttatagatgt agaatttata cctagttggg taagcaactg 240
 gtttagtaat tggtaaatc tcaataagtt aatttttagaa ttcaggagag aagaagtaat 300
 aagaacccgt tcaatcttgt gcaggctcatt aggtaaatta gtttttattg tatcatcata 360
 tggatgtatc gtcaagagca acaaaagcaa aagagtgcgc ttctttacat acaatcaact 420
 gttaacatgg aaagatgtga tgtaaatgctg 450

<210> 77
 <211> 450
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(450)
 <223> human metapneumovirus, strain Quebec Isolate No
 hMPV-163

<400> 77
 ttgaaatattc agattacagg atagtagagc cagtaaacat gcaacatgaa attatgaaga 60
 atgtacacag ttgtgagctc acattattaa aacagttttt aacaaggagt aaaaatatta 120
 gcactctcaa attaaatatt atattgtgatt ggctgcagtt aaaaatctaca tcagatgata 180
 cctcaatctt aagttttata gatgtagaat ttatacctag ctgggtaagc aattggttta 240
 gtaattggta caatctcaac aagttgattc tggaaattcag gaaagaagaa gtaataagaa 300
 ctgggtcaat cttgtgtagg tcattaggta aattagtttt tgttgtatca tcatatggat 360
 gtatagtcaa gagcaacaaa agcaaaagag tgagcttctt cacatacaat caactgttaa 420
 catggaaaga tgtgatgtta agtagattca 450

<210> 78
 <211> 500
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(500)
 <223> human metapneumovirus, strain Quebec Isolate No
 hMPV-174

<400> 78
 gagaatcctg ttatcgagca tgtagattc aaaaatgcaa tcaatctaaa gatgaaaata 60
 tcagattaca ggatagtaga gccagtaaac atgcaacatg aaattatgaa gaatgtacac 120
 agttgtgagc tcacattatt aaaacagttt ttaacaagga gtaaaaatat tagcactctc 180
 aaattaaaata tgatatgtga ttggctgcag ttaaaagtcta catcagatga tacctcaatc 240
 ttaagtttta tagatgtaga atttatacct agctgggttaa gcaattgggt tagtaattgg 300
 tacaatctca acaagtgtat tctggaattc aggaagaag aagtaataag aactggttca 360
 atcttgtgta ggtcattggg taaattagtt ttgttgttat catcatatgg atgtatagtc 420
 aagagcaaca aaagcaaaag agtgagcttc ttcacatata atcaactgtt aacatggaaa 480
 gatgtgatgt taagtagatt 500

<210> 79
 <211> 450
 <212> DNA
 <213> human metapneumovirus

<220>

33/52

<221> gene
 <222> (1)...(450)
 <223> human metapneumovirus, strain Quebec Isolate No
 hMPV-184

<400> 79
 attgaaatat cagattacag gatagtagag ccagtaaaaca tgcaacatga aattatgaag 60
 aatgtacaca gtgtgtgagct cacattatta aaacagtttt taacaaggag taaaaatatt 120
 agcactctca aattaaatat gatattgtgat tggctgcagt taaagtctac atcagatgat 180
 acctcaatct taagttttat agatgtagaa ttataacctt gctgggtaag caattgggtt 240
 agtaattggt acaatctcaa caagttgatt ctggaattca ggaagaaga agtaataaga 300
 actgggttcaa tcttgtgtag gtcattagggt aaattagttt ttgttgratc atcatatgga 360
 tgtatagtca agagcaacaa aagcaaaaga gtgagcttct tcacatacaa tcaactgtta 420
 acatggaaaag atgtgtatgtt aagtagattc 450

<210> 80
 <211> 500
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(500)
 <223> human metapneumovirus, strain Quebec Isolate No
 hMPV-196

<400> 80
 ttgcccatag agaatcctgt tattgagcat gtgagactca aaaatgcagt caattctaaa 60
 atgaaaaatat cagattacaa ggtagtagag ccagtaaaaca tgcaacatga aataatgaag 120
 aatgtacaca gtgtgtgagct cacactattg aaacagtttt taacaaggag taaaaacatt 180
 agcactctca aattaaatat gatattgtgat tggctgcaat taaagtctac atcagatgat 240
 acctcaatcc taagtttcat agatgtagaa ttataacctt gttgggtaag caactgggtt 300
 agtaattggt acaatctcaa taagttaatt ttggaattca gaagagaaga agtaataaga 360
 accgggtcaa tcttatgcag gtcattgggt aaattagttt ttattgtatc atcatatgga 420
 tgtatcgtca agagcaacaa aagcaaaaga gtgagcttct tcacatacaa tcaactgtta 480
 acatggaaaag atgtgtatgtt 500

<210> 81
 <211> 450
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(450)
 <223> human metapneumovirus, strain Quebec Isolate No
 C-76837

<400> 81
 agatgaaaat atcagattac aggatagtag agccagtaaa catgcaacat gaaattatga 60
 agaattgtaca cagttgtgag ctacacattat taaaacagtt tttaacaagg agtaaaaata 120
 ttagcactct caaattaaat atgatattgt attggctgca gttaaagtct acatcagatg 180
 atacctcaat cttaagtttt atagattgtag aatttatacc tagctgggta agcaattggt 240
 ttagtaattg gtacaatctc aacaagttga ttctggaatt caggaaagaa gaagtaataa 300
 gaactggttc aatcttgtgc aggtctttgg gtaaatagtt ttttgttgta tcatcatatg 360
 gatgtatagt caagagcaac aaaagcaaaa gagtgtgagct ttccacatac aatcaactgt 420
 taacatggaa agatgtgatg ttaagtagat 450

<210> 82
 <211> 450
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(450)
 <223> human metapneumovirus, strain Quebec Isolate No
 C-77807

<400> 82
 taagatgaaa atatcagatt acaggatagt agagccagta aacatgcaac atgaaattat 60
 gaagaaatgta cacagttgtg agctcacatt attaaaacag tttttaacaa ggagtaaaaa 120

34/52

tatttagcact	ctcaaattaa	atatgatatg	tgattggctg	cagttaaagt	ctacatcaga	180
tgataacctca	atcttaagtt	ttatagatgt	agaattttata	cctagctggg	taagcaattg	240
gitttagtaat	tggtacaatc	tcaacaagtt	gattctggaa	ttcaggaaaag	aagaagtaat	300
aagaactggg	tcaatcttgt	gtaggtcatt	gggtaaaatta	gtttttgttg	tatcatcata	360
cggatgtata	gtcaagagca	acaaaagcaa	aagagtggagc	ttcttcacat	acaatcaact	420
gttaacatgg	aaagatgtga	tgtaagtag				450

<210> 83
 <211> 450
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(450)
 <223> human metapneumovirus, strain Quebec Isolate No
 hmpv-185

<400> 83	taaaattgaa	atatcagatt	acaaggtagt	agagccagta	aacatgcaac	atgaaataat	60
	gaagaatgta	cacagttgtg	agctcacact	attgaaaacag	tttttaacaa	ggagtataaaa	120
	cattagcact	ctcaaattaa	atatgatatg	tgattggctg	caattaaagt	ctacatcaga	180
	tgataacctca	atcctaagtt	tcataagatgt	agaattttata	cctagttggg	taagcaactg	240
	gttttagtaat	tggtacaatc	tcaataagtt	aattttggaa	ttcagaagag	aagaagtaat	300
	aagaaccggg	tcaatcttat	gcaggtcatt	gggtaaaatta	gtttttattg	tatcatcata	360
	tggtatgtatc	gtcaagagca	acaaaagcaa	aagagtggagc	ttcttcacat	acaatcaact	420
	gttaacatgg	aaagatgtga	tgtaagtag				450

<210> 84
 <211> 500
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(500)
 <223> human metapneumovirus, strain Quebec Isolate No
 C-78123

<400> 84	atcctgttat	cgagcatgtt	agactcaaaa	atgcaatcaa	ttctaagatg	aaaatatcag	60
	attacaggat	agtagagcca	gtaaacatgc	aacatgaaat	tatgaagaat	gtacacagtt	120
	gtgagctcac	attattaaaa	cagtttttaa	caaggagtaa	aaatattagc	actctcaaat	180
	taaaatgat	atgtgattgg	ctacagttaa	agctciacac	agatgatacc	tcaatcttaa	240
	gttttataga	tgtagaattt	atacctagct	gggtaaagcaa	ttggtttagt	aattgggtaca	300
	atctcaacaa	gttgattctg	gaattcagga	aagaagaagt	aataagaact	ggttcaatct	360
	tggtgcaggtc	tttgggtaaa	ttagtttttg	ttgtatcatc	atatggatgt	atagtcaaga	420
	gcacacaaaag	caaaagagtg	agcttcttca	catacaatca	actgttaaca	tggaaagatg	480
	tgatgtttaag	tagatttcaat					500

<210> 85
 <211> 450
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(450)
 <223> human metapneumovirus, strain Quebec Isolate No
 C-91205

<400> 85	caatttctaaa	atgaaaatat	cagattacaa	ggtagtagag	ccagtaaaaca	tgcaacatga	60
	aataatgaag	aatgtacaca	gttgtgagct	cacactattg	aaacagtttt	taacaaggag	120
	taaaaacatt	agcactctca	aattaaatat	gatatgtgat	tggctgcaat	taaggtctac	180
	atcagatgat	acctcaatcc	taagtttcat	agatgtagaa	tttataccta	gttgggtaag	240
	caactgggtt	agtaattggg	acaatctcaa	taagttaatt	ttggaattca	gaagagaaga	300
	agtaataaga	accggttcaa	tcttatgcag	gtcattgggt	aaattagttt	ttattgtatc	360
	atcatatgga	tgtattgtca	agagcaacaa	aagcaaaaaga	gtgagcttct	tcacatacaa	420
	tcaactgtta	acatggaaaag	atgtgatgtt				450

<210> 86

35/52

<211> 400
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(400)
 <223> human metapneumovirus, strain Quebec Isolate No C-91364

<400> 86	ttgcatagag aatcctgtta ttgagcatgt cagactcaaa aatggcagta attctaaaat	60
	gaaaatatca gattacaagg tagtagaacc agtaaacatg caacatgaaa taatgaagaa	120
	tgtacacagc tigtgacaca cactattgaa acagttttta acaaggagta aaaacattag	180
	cactctcaaa ttaaataatga tatgtgattg gctgcaatta aaatctacat cagatgggtac	240
	ctcaatccta agtttttatag atgtagaatt tatacctagt tgggtaagca actgggtttag	300
	taattggcac aatctcaata agttaatttt agaattcagg agagaagaag taataagaac	360
	cggttcaatc ttgtgcagggt cattaggtaa attagttttt	400

<210> 87
 <211> 500
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(500)
 <223> human metapneumovirus, strain Quebec Isolate No C-91749

<400> 87	atagagaatc ctggtattga gcatgtgaga ctcaaaaatg cagtcaattc taaaatgaaa	60
	atatcagatt acaaggtagt agagccagta aacatgcaac atgaaataat gaagaatgta	120
	cacagttgtg agctcacact attgaaacag tttttaacta ggagtaaaaa cattagcact	180
	ctcaaatata atatgatatg tgattggctg caartaaagt ctacatcaga tgataacctca	240
	atcctaagtt tcatagatgt agaatttata cctagttggg taagcaactg gtttagtaat	300
	tggtacaatc tcaataagtt aatttttgaa ttcagaagag aagaagtaat aagaaccggt	360
	tcaatctttt gcagggtcatt gggtaaatta gtttttatg tatcatcata tggatgtatc	420
	gtcaagagca acaaaagcaa aagagtgagc ttcttcacat acaatcaact gttaacatgg	480
	aaagatgtga tgttaagtng	500

<210> 88
 <211> 450
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(450)
 <223> human metapneumovirus, strain Quebec Isolate No hMPV-Q86

<400> 88	aattctaaaa tggaaatata agattacaag gtagtagaac caataaacat gcaacatgaa	60
	ataatgaaga atgtacacag tigtgagctc acactattga aacagttttt aacaaggagt	120
	aaaaacatta gcactctcaa attaaaatag atatgtgatt ggctgcaatt aaaatctaca	180
	tcagatgata cctcaatcct aagttttata gatgtagaat ttatacctag ttgggtaagc	240
	aactgggtta gtaattggta caatctcaat aagttaattt tagaattcag gagagaggaa	300
	gtaataagaa ccggttcaat ctgtgtcagg tcattaggta aattagtttt tattgtatca	360
	tcatatggat gtatcgtcaa gagcaacaaa agcaaaaagag tgagcttctt cacatacaat	420
	caactgrraa catggaagaa tgtgatgtta	450

<210> 89
 <211> 450
 <212> DNA
 <213> human metapneumovirus

<220>
 <221> gene
 <222> (1)...(450)
 <223> human metapneumovirus, strain Quebec Isolate No hMPV-Q97

36/52

```

<400> 89
aaaatgaaaa tatcagatta caaggtagta gagccagtaa acatgcaaca tgaaataatg      60
aagaatgtac acagttgtga gctcacacta ttgaacagtt ttttaactag gagtaaaaac      120
attagcactc tcaaattaaa tatgatattg gattggctgc aattaaagtc tacatcagat      180
gataacctca tcctaagttt catagatgta gaatttatac ctagtgggtt aagcaactgg      240
tttagtaatt ggtacaatct caataagtta attttggaat tcagaagaga agaagtaata      300
agaaccgggt caatcttatg caggtcattg ggtaaattag tttttattgt atcatcatat      360
ggatgtatcg tcaagagcaa caaaagcaaa agagtgagct tcttcacata caatcaactg      420
ttaacatgga aagatgtgat gttaaagtaga

```

```

<210> 90
<211> 537
<212> DNA
<213> human metapneumovirus

```

```

<220>
<221> gene
<222> (1)...(537)
<223> human metapneumovirus, strain Can 97-83

```

```

<400> 90
agaatcctgt tattgagcat gtgagactca aaaatggcgg tcattctaaa atgaaaatat      60
cagattacaa ggtagtagag ccagtaaaaca tgcaacatga aataatgaag aatgtacaca      120
gttgtgagct cacactattg aaacagtttt taacaaggag taaaaacatt agcactctca      180
aattgaatat gatattgat ttgctgcaat taaagtctac atcagatgat acctcaatcc      240
taagtttcat agatgtagaa ttatataccta gttgggttaa caactgggtt agtaattggt      300
acaattctca taagttaatt ttggaattca gaagagagga agtaataaga accgggtcaa      360
tcttatgcag gtcattgggt aaattagttt ttattgtatc atcatatgga tgtatcgta      420
agagcaacaa aagcaaaaga gtgagcttct tcacatacaa tcaactgtta acatggaaag      480
atgtgatgtt aagtagattt aatgcgaatt ttgtatatg ggtaagcaac agttctg      537

```

```

<210> 91
<211> 20
<212> DNA
<213> human metapneumovirus

```

```

<220>
<223> primer no 55

```

```

<400> 91
atgggacaag tgaaaatgtc      20

```

```

<210> 92
<211> 19
<212> DNA
<213> human metapneumovirus

```

```

<220>
<223> primer no 56

```

```

<400> 92
gagtctcagt acacaataa      19

```

```

<210> 93
<211> 18
<212> DNA
<213> human metapneumovirus

```

```

<220>
<223> primer no 57

```

```

<400> 93
gtcactgcag ttgttgta      18

```

```

<210> 94
<211> 19
<212> DNA
<213> human metapneumovirus

```

```

<220>
<223> primer no 58

```

37/52

<400> 94
jcatttccga gaacaacac 19
<210> 95
<211> 19
<212> DNA
<213> human metapneumovirus
<220>
<223> primer no 18 multiplex assay
<400> 95
gagtctcagt acacaataa 19
<210> 96
<211> 19
<212> DNA
<213> human metapneumovirus
<220>
<223> primer no 19 multiplex assay
<400> 96
gcatttccga gaacaacac 19
<210> 97
<211> 18
<212> DNA
<213> human metapneumovirus
<220>
<223> primer no 59
<400> 97
atgtcttgga aagtgggtg 18
<210> 98
<211> 17
<212> DNA
<213> human metapneumovirus
<220>
<223> primer no 60
<400> 98
tttcttacc attgcac 17
<210> 99
<211> 20
<212> DNA
<213> human metapneumovirus
<220>
<223> primer no 61
<400> 99
ctaattatgt ggtatgaagc 20
<210> 100
<211> 18
<212> DNA
<213> human metapneumovirus
<220>
<223> primer no 62
<400> 100
atggagtcct acctagta 18
<210> 101
<211> 19

38/52

<212> DNA
<213> human metapneumovirus

<220>
<223> primer no 63

<400> 101
aaggtgcttg gttgttatc

19

<210> 102
<211> 19
<212> DNA
<213> human metapneumovirus

<220>
<223> primer no 64

<400> 102
atgtcattcc ctgaaggaa

19

<210> 103
<211> 19
<212> DNA
<213> human metapneumovirus

<220>
<223> primer no 65

<400> 103
ttaactggta aatctcatc

19

<210> 104
<211> 19
<212> DNA
<213> human metapneumovirus

<220>
<223> primer no 66

<400> 104
catgggacaa gtagttatg

19

<210> 105
<211> 19
<212> DNA
<213> human metapneumovirus

<220>
<223> primer no 67

<400> 105
atggaggtga aagtggaga

19

<210> 106
<211> 19
<212> DNA
<213> human metapneumovirus

<220>
<223> primer no 68

<400> 106
ttaactagtt tgggtgtat

19

<210> 107
<211> 19
<212> DNA
<213> human metapneumovirus

<220>
<223> primer no 69

39/52

<400> 107 tttagagtta tttgtatt	19
<210> 108 <211> 24 <212> DNA <213> human metapneumovirus	
<220> <223> primer no 70	
<400> 108 ggacaagtag ttatggaggt gaaa	24
<210> 109 <211> 28 <212> DNA <213> human metapneumovirus	
<220> <223> primer no 71	
<400> 109 ctcctttaag atatgagta ggmagta	28
<210> 110 <211> 22 <212> DNA <213> human metapneumovirus	
<220> <223> primer no 20 multiplex assay	
<400> 110 gttgccatag agaatcctgt ta	22
<210> 111 <211> 22 <212> DNA <213> human metapneumovirus	
<220> <223> primer no 21 multiplex assay	
<400> 111 cattcagact gttgcttacc ca	22
<210> 112 <211> 22 <212> DNA <213> human metapneumovirus	
<220> <223> primer no 72	
<400> 112 gttgccatag agaatcctgt ta	22
<210> 113 <211> 22 <212> DNA <213> human metapneumovirus	
<220> <223> primer no 73	
<400> 113 cattcagact gttgcttacc ca	22
<210> 114 <211> 27 <212> DNA	

40/52

<213> human Metapneumovirus

<220>

<223> human Metapneumovirus
primer A1

<400> 114

ccaattacta aaccaattgc ttacca

27

<210> 115

<211> 21

<212> DNA

<213> human metapneumovirus

<220>

<223> probe no 74

<400> 115

gcaagcttat ggggccgggc a

21

<210> 116

<211> 25

<212> DNA

<213> human metapneumovirus

<220>

<223> probe no 75

<400> 116

acaatgctaa ggtggggggt cattg

25

<210> 117

<211> 23

<212> DNA

<213> human metapneumovirus

<220>

<223> probe no 76

<400> 117

gttctgagga caggttggtgta cac

23

<210> 118

<211> 23

<212> DNA

<213> human metapneumovirus

<220>

<223> probe no 77

<400> 118

aatgttttta cactggaggt agg

23

<210> 119

<211> 22

<212> DNA

<213> human metapneumovirus

<220>

<223> probe no 78

<400> 119

gttacaatac cagcattcat ca

22

<210> 120

<211> 25

<212> DNA

<213> human metapneumovirus

<220>

<223> probe no 79

41/52

<400> 120 atcagtttca atcaaagaga gtgag	25
<210> 121 <211> 25 <212> DNA <213> human metapneumovirus	
<220> <223> probe no 80	
<400> 121 taaagcaagc aatcaaagtc atgga	25
<210> 122 <211> 25 <212> DNA <213> human metapneumovirus	
<220> <223> probe no 81	
<400> 122 cccattgaag aagaagagtc taccg	25
<210> 123 <211> 20 <212> DNA <213> human metapneumovirus	
<220> <223> probe no 82	
<400> 123 actcaagccc acagcatcca	20
<210> 124 <211> 23 <212> DNA <213> human metapneumovirus	
<220> <223> probe no 83	
<400> 124 ctcaacagtc cacagaaggc tcc	23
<210> 125 <211> 26 <212> DNA <213> human metapneumovirus	
<220> <223> probe no 84	
<400> 125 attggttttag taattggtac aatctc	26
<210> 126 <211> 26 <212> DNA <213> human metapneumovirus	
<220> <223> probe no 85	
<400> 126 acaagttgat tctggaattc aggaaa	26
<210> 127 <211> 25 <212> DNA	

42/52

<213> human Metapneumovirus

<220>

<223> human Metapneumovirus
probe A2

<400> 127

cgagcatgtt agactcaaaa atgca

25

<210> 128

<211> 23

<212> DNA

<213> human metapneumovirus

<220>

<223> probe no 33 multiplex assay

<400> 128

atgtatccgt ccaagctgag tta

23

<210> 129

<211> 26

<212> DNA

<213> human metapneumovirus

<220>

<223> probe no 34 multiplex assay

<400> 129

attggtttag taattggtac aatctc

26

<210> 130

<211> 1027

<212> DNA

<213> human Influenza A virus

<220>

<221> gene

<222> (1)...(1027)

<223> human Influenza A virus
strain A/Hong Kong/1180/99(H3N2)
accession number af386771

<400> 130

agcaaaagca	ggtagatatt	gaaagatgag	ccttctaccc	gaggtcgaaa	cgtatgttct	60
ctctatcggt	ccatcaggcc	ccctcaaagc	cgaaatcgcg	cagagacttg	aagatgtctt	120
tgctgggaaa	aacacagatc	ttgaggctct	catgggaatgg	ctaaagacaa	gaccaatcct	180
gtcaccctcg	actaaggggg	ttttagggtt	tggtttcacg	ctcaccgtgc	ccagtggagcg	240
aggactgcag	cgtagacgct	ttgtccaaaa	tgccctcaat	gggaatgggg	atccaaataa	300
catggacaaa	gcagttaaac	tgtatagaaa	acttaagagg	gagataacat	tccatggggc	360
caaagaaata	gcactcagtt	attctgctgg	tgcaacttgc	agttgcatgg	gcctcatata	420
caataggatg	ggggctgtaa	ccactgaagt	ggcatttggc	ctggatgtgt	caacatgtga	480
acagattgct	gactccagc	acaggctctca	taggcaaatg	gtggcaacaa	ccaatccatt	540
aataagacat	gagaacagaa	tggttttggc	cagcactaca	gctaaggcta	tggagcaaat	600
ggctggatca	agttagcagg	cagcggaggc	catggagatt	gctagtcagg	ccaggcaaat	660
gggtgcaggca	atgagagccg	ttgggactca	tcctagctcc	agtaactggc	taagagatga	720
tcttcttgaa	aatttgaga	cctatcagaa	acggatgggg	gtgcagatgc	aacgattcaa	780
gtgaccgcgt	tgttgttgcc	gcgagtatca	ttgggactct	gcacttgata	ttgtggattc	840
ttgatcgtct	ttttttcaaa	tgcatctatc	gactcttcaa	acacggcctt	aaaagagggc	900
cttctacgga	aggagtacct	gagtctatga	gggaagaata	tcaaaaggaa	cagcagaatg	960
ctttggatgc	tgaccacagt	cattttgtca	gcataaagtt	ggagtataaaa	actaccttgt	1020
ttctact						1027

<210> 131

<211> 987

<212> DNA

<213> human Influenza A virus

<220>

<221> gene

<222> (1)...(987)

<223> human Influenza A virus

43/52

strain A/Charlottesville/31/95 (H1N1)
accession number af398876

```
<400> 131
atgagtccttc taaccgaggt cgaacgtac gttctctcta tcgtcccgtc agggccccc 60
aaagcccgaga tcgcacagag acctggaagat gtctttgctg gaaagaacac cgtctttgag 120
gctctcatgg agtggctaaa gacaagaccg atcctgtcac ctctgactaa ggggatttta 180
ggattttgtg tcacgctcac cgtgcccagt gagcgaggac tgcagcgtag acgctttgtc 240
caaaatgccc ttaatgggaa tggggatcca aataacatgg acagagcagt taaactgtat 300
agaaagctta agagggagat aacattccat ggggccaaag aaatagcact cagttattct 360
gctgggtcac ttgccagttg tatgggcctc atatacaaca ggatgggggc tgtgaccacc 420
gaatcagcat ttggcctgat atgcgcaacc tgtgaacaga ttgctgactc ccagcataag 480
tctcataggc aaatggtaac aacaaccaat ccattaataa gacatgagaa cagaatgggt 540
ctggccagca ctacagctaa agctatggag caaatggctg gatcgagtga acaagcagct 600
gagggccatg aggttctag tcaggccagg caaatggctg aggcaatgag agccattggg 660
actcatccta gctctagcac tggctctgaa atgatcttc ttgaaaattt gcaggcctat 720
cagaacagaa tgggggtgca gatgcaacga ttcaagtgat cctctgtttg ttgccgcaag 780
tatcattggg attgtgcacc tgatattgtg gattattgat cgcctttttt tcaaatgcat 840
ttatcgtatc ttaaacacg gtctgaaaag agggccttct acggaaggag taccagagtc 900
tatgagggaa gaatatcgag aggaacagca gaatgctgtg gatgctgacg aaggtcattt 960
tgtcagcata gagctggagt aaaaaaac 987
```

<210> 132
<211> 1076
<212> DNA
<213> human Influenza B virus

<220>
<221> gene
<222> (1)...(1076)
<223> human Influenza B virus
strain B/Nagoya/20/99

```
<400> 132
atgtcgtgtg ttggagacac aattgcctac ctgctttcat tgacggaaga tggagaaggc 60
aaagcagaac tagcagaaaa attacactgt tggttcgggt ggaaagaatt tgacctagac 120
tctgccttgg aatggataaa aaacaaaaaga tgccttaactg atatacaaaa agcactaatt 180
ggtgcctcta tctgcttttt aaaaaccctaa gaccaagaaa gaaaaagaag attcatcaca 240
gagcccttat caggaaatggg aacaacagca acaaaaaaga aaggcctgat tctagctgag 300
agaaaaatga gaagatgtgt gagctttcat gaagcatttg aaatagcaga aggccatgaa 360
agctcagcgc tactatatgt tctcatggtc atgtacctga accctggaaa ttattcaatg 420
caagtataac taggaacgct ctgtgctttg tgcgagaac aagcatcaca ttcacacagg 480
gctcatagca gagcagcgag atcttcagtg cctggagtga ggcgagaat gcaaatgggtc 540
tcagctatga acacagcaaa aacaatgaat ggaatgggaa agggagaaga cgtccaaaaa 600
ctggcagaag aactgcaaa caacattgga gtgttgagat ctcttgagc aagtcaaaag 660
aatgggggag gaattgcaaa ggaatgtaat gaagtgttaa agcagagctc tatgggaaat 720
tcagctcttg tgaagaataa cctataatgc ttgaaccatt tcagattctt tcaattttgt 780
cttttatctt atcagctctc catttcatgg cttggacaat agggcatttg agtcaataaa 840
aaagaggagt aaacatgaaa atacgaataa aaggtccaaa taaagagaca ataaacagag 900
aagtatcaat ttgagacac aattaccaa aagaaatcca ggccaaagaa acaatgaagg 960
aagtgtcttc tgacaacata gaagtattga gtgaccacat agtgattgag gggctttctg 1020
ctgaagagat aataaaaaatg ggcaaaacag ttttggaggt agaaaaattg cattaa 1076
```

<210> 133
<211> 1725
<212> DNA
<213> human Respiratory Syncytial Virus

<220>
<221> gene
<222> (1)...(1725)
<223> human Respiratory Syncytial Virus
strain B1
accession number af013254

```
<400> 133
atggagctgc tgatccacag gtttaagtga atcttcttaa ctcttgctat taatgcattg 60
tacctcacct caagtcagaa cataactgag gaggtttacc aatcgacatg tagtgagtt 120
agcagaggtt attttagtgc ttaagaaca ggttggata ccagtgctat aacaatagaa 180
ttaagtaata taaaagaaac caaatgcaat ggaactgaca cttaaagttaa acttataaaa 240
caagaattag ataagtataa gaatgcagtg acagaattac agctacttat gcaaaacaca 300
ccagctgcca acaaccgggc cagaagagaa gcaccacagt atatgaacta tacaatcaat 360
```

44/52

accactaaaa	acctaaatgt	atcaataaagc	aagaagagga	aacgaagatt	tctgggcttc	420
ttgttaggtg	taggatctgc	aatagcaagt	ggtagagctg	tatccaaagt	tctacacctt	480
gaaggagaag	tgaacaagat	caaaaatgct	ttgttatcta	caaacaaagc	tgtagtcagt	540
ctatcaaatg	gggtcagtg	tttaaccagc	aaagtgttag	atctcaagaa	ttacataaat	600
aaccaartat	taccatagat	aatcaacag	agctgtcgca	tctccaacat	tgaacagatt	660
atagaartcc	agcagaagaa	cagcagattg	ttggaaatca	acagagaatt	cagtgtcaat	720
gcaggtgtta	caacaccttt	aagcacttaa	atgttaacaa	acagtgaatt	actatcattg	780
atcaatgata	tgcttataac	aaatgatcag	aaaaaattaa	tgtcaagcaa	tggttcagata	840
gtaaggcaac	aaagtatttc	tatcatgtct	ataataaagg	aagaagtcct	tgcatatggt	900
gtacagctac	ctatctatgg	tgtaatatag	acaccttgct	ggaaattaca	cacatcacct	960
ctatgcacca	ccaacatcaa	agaaggatca	aataatttgg	taacaaggac	tgatagagga	1020
tggtattgtg	ataatgcagg	atcagtatcc	ttctttccac	aggctgacac	ttgtaaaagta	1080
cagtccaatc	gagtattttg	tgacactatg	aacagtttga	cattaccaag	tgaagtcagc	1140
ctttgtaaca	ctgacatatt	caatttccaag	tatgactgca	aaattatgac	atcaaaaaca	1200
gacataagca	gctcagtaat	tacttctctt	ggagctatag	tgctatgcta	tggtaaaact	1260
aaatgcactg	catccaacaa	aaatcggtgg	attataaaga	cattttctaa	tggtgtgac	1320
tatgtgtcaa	acaaaggagt	agatactgtg	tcagtgggca	acactttata	ctatgtaaac	1380
aaagtgtgaag	gcaagaacct	ttatgtaaaa	ggggaacctc	taataaatta	ctatgacctt	1440
ctagtgtttc	ctttctgatg	gtttgatgca	tcaatatctc	aagtcaatga	aaaaatcaat	1500
caaagtrtag	cttttattcg	tagatctgat	gaattactac	ataatgtaaa	tactggcaaa	1560
tctactacaa	atattatgat	aactacaatt	attatagtaa	tcattgtagt	attgttatca	1620
ttaatagcta	ttggtttgct	gtttgtattgc	aaagccaaaa	acacaccagt	tactactaagc	1680
aaagaccaac	taagtggaa	caataatatt	gcattcagca	aatag		1725

<210> 134

<211> 1575

<212> DNA

<213> human Parainfluenza 1 virus

<220>

<221> gene

<222> (1)...(1575)

<223> human Parainfluenza 1 virus strain
 Washington/1964
 accession number nc003461

<400> 134

atggccgggc	tactaagtac	ttttgacaca	tttagttcca	ggagaagtga	gagcatcaat	60
aagtctggcg	gaggagcaat	tatacctggg	caaagaagta	ccgtttctgt	cttcacatta	120
ggcccggagt	tgacagatga	tgacagataaa	ttattaatag	caaccacttt	cttagcccac	180
tcattggaca	cagataaaca	acactctcaa	agaggaggat	ttttagtatc	actccttgca	240
atggcctaca	gtagtccgga	gttatatctc	actacaaacg	gtgtcaatgc	tgatgtcaag	300
tatgtgatat	acaatataga	gagagatcct	aaaagaacaa	aaacagatgg	gttcattgtc	360
aaaacaagag	acatggagta	tgaaagaaca	acagagtggg	tggttgacc	tatgatcaac	420
aagaacccat	tggtccaagg	gcaaaagagag	aatgcggatc	tagaggcatt	gcttcagaca	480
tatggatatc	ctgcatgtct	cggagctata	atagttcaag	tttggatagt	gttgggtaaa	540
gccataacaa	gtagtgtctg	tctaagaaaa	ggattcttca	atagattaga	agcattcaga	600
caggatggaa	ccgttaaaag	tgccctggtc	ttcacaggag	acacagttga	aggtattggt	660
gcagtgtatg	ggtcacaaca	aagcttagta	tctcttatgg	tagaaactct	ggtagctatg	720
aacacatcca	ggtcagattt	aactacatta	gagaagaaca	ttcagattgt	aggaattac	780
ataagagatg	caggatttagc	atctttcatg	aacaccatca	agtatgggtg	agaaacgaag	840
atggccgccc	tgacactatc	aaatctgaga	ccagatataa	acaaattgag	aagccttggt	900
gatattctatc	tatcaaaggg	agcccagacc	ccttttatat	gtatactcag	agaccagtt	960
catggagact	ttgcccttgg	aaactatcca	gcactgtgga	gctacgcaat	gggcgttgct	1020
gtggtagaaa	acaaagctat	gcaacagtat	gtaactggaa	gaacatattt	ggacatggaa	1080
atgttcttac	ttggacaagc	tgtagctaaa	gatgctgatt	ccaaaatcag	cagtgtctcg	1140
gagggaagaac	taggtgtgac	agatacagca	aaagagagac	taagacacca	tctgacaaac	1200
ctttcaggag	gggatgggtg	gtaccacaag	cctacaggtg	gtggagctat	agaagtggca	1260
attgatcata	cagacataac	atttggagtc	gaggacactg	ctgatcggga	caacaagaac	1320
tggaacaaatg	acagcaatga	aagatggatg	aatcactcga	tcagcaacca	cacaatcacg	1380
attcgtgggtg	cagaagaact	tgaagaagag	acaaatgatg	aagacatcac	tgatatagaa	1440
aacaagattg	cacgaaggct	ggccgacaga	aaacagagac	taagccaggc	aaacaataaa	1500
cgagacacca	gcagtgtatg	tgactatgag	aatgatgatg	atgctacagc	ggctgcaggg	1560
ataggaggaa	tttaa					1575

<210> 135

<211> 1548

<212> DNA

<213> human Parainfluenza 3 virus

<220>

<221> gene

45/52

<222> (1)...(1548)

<223> human Parainfluenza 3 virus
strain GP
accession number ab012132

<400> 135

atgttgagcc	tatttgatgc	atttaattgca	cgtaggcaag	aaaacataac	aaaatcagcc	60
ggtaggagcta	tcatttctg	acagaaaaat	actgtctcta	tatttgctct	tggaccgaca	120
ataactgatg	ataatgagaa	aatgacatta	gctcttcttt	ttttatctca	ttcactggat	180
aatgagaaac	aacatgcaca	aagggcaggg	ttcctgggtg	ccttattatc	aatggcttat	240
gccaatccag	agctctacct	aacaacaaat	ggagagtaatg	cagatgtcaa	gtatgtcata	300
tacatgatcg	agaaagatct	aaaacggcaa	aagtatggag	gatttgggtg	taagacgaga	360
gagatgggtat	atgacaagac	aactgattgg	atatttggaa	gtgacctgga	ttgtgatcag	420
gaaactatgt	tgcagaacgg	aagaaacaat	tcaacaattg	aagacctgtg	ccacacattt	480
gggtatccat	catgtttagg	agctcttata	atacagatct	ggatagttct	ggcacaagct	540
atcactagta	tctcaggggt	aagaaaaggc	tttttcccc	gattggaagc	tttcagacaa	600
gatggaacag	tgcaggcagg	gctgggtattg	agcgggtgaca	cagtggatca	gattgggtca	660
attatgcggt	ctcaacagag	cttggtaact	cttatgggtg	aaacattaat	aacaatgaat	720
actagcagaa	atgacctcac	aaccatagaa	aagaatatac	aaattgttgg	taactatata	780
agagatgcag	gtctcgcttc	attcttcaat	acaatcagat	atggaattga	gactagaatg	840
gcagctttga	ctctatccac	tctcagacca	gacatcaata	gattaaaagc	tttgatggaa	900
ctgtattttat	caaaagggacc	acgcgctcct	ttcatctgta	tcctcagaga	tcccatacat	960
ggtgagttcg	caccaggcaa	ctatcctgccc	atatggagct	atgcaatggg	agtggcagtt	1020
gtacaaaata	gagccatgca	acagtatgtg	acgggaagat	catatctgga	tattgatatg	1080
ttccagctag	gacaagcagt	agcacgtgat	gctgaagctc	agatgagctc	aacactagaa	1140
gatgaacttg	gagtgacaca	cgaaagctaaa	gaaagcttga	agagacatat	aaggaacata	1200
aatagttcag	agacatcttt	ccacaaaacca	acaggtggat	cagccataga	gatggcaata	1260
gatgaagagc	cagaacaatt	cgaacataga	tcagatcaag	aacgagatgg	agaacctcaa	1320
tcattctataa	ttcaatatgc	ttgggcagaa	ggaaacagaa	gcgatgatcg	gactgagcaa	1380
gatacagaat	ctgacaatat	caagactgaa	caacaaaaca	tcagagacag	actaaacaag	1440
agactcaacg	aaaagaagaa	acaaggcagt	caaccaccta	ccaatcccac	aaacagaaacg	1500
aatcaggacg	aaatagatga	tctgtttaat	gcatttggaa	gcaactaa		1548

<210> 136

<211> 2910

<212> DNA

<213> human Adenovirus

<220>

<221> gene

<222> (1)...(2910)

<223> human Adenovirus

strain 105

accession number aj293903

<400> 136

atggctacc	cttcgatgat	gccgcagtg	tcttacatgc	acatctcggg	ccaggacgcc	60
tcggagtagc	tgagccccgg	gctgggtgcag	tttccccgcg	ccaccgagac	gtacttcagc	120
ctgaataaca	agtttagaaa	ccccacggtg	gcgcctacgc	acgacgtgac	cacagaccgg	180
ttccagcggt	tgacgctgcg	gttcattcct	gtggatcgcg	aggataccgc	gtactcgtac	240
aaggcgcggt	tcaccctggc	tgtgggtgac	aaccgcgtgc	ttgatatggc	ttccacgtac	300
tttgacatcc	gcggcggtgct	ggaacaggggc	cctaactttca	agccctactc	tggcactgcc	360
tacaacgctc	tagctcccaa	gggcgctccc	aactcctgtg	agtgggaaca	aaccgaagat	420
agcggccggg	cggttgccga	ggatgaagaa	gaagaggaa	atgaagatga	agaagaggaa	480
gaggaagagc	aaaacgctcg	agatcaggct	actaagaaaa	catatgttta	tgcccaggct	540
ctttgtctg	gagaaacaat	tacaaaaagc	gggctacaaa	taggatcaga	caatgcagaa	600
acacaagcta	aacctgtata	tgcagatcct	tcctatcaac	cagaacctca	aattggcgaa	660
tctcagtggg	acgaagctga	tgctaattga	gcaggaggga	gagtgcttaa	aaaaacaact	720
cccatgaaac	catgctatgg	atcttatgdc	aggcctacaa	atccitttgg	tggccaatcc	780
gtcctgggtc	cggatgaaaa	aggggtgctc	cttccaaagg	ttgacttgca	attcttctca	840
aatactacct	ctttgaacga	ccggcaaggc	aatgccacta	aaccaaaagt	ggtgtgtgtac	900
agtgaagatg	taaatttggg	aaccccagac	acacatctgt	cttacaaaac	tggaaaaggt	960
gatgaaaaat	ctaaagctat	gttgggtcaa	caatctatgc	caaacagacc	caattacatc	1020
gctttcaggg	acaattttat	tggcctaattg	tattataaca	gcactggcaa	catgggtgtt	1080
tttgctgggt	agggcatcgca	gctaaaatgcc	gtggtagatt	tgcaagacag	aaacacagag	1140
ctgtcctatc	aacttttgc	tgattccata	ggtgatagaa	ccagatattt	ttctatgtgg	1200
aatcaggctg	tagacagcta	tgaccagat	gtagaatca	ttgaaaacca	tggaaactgag	1260
gatgaattgc	caaattattg	tttccctctt	gggggtattg	gggttaactga	cacctatcaa	1320
gctattaagg	ctaattggcaa	tggcgaggt	gataatggaa	atactacatg	gacaaaagat	1380
gaaacttttg	caacacgtaa	tgaaatagga	gtgggttaaca	actttgcat	ggaaattaac	1440
ctaatgcca	acctatggag	aaatttctct	tactccaata	ttgcactata	cttgccagac	1500
aagctaaaa	acaacccac	caacgtggaa	atatctgaca	accccaaac	ctacgactac	1560

46/52

atgaacaagc	gagtgggtgc	tcctgggctt	gtagactgct	acattaacct	tggggcgcg	1620
tggctcttgg	actacatgga	caacgttaat	ccctttaacc	accaccgcaa	tgcgggcctg	1680
cgttaccgct	ccatgttggt	gggaaacgga	cgctacgtgc	cttttcacat	tcaggtgccc	1740
caaaagtitt	ttgccattaa	aaacctcctc	ctcctgccag	gctcatacac	atatgaatgg	1800
aacttcagga	aggatgttaa	catggttctg	cagagctctc	tgggaaacga	ccttagagtt	1860
gacggggcta	gcattaaagt	tgacagcatt	tgtctttacg	ccacrttctt	ccccatggcc	1920
cacaacacgg	cttccacgct	ggaagccatg	ctcagaaatg	acaccaacga	ccagtccttt	1980
aatgactacc	tttccgcgcg	caacatgcta	tatcccatat	ccgccaacgc	caccaacgtg	2040
cccattctca	tcccatcgcg	caactgggca	gcatttcgcg	gttgggcctt	cacacgcttg	2100
aagacaaaagg	aaaccccttc	cctgggatca	ggctacgacc	cttactacac	ctactctggc	2160
tcataccat	accttgacgg	aaccttctat	cttaatcaca	cccttaagaa	ggtggccatt	2220
acttttgact	cttctgttag	ctggcggggc	aacgaccgcc	tgcttactcc	caatgagttt	2280
gagattaaag	gctcagttga	cggggaggggc	tataacgtag	ctcagtgcaa	catgacaaag	2340
gactgggtcc	tagtgacagt	gttggccaac	tacaatatgt	gctaccaggg	cttctacatt	2400
ccagaaagct	acaaagaccg	catgtactcg	ttcttcagaa	acttccagcc	catgagccgg	2460
caagtgggtg	acgatactaa	atacaaagat	tatcagcagg	ttggaattat	ccaccagcat	2520
aacaactcag	gcttcgtagg	ctacctcgct	cccaccatgc	gcgagggaca	agcttaccct	2580
gctaattgtt	ctacccccct	aataggcaca	accgcggttg	atagtattac	ccagaaaaag	2640
tttctttgcg	accgcaccct	gtggcgcatc	ccattctcca	gtaactttat	gtccatgggt	2700
gcgctcacag	acctggggca	aaacctttct	tacgaaaact	ccgcccacgc	gctagacatg	2760
acctttgagg	tggtaccat	ggacgagccc	acccttcttt	atgttttgtt	tgaagtcttt	2820
gacgtggtcc	gtgtgcacca	gccgcaccgc	ggcgtcatcg	agaccgtgta	cctgcgcacg	2880
cccttctcgg	ccggcaacgc	cacaacataa				2910

<210> 137

<211> 810

<212> DNA

<213> human Enterovirus

<220>

<221> gene

<222> (1)...(810)

<223> human Enterovirus
strain Coxsackievirus B1
accession number M16560

<400> 137

cggccccctga	atgcggctaa	tcttaactgc	ggagcacata	ccctcaaac	agggggcagt	60
gtgtcgtaac	gggcaactct	gcagcggaa	cgactacttt	gggtgtccgt	gtttcatttt	120
attccctatac	tggctgttta	tggtagcaat	tgacaggttg	ttaccatata	gttattggat	180
tggccatccg	tggactaaca	gagcaattat	atatctctti	gttgggttta	taccacttag	240
cttgaaagag	gttaaaacac	tacatctcat	cattaaaacta	aatacaacaa	aatgggggct	300
caagtatcaa	cacaaaagac	tggagcacat	gagaccgggc	tgaatgcaag	cgggaattcc	360
atcatccatt	acacaaacat	aaactactat	aaagatgctg	catccaactc	agccaacaga	420
caggattttca	ctcaagaccc	aggtaaaatt	actgagccag	tgaaggacat	tatgatcaaa	480
tcgattgccag	cattgaaactc	cccctctgcc	gaagagtgtg	gttatagtga	cagggttcga	540
tcaataaccc	tccgggaactc	cactatcaca	acacaggagt	gtgctaattgt	tgtggttggg	600
tatgggtgtgt	ggccagaata	tttgaaggac	aatgaagcca	caggcgagga	ccaaccaaca	660
caacctcgacg	tggccacatg	tcggttctac	actttagagt	ccgtgcagtg	gatgaagaat	720
tcagcaggtt	gggtgtggaa	gttaccagat	gcactttcac	aaatgggggt	gtttggacaa	780
aatatgcagt	accactactt	agggagaaca				810

<210> 138

<211> 681

<212> DNA

<213> human Rhinovirus

<220>

<221> gene

<222> (1)...(681)

<223> human Rhinovirus
strain 14
accession number K02121

<400> 138

taacctctaga	gccttatgcc	acgatccagt	ggttgtaagg	tcgtaatgag	caattccggg	60
acgggaccga	ctactttggg	tgtccgtgtt	tctcattttt	cttcataattg	tcttatgggtc	120
acagcatata	tatacatata	ctgtgatcat	gggcgctcag	gtttctacac	agaaaagtgg	180
atctcacgaa	aatcaaaaca	ttttgaccaa	tggatcaaat	cagactttca	cagttataaa	240
ttactataag	gatgcagcaa	gtacatcatc	agctgggtcaa	tcactgtcaa	tggacccatc	300
taagtattaca	gaaccagtta	aagatctcat	gcttaagggt	gcaccagcat	tgaattcacc	360
caatgttgag	gcctgtggtt	atagtatag	agtacaacaa	atcacactcg	ggaattcaac	420

47/52

aataacaaca	caagaagcag	ccaacgctgt	tgtgtgttat	gctgaatggc	cagagtacct	480
tccagatgtg	gacgctagtg	atgtcaataa	aacttcaaaa	ccagacacit	ctgtctgtag	540
gttttacaca	ttggatagta	agacatggac	aacagggttct	aaaggctggt	gctggaaaatt	600
accagatgca	ctcaaggata	tgggtgtgtt	cgggcaaaac	atgtttttcc	actcactagg	660
aagatcaggt	tacacagtac	a				681

<210> 139
 <211> 21
 <212> DNA
 <213> human Influenza A virus

<220>
 <223> primer no 12 multiplex assay

<400> 139
 cttctaaccg aggtcgaac g 21

<210> 140
 <211> 24
 <212> DNA
 <213> human Influenza A virus

<220>
 <223> primer no 13 multiplex assay

<400> 140
 agggcatttt ggacaaagcg tcta 24

<210> 141
 <211> 20
 <212> DNA
 <213> human Influenza B virus

<220>
 <223> primer no 14 multiplex assay

<400> 141
 ttacactgtt gggtcgggtgg 20

<210> 142
 <211> 20
 <212> DNA
 <213> human Influenza B virus

<220>
 <223> primer no 15 multiplex assay

<400> 142
 gccagttttt ggacgtcttc 20

<210> 143
 <211> 23
 <212> DNA
 <213> human Respiratory Syncytial Virus

<220>
 <223> primer no 16 multiplex assay

<400> 143
 aacagtttaa cattaccaag tga 23

<210> 144
 <211> 23
 <212> DNA
 <213> human Respiratory Syncytial virus

<220>
 <223> primer no 17 multiplex assay

<400> 144
 tcattgactt gagatattga tgc 23

48/52

<210> 145
 <211> 26
 <212> DNA
 <213> human Parainfluenza 1 virus

<220>
 <223> primer no 22 multiplex assay

<400> 145
 tctggcggag gagcaattat acctgg 26

<210> 146
 <211> 26
 <212> DNA
 <213> human Parainfluenza 1 virus

<220>
 <223> primer no 23 multiplex assay

<400> 146
 atctgcatca tctgtcacac tcgggc 26

<210> 147
 <211> 22
 <212> DNA
 <213> human Parainfluenza 1 virus

<220>
 <223> human Parainfluenza 1 virus
 primer P1

<400> 147
 gtatggtgta gaaacgaaga tg 22

<210> 148
 <211> 22
 <212> DNA
 <213> human Parainfluenza 1 virus

<220>
 <223> human Parainfluenza 1 virus
 primer P2

<400> 148
 ttgtaccaca gcaacaccca tt 22

<210> 149
 <211> 26
 <212> DNA
 <213> human Parainfluenza 3 virus

<220>
 <223> primer no 24 multiplex assay

<400> 149
 aacaggaaac tatgctgcag aacggc 26

<210> 150
 <211> 26
 <212> DNA
 <213> human Parainfluenza 3 virus

<220>
 <223> primer no 25 multiplex assay

<400> 150
 gatccactgt gtcaccgctc aatacc 26

<210> 151
 <211> 25
 <212> DNA
 <213> human Parainfluenza virus

49/52

<220>
 <223> humna Parainfluenza virus
 primer P3

<400> 151
 tcttgcttca ttcttcaata caatc

25

<210> 152
 <211> 23
 <212> DNA
 <213> human Parainfluenza 3 virus

<220>
 <223> human Parainfluenza 3 virus
 primer P4

<400> 152
 aattccatca gagcttttaa tct

23

<210> 153
 <211> 18
 <212> DNA
 <213> human Adenovirus

<220>
 <223> primer human Adenovirus P5

<400> 153
 actccctcga tgatgccg

18

<210> 154
 <211> 26
 <212> DNA
 <213> human Adenovirus

<220>
 <223> primer no 26 multiplex assay

<400> 154
 cctacgcacg atgtgaccac agaccg

26

<210> 155
 <211> 26
 <212> DNA
 <213> human Adenovirus

<220>
 <223> primer no 27 multiplex assay

<400> 155
 gtgttgtagg cagtgccgga gtaggg

26

<210> 156
 <211> 21
 <212> DNA
 <213> human Sars Coronavirus

<220>
 <223> primer SARS no P5

<400> 156
 ctaacatgct taggataatg g

21

<210> 157
 <211> 21
 <212> DNA
 <213> human Sars Coronavirus

<220>
 <223> human Sars Coronavirus
 primer P6

50/52

<400> 157 caggtaagcg taaaactcat c	21
<210> 158 <211> 24 <212> DNA <213> human Sars Coronavirus	
<220> <223> human Sars Coronavirus primer P7	
<400> 158 atgaattacc aagtcaatgg ttac	24
<210> 159 <211> 22 <212> DNA <213> human Sars Coronavirus	
<220> <223> human Sars Coronavirus primer P8	
<400> 159 cataaccagt cggtagcagct ac	22
<210> 160 <211> 16 <212> DNA <213> human Enterovirus/human Rhinovirus	
<220> <223> primer no 28 multiplex assay	
<400> 160 ctactttggg tgtccg	16
<210> 161 <211> 19 <212> DNA <213> human Enterovirus/human Rhinovirus	
<220> <223> primer no 29 multiplex assay	
<400> 161 ggtaattcca ccaccancc	19
<210> 162 <211> 23 <212> DNA <213> human Influenza A virus	
<220> <223> probe no 30 multiplex assay	
<400> 162 tcttcaagtc tctgtgcgat etc	23
<210> 163 <211> 23 <212> DNA <213> human Influenza B virus	
<220> <223> probe no 31 multiplex assay	
<400> 163 agctcagcgc tactatattg tct	23

51/52

<210> 164
 <211> 23
 <212> DNA
 <213> human Respiratory Syncytial virus

<220>
 <223> probe no 32 multiplex assay

<400> 164
 ccttcagct tgttacata gta

23

<210> 165
 <211> 23
 <212> DNA
 <213> human Parainfluenza 1 virus

<220>
 <223> probe no 35 multiplex assay

<400> 165
 aagtaccgtt tctgtcttca cat

23

<210> 166
 <211> 23
 <212> DNA
 <213> human Parainfluenza 3 virus

<220>
 <223> probe no 36 multiplex assay

<400> 166
 cctgcactgt tccatcttgt ctg

23

<210> 167
 <211> 18
 <212> DNA
 <213> human Adenovirus

<220>
 <223> probe no 37 multiplex assay

<400> 167
 cgcgtactcg tacaaggc

18

<210> 168
 <211> 23
 <212> DNA
 <213> human Rhinovirus

<220>
 <223> probe no 38 multiplex assay

<400> 168
 attcagcata acacacaaca gcg

23

<210> 169
 <211> 23
 <212> DNA
 <213> human Enterovirus

<220>
 <223> probe no 39 multiplex assay

<400> 169
 cctgtggctt cattgtcctt caa

23

<210> 170
 <211> 558
 <212> DNA
 <213> human Herpesvirus 2

<220>

52/52

<223> modified human Herpesvirus 2
internal control
multiplex no 1

<400> 170
ttacactgtt ggttcggttg cgactttgcc agcctgtacc ccagcatcat ccaggccac 60
aacctgtgct tcagtacgct ttccctgcgg cccgaggccg tcgcgacact ggaggcggac 120
cgggactacc tggagatcga ggtggggggc cgacggctgt tcttcgtgaa ggcccacgta 180
cgcgagagcc tgctgagcat cctgctgcgc gactggctgg ccattgcgaaa gcagatccgc 240
tcgcggatcc cccagagcac ccccgaggag gccgtcctcc tcgacaagca acaggccgcc 300
atcaaggtgg tgtgcaactc ggtgtacggg ttccaccggg tgacgacgg tcttctgccc 360
tgccctgcag tggccgccac cgtgacgacc atcggccgcg agatgctcct cgcgacgcgc 420
gcgtacgtgc acgcgcgctg ggcggagttc gatcagctgc tggccgactt tccggaggcg 480
gccgcatgc gcgccccgg tccgtactcc atgcatca tctacgggga cagggactga 540
agacgtcaa aaactggc 558

<210> 171

<211> 554

<212> DNA

<213> human Herpesvirus 2

<220>

<223> modified human Herpesvirus 2
internal control
multiplex no 2

<400> 171
ctactttggg tgtccgcgac tttgccagcc tgtaccccag catcatccag gccacaacc 60
tgtgcttcag tacgctctcc ctgcggcccc aggccgtcgc gcacctggag gcggaccggg 120
actacctgga gatcgagggt gggggccgac ggctgttctt cgtgaaggcc cactacgcg 180
agagcctgct gagcatcctg ctgcgcgact ggctggccat gcgaaagcag atccgctcgc 240
ggatccccc gagcaccccc gaggaggccg tcctcctcga caagcaacag gccgccatca 300
aggtggtgtg caactcgggt tacgggttca ccgggggtga gcacggtcct ctgcccctgcc 360
tgcatgtggc cgccaccgtg acgaccatcg gccgcgagat gctcctcgcg acgcgcgcgt 420
acgtgcacgc gcgctgggcg gatttcgatc agctgtggc cgactttccg gaggcggccg 480
gcatgcgcgc ccccggtccg tactccatgc gcatcatcta cggggacacg gactggctgg 540
tggtggaat tacc 554

<210> 172

<211> 23

<212> DNA

<213> human Herpesvirus

<220>

<223> Internal Control probe no 42
multiplex assay

<400> 172

acaccgagtt gcacaccacc ttg

23

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☒ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.